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Abstract 
 
The overall aim of this work was to investigate the intestinal absorption of the sesquiterpene lactone 
nobilin from the flowers of Anthemis nobilis L. (Chamomillae romanae flos) in the in vitro Caco-2 model 
and identify strategies for its improvement. The influence of physicochemical processes i.e., stability and 
solubility and biochemical processes i.e., bioconversion and membrane permeation by passive diffusion 
and carrier mediated transport on nobilin absorption were elucidated to gain a basic mechanistic 
understanding of the absorption of the compound. Physiologically based multi-compartment kinetic 
modeling was employed to delineate the influence of simultaneously acting phenomena. Based on this 
understanding, possibilities were finally explored to improve absorption of nobilin utilizing plant extract, 
formulation, and post-prandial application approaches. The thesis is divided into one theoretical part 
and three experimental studies, each addressing other aspects of physicochemical and biochemical 
processes affecting nobilin absorption.    
The first study focused on chemical degradation of nobilin and its solubility under conditions of 
concurrent degradation and the effect of biorelevant media used in the in vitro measurement of 
intestinal absorption. Purely aqueous medium (aq-TMCaco), fasted and fed state simulated intestinal fluid 
(FaSSIF-TMCaco and FeSSIF-TMCaco), and two liposomal formulations (LiposomesFaSSIF and LiposomesFeSSIF) 
with the same lipid concentration as FaSSIF-TMCaco and FeSSIF-TMCaco were used. Degradation products 
were identified by NMR and X-ray crystallography and the order of reaction kinetics was determined. 
Solubility was deduced with a mathematical model encompassing dissolution and degradation kinetics 
that took into account particle size distribution of the solid material. Degradation mechanism of nobilin 
involved water catalyzed opening of the lactone ring and transannular cyclization resulting in five 
degradation products. Degradation followed first order kinetics in aq-TMCaco and FaSSIF-TMCaco and 
higher order kinetics in FeSSIF-TMCaco and the two liposomal formulations while degradation in the latter 
media was reduced. Solubility of purified nobilin increased in the order: aq-TMCaco < FaSSIF-TMCaco < 
LiposomesFaSSIF < FeSSIF-TMCaco < LiposomesFeSSIF. Improvement of stability and solubility of nobilin was 
consistent with incorporation of the molecule into colloidal lipid particles. The developed kinetic model 
is proposed to be a useful tool for deducing solubility of a highly unstable compound with a wide 
particle size distribution. 
Abstract   ii 
    
 
 
 
 
In the second study, the role of bioconversion and carrier mediated efflux of conjugation products in the 
absorption mechanism of nobilin in the Caco-2 model and the impact of the extract of Chamomillae 
romanae flos and its ingredients on bioconversion and efflux was investigated. Permeation and 
bioconversion parameter values were deduced by means of kinetic multi-compartment modeling. 
Nobilin exhibited high permeability, low absorption and fast bioconversion producing glucuronide, 
cysteine conjugate, and glutathione conjugate that were transported by P-gp (the first two), apical 
MRP2 and basal MRP3 and possibly MRP1 out of the cell. Inhibition of efflux resulted in diminished 
bioconversion and improved absorption. The extract increased the relative fraction absorbed primarily 
by directly inhibiting bioconversion but also by reducing efflux. This effect of the extract was only partly 
explained by its individual ingredients. The transport-bioconversion interplay is shown to be a possible 
mechanism for increasing absorption of a compound undergoing extensive bioconversion. Plant extracts 
may increase absorption by this mechanism in addition to metabolic enzyme inhibition.   
The focus of the third study was the effect of biorelevant media and two lipid based formulations 
(SMEDSS1 and SMEDDS2) on in vitro absorption of nobilin applied as a pure compound or as a full 
ethanolic extract of Chamomillae romanae flos. Permeation and bioconversion parameters were 
deduced by means of kinetic multi-compartment modeling. FaSSIF-TMCaco reduced apical efflux of all 
conjugates but did not affect nobilin absorption while FeSSIF-TMCaco increased absorption which was 
attributed to the increased chemical stability in the medium and decreased bioconversion while 
permeability coefficient was also decreased. SMEDDS1 increased and SMEDDS2 decreased absorption 
due to a decrease and an increase of bioconversion, respectively, although both formulations improved 
chemical stability and decreased permeability coefficient. The effect of FeSSIF-TMCaco, SMEDDS1, and 
SMEDDS2 is consistent with an incorporation of nobilin into colloidal lipid particles while FeSSIF-TMCaco, 
SMEDDS1 appeared to inhibit and SMEDDS2 to promote enzymatic reaction in the cell. In combination 
with the extract, no additional effect was observed. Formulation and transport media influence, 
therefore, in vitro absorption by changing bioconversion, chemical stability and permeation parameters. 
This work gives an insight in the absorption mechanism of nobilin and shows the effect of 
physicochemical and biochemical processes on absorption and possibilities to improve it. With multi-
compartment modeling simultaneous processes which took place during absorption were unraveled and 
their contribution to absorption was elucidated. This technique allowed studying the effect of external 
factors such as inhibitors of transporters, plant extract, formulations, and biorelevant media on 
individual processes, on the interplay between these processes and further on the entire absorption 
mechanism. The work contributes towards raising the awareness that intestinal absorption is a complex 
puzzle of different processes which can be influenced by external factors and which bear a high 
potential for interaction.  
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Chapter 1 
 
Introduction 
 
1.1  BACKGROUND 
Per oral administration is the most convenient way of systemic application of a pharmacologically active 
compound. To reach satisfactory bioavailability, good absorption in the small intestine is required. 
Several factors may limit absorption such as chemical instability and poor solubility of the drug in the 
gastrointestinal tract, bioconversion by metabolizing enzymes, low permeation by diffusion and carrier 
mediated epithelial efflux transport at the plasma membrane of enterocytes.1,2  
Chemical stability and solubility in the gastrointestinal tract are influenced by the aqueous environment, 
the pH range of 1 to 8 and ingredients such as bile salts, phospholipids, digestive enzymes, food 
components, and digestion products.1,3 The biopharmaceutics classification system (BCS) classifies 
compounds with respect to intestinal absorption based on their intestinal permeability and their 
solubility4 whereas solubility of the largest dose strength in 250 mL or less of purely aqueous media over 
the pH range of 1 to 7.5 defines a highly soluble compound.5 Several drug compounds do not fulfill this 
requirement including danazol, mefenamic acid, ketoconazole, glyburide, troglitazone, atovaquone, 
sanfetrinem cilexetil, dantrolene, indinavir, saquinavir, sirolimus, albendazole, 9-nitrocamptothecin, and 
curcumin.6-21 Additionally, chemical instability in the gastrointestinal tract has been reported to 
compromise absorption such as for curcumin or sirolimus.14,15 Issues of poor stability of a compound are 
frequently accompanied by low solubility. Penicillins, for instance, show pH dependent degradation and 
solubility with a maximum stability and lowest solubility at pH 6-7.22,23  
In recent years, components of the gastrointestinal tract were considered in connection with food effect 
on absorption. The bioavailability of the poorly water-soluble drug danazol, for example, was found to 
be increased by food whereas its solubility was increased by micelles of bile salts, phospholipids, and 
lipolysis products.10,11,16,20 Food effect has become the subject of a guidance for the industry issued by 
the FDA.24 Therefore, several attempts have been made to develop biorelevant media to simulate the 
conditions in the intestine in the fasted and fed state.1,6,7,16,25,26 An in vitro-in vivo correlation between in 
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vivo bioavailability and in vitro dissolution using these media was seen.7-9,16-18,25,27 Recently, biorelevant 
transport media for in vitro absorption studies with the Caco-2 cell model simulating intestinal fluid in 
the fasted and the fed state, FaSSIF-TMCaco and FeSSIF-TMCaco, respectively, were developed.
12 The 
influence of these media on solubility and stability is essential for their role in drug absorption. 
Enterocytes, which constitute the barrier in the intestinal tract between the intestinal fluid and the 
blood circulation, show high level of apical and basal membrane transporters and metabolizing 
enzymes. Paclitaxel, digoxin, verapamil, and fexofenadine are some of the drugs that are transported 
apically out of the intestinal cell by the well characterized transporter protein P-gp (P-glycoprotein, 
ABCB1).28-30 Fexofenadine is in addition substrate of the apical MRP2 (multidrug resistance protein, 
ABCC2) and the basal MRP3 (ABCC3).28,30 Methotrexate, further, is substrate of the apical MRP2, and 
BCRP (breast cancer resistance protein, ABCG2) and the basal MRP3, and MRP1 (ABCC1).28,31 
Fexofenadine is not only substrate of efflux carriers but also of the influx transporter protein OATP2B1 
(organic anion transporting polypeptide, SLCO2B1) at the apical membrane.28,30  
Numerous drugs undergo phase I metabolism by different cytochrome P450 (CYP) enzymes in the 
enterocytes, e.g., verapamil and midazolam.29,32 Other drugs are substrates of phase II metabolizing 
enzymes such as the flavonoid apigenin which is glucuronidated by UDP-glucuronosyltransferase and 
sulfonated by sulfotransferase or busulfan which is conjugated by glutathione S-transferase to the 
glutathione conjugate.33,34 These metabolites are often substrates of the above mentioned efflux 
carriers. The metabolites of verapamil are transported by P-gp, apigenin glucuronide and sulfate are 
substrates of MRPs and/or BCRP and glutathione conjugates such as the endogenous leukotriene C4 are 
transported by MRPs.29,34-36 Furthermore, the influx carriers OATP transport steroid conjugates.28   
Interestingly, some cases of functional interplay between metabolizing enzymes and transporter 
proteins were observed in recent years. For instance, metabolism of K77 and sirolimus, which are 
substrates of cytochrome P450 and P-gp, was decreased by inhibition of the efflux transporter in the 
Caco-2 model whereas the inhibition did not reduce metabolism of the non P-gp substrates midazolam 
and felodipine.32,37 Also, interplay between phase II metabolism and transporters was suggested such as 
for the glucuronidation of apigenin and genistein with BCRP or glucuronidation and sulfonation of 
apigenin with MRPs.34,36,38,39 
In vitro study of intestinal absorption which can take into consideration these factors is routinely carried 
out using the Caco-2 cell culture model.40-43 This well-established and well characterized model shows a 
largely similar expression pattern of transporters and metabolizing enzymes as intestinal cells.44-46 In a 
study involving 10 different laboratories, Caco-2 cells were shown to well express the transporters P-gp, 
BCRP, MRP2, MRP3, MRP1, and OATP. In contrast to the intestine, phase I metabolizing enzyme CYP was 
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poorly expressed whereas the phase II conjugating enzymes glutathione S-transferase and  
UDP-glucuronosyltrasferase were well expressed.43 
The above mentioned factors bear a high potential of interaction between different compounds 
affecting their absorption behavior. Interaction between synthetic drugs has been extensively studied 
whereas in recent years the interest in the absorption of compounds from phytopharmaceuticals being 
multi-component mixtures has risen. Increased absorption of a compound applied as full plant extract 
was reported for instance for paclitaxel from Taxus yunnanensis, aconitine, mesaconitine, and 
hypaconitine from Aconitum species, and rosmarinic acid from Plectranthus barbatus.47-49  
The influence of formulation ingredients on absorption has been extensively discussed in recent  
years.50-52 Lipid based formulations such as self-(micro)emulsifying drug delivery systems (S(M)EDDS) 
were shown to increase absorption of several poorly water soluble drugs including cyclosporine which is 
commercially available as a lipid based formulation (Neoral®)53 and sirolimus whose stability and 
solubility was improved in the presence of D-α-tocopheryl polyethylene glycol succinate micelles or 
SMEDDS.14,54  
Nobilin, a sesquiterpene lactone of the germacranolide type is a marker compound isolated from the 
flowers of Anthemis nobilis L. called Chamomillae romanae flos.55 No reports about the chemical 
stability and solubility of this compound in the intestinal tract exist in the literature. Also, nothing is 
known about bioavailability of nobilin and the effect of food, formulation, metabolism and cellular 
transport on absorption. Further, the role of the plant extract on the absorption of nobilin is unknown.  
The increase of absorption frequently observed for plant extracts and mixtures of compounds consisting 
of food or pharmaceutical formulation ingredients is generally poorly understood. Also, the role of the 
interplay between metabolism and carrier mediated transport and its possible modulation by multi-
component mixtures has not been fully elucidated. Finally, established methodology to determine 
dissolution of chemically instable material is not available.   
1.2 OBJECTIVES 
The overall aim of this work was to investigate the intestinal absorption of nobilin in vitro and identify 
strategies for its improvement. Factors determining nobilin absorption were investigated taking into 
account chemical stability, solubility, metabolism, and membrane permeation by passive diffusion and 
carrier mediated transport in order to gain a basic mechanistic understanding of the absorption process 
of the compound. Physiologically based multi-compartment kinetic modeling was employed to delineate 
the influence of simultaneously acting phenomena. Based on this understanding, possibilities are finally 
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explored to improve absorption of nobilin utilizing plant extract, formulation, and post-prandial 
application approaches. The thesis is divided into four chapters. 
Chapter 2 provides a review on one hand of the intestinal absorption of phytopharmaceutical drugs in 
the Caco-2 model and on the other hand of the present knowledge of transporters and metabolizing 
enzymes in Caco-2 studies. Additionally, it gives a short overview of the plant Anthemis nobilis L. and its 
sesquiterpene lactone nobilin.  
Chapter 3 focuses on chemical stability and solubility of nobilin. The aim was to study mechanism and 
kinetics of degradation of purified nobilin and identify its degradation products, and, further, to 
determine the solubility of nobilin under conditions of concurrent rapid chemical degradation. To 
accomplish the latter goal, the use of a kinetic model is proposed. Moreover, the effect of media 
simulating the environment of the intestinal tract and of vehicles used in in vitro Caco-2 absorption 
studies on stability and solubility of purified nobilin was investigated. The ultimate goal was to derive a 
basic understanding of the effect of the media on stability and solubility and its consequence for the 
bioavailability of nobilin.  
The objective of Chapter 4 is the investigation of the mechanism of intestinal absorption of nobilin in the 
Caco-2 model. The first specific aim was to investigate the effect of bioconversion and of carrier 
mediated efflux of the ensuing conjugation products on nobilin absorption and to ascertain a possible 
interplay between bioconversion and efflux. A kinetic model-based approach was employed to this end. 
The second aim was to elucidate the impact of the full extract of Chamomillae romanae flos and its 
ingredients, i.e., sesquiterpene lactones, essential oil and flavonoids56 on metabolizing enzymes and 
transporter proteins that influence nobilin absorption. By unraveling the interplay between 
bioconversion and efflux and the interaction between the plant extract and nobilin or nobilin 
bioconversion products with respect to these processes, biochemical principles for absorption 
improvement of nobilin should be derived. 
The focus of Chapter 5 is the effect of biorelevant media and lipid based formulations on nobilin 
absorption taking into consideration chemical stability, bioconversion, and efflux of the conjugation 
products. The effect of the plant extract in combination with biorelevant media and lipid based 
formulations on nobilin absorption is also studied. The objective of this part of the work was to first use 
stabilization as a physicochemical approach for absorption improvement that would then be 
investigated as a means to influence biochemical processes relevant for absorption. 
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Chapter 2 
 
Theoretical section: An overview 
 
2.1  ABSORPTION OF PHYTOPHARMACEUTICALS  
2.1.1   Bioavailability of phytopharmaceuticals 
The use of phytopharmaceuticals is as old as mankind. It is estimated that nowadays there are more 
than 11,000 species used and 300 of them frequently. Approximately one third of the adults in 
developed countries and more than 80% in developing countries use phytopharmaceuticals. In the last 
years the interest in pharmacokinetics of such drugs increased but still more investigations have to be 
done to bring light into this field.1  
Most phytopharmaceuticals are orally administered but little is known about bioavailability of the 
ingredients of such drugs. They are mixtures of different compounds which show often poor 
bioavailability due to physicochemical properties, to being substrate of transporter proteins, or to being 
extensively metabolized by phase I and phase II enzymes.1  
Curcumin from Curcuma longa and hypericin from Hypericum perforatum, for example, are active 
compounds of those plants. They are poorly water soluble and curcumin is further instable at neutral 
and basic pH which results in poor bioavailability.2-4 Furthermore, polyphenols which are often present 
in their glycosylated form show poor bioavailability because of their chemical structure compared to 
their aglycones. They are hydrolyzed in the small intestine either by the brush border membrane 
enzyme lactase phloridizin hydrolase (LPH) or they are transported into the enterocytes by SGLT1 
(sodium-dependent glucose transporter, SLC5A1) where they are hydrolyzed by the cytosolic  
β-glucosidase. Later in the colon they are hydrolyzed by intestinal bacteria to the aglycone and further 
converted to phenolic acids which was reported for daidzein metabolized to equol.5  
Reduced bioavailability of phenolics was also often observed in vivo due to extensive metabolism, as 
they are substrates of phase I and phase II metabolism. Curcumin, for example, is extensively 
metabolized in vivo by the phase I metabolizing enzymes reductases and also by the phase II  
UDP-glucuronosyltransferase and sulfotransferase.1,4 Quercetin, which is widely distributed in plants, 
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such as in Hypericum perforatum, is glucuronidated and methylated or the catechin epigallocatechin 
gallate (EGCG) present in green tea is methylated and other catechins are mainly glucuronidated or 
sulfonated.5-7 Alkaloids are also metabolized, for example, berberine from Rhizoma coptidis is 
extensively demethylated (phase I) followed by glucuronidation (phase II) in vivo.8  
Berberine was further shown in vivo to be substrate of the efflux transporter protein P-gp  
(P-glycoprotein, ABCB1) and some flavonoids were reported to be transported by P-gp, BCRP (breast 
cancer resistance protein, ABCG2), and MRPs (multidrug resistance proteins, ABCC).9,10 11,12 
Considering all those mechanisms which influence bioavailability it is not surprising that interactions 
occur between the ingredients of a phytopharmaceutical that alter bioavailability. The aqueous 
solubility of hypericin for example was increased with pure dimeric procyanidin B2 and trimeric 
procyanidin C1.3 It was suggested that also other polyphenols of the plant extract have an influence on 
solubility.13 This mechanism was proposed to be the reason of increased bioavailability in rats by 
administering hypericin with proanthocyanidin or quercetin glycoside.14 Another example is the 
increased bioavailability of ascorbic acid in citrus fruits which is supposed to be due to flavonoids in the 
extract that increase absorption and stability of ascorbic acid. Bioavailability of Kavain was improved by 
a special extract from Kava-kava and also absorption of gitoxin in a fraction of Digitalis purpurea extract 
could be increased.15  
This high potential of interaction of natural products was also recognized by administering them with 
commercial synthetic drugs. Probably the two best known examples of such natural products are 
grapefruit juice and Hypericum perforatum. Grapefruit juice inhibits cytochrome P450 3A4, the influx 
transporters OATPs (organic anion transporting polypeptide), and efflux carrier P-gp. Bioavailability of 
felodipine which undergoes first-pass metabolism by CYP 3A4 was increased with grapefruit juice. This 
interaction was extensively studied in the last years and many drugs were identified to interact with 
grapefruit juice.16 The inhibitory effect of grapefruit juice on P-gp using the substrate digoxin was not 
seen in vivo but the inhibition of the influx transporter increased bioavailability of talinolol.17,18 
Hypericum perforatum was reported to induce CYPs (mainly the subfamily 2C and 3A) and P-gp which 
resulted in a decreased bioavailability of CYP and P-gp substrates such as digoxin or simvastatin.19-21 
Other plants for which herbal-drug interactions were reported are, for example, Crataegus 
monogyna/osyacantha, Valeriana officinalis, and Silybum marianum.20,22,23 As a consequence of herbal-
drug interaction also herb-herb interaction can occur which is of great interest in traditional Chinese 
medicine.24  
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2.1.2   Absorption of phytopharmaceuticals in the Caco-2 model 
The Caco-2 cell monolayer is a well-established and well characterized in vitro intestinal absorption 
model to study routinely in vitro absorption of synthetic drugs.25-28 Therefore, it is also a useful tool to 
study absorption of phytopharmaceuticals.29 A more detailed description of the Caco-2 cells regarding 
carriers and metabolizing enzymes is given below. 
2.1.2.1   Absorption of single phytopharmaceutical compounds 
The increased interest in elucidating absorption processes of phytopharmaceutical compounds is 
reflected in the increasing numbers of published Caco-2 studies with isolated compounds in the last 
decade. Transport processes by passive diffusion and carriers, and metabolism were elucidated with 
Caco-2 cells.  
Numerous investigations were carried out with polyphenols which are widely spread in plants. In a study 
involving 36 different flavonoids only five were proposed to be substrate of efflux transporters and the 
rest was assumed to be absorbed by passive diffusion in the Caco-2 model.30 Naringin, for example, is 
substrate of P-gp and morin of MRPs whereas apigenin crosses the monolayer by passive diffusion.31-33 
Furthermore, the well-known extensive metabolism of flavonoids was studied. Apigenin, for instance, is 
extensively metabolized to glucuronides and sulfates which are further substrates of MRP2 (multidrug 
resistance protein, ABCC2).33 A similar observation was reported for emodin which is glucuronidated and 
the metabolites are transported by MRPs.34 Also inhibitory and inductive properties of polyphenols on 
transporter proteins and metabolic enzymes were investigated. The efflux transport of 2-amino-1-
methyl-6-phenylimidazol[3,4-b]pyridine (PhIP) by P-gp, BCRP, and MRP could be decreased in presence 
of flavonoids quercetin, apigenin, luteolin, naringenin, and myricetin.35-37 Luteolin further inhibited the 
apical efflux of benzo[a]pyrene by BCRP, quercetin the efflux of N-acetyl 5-aminosalicylic acid (Ac-5-ASA) 
by MRP2, and naringenin, quercetin, genistein, and xanthohumol reduced P-gp mediated transport of 
cimetidine.38-40 Also influx transporters such as MCT1 (monocarboxylic acid transporter 1, SLC16A1) 
were reported to be inhibited by flavonoids.41 Furthermore, inductive effects on transporter proteins 
such as P-gp, BCRP, and MRP and stimulated apical efflux were observed in the presence of polyphenols 
in Caco-2 cells.42-45   
Inhibition of metabolizing enzymes such as sulfotransferases by epigallocatechine gallate and other 
polyphenols, CYPs by certain polyphenols of apple juice and luteolin, and esterase by grapefruit juice 
flavonoids kaempferol and naringenin was documented.38,46-49 Induction of  
UDP-glucuronosyltransferases was observed in presence of quercetin and induction of CYPs was seen 
with polyphenols of apple juice and flavone.45,48,50,51        
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Besides polyphenols other phytopharmaceutical compounds were reported being investigated with    
Caco-2 cells with respect to their transport mechanism, metabolism, inhibitory and inductive activity. 
Examples include alkaloids such as berberine, sinomenine, different terpenoids and steroids involving 
carotenoids and gingsenosides, further phenolic compounds such as curcumin, furanocoumarin 
derivatives, or isothiocyanate like sulforaphane.10,50,52-57   
2.1.2.2   Influence of plant extracts on absorption of phytopharmaceutical compounds 
Beside the rising interest in the absorption profile of single phytopharmaceutical compounds also the 
awareness of the effect of the full extract on absorption of those compounds has risen in the last years. 
This is shown by the increasing numbers of published Caco-2 studies on this topic even though their 
quantity is still quite small. Table 1 shows reported Caco-2 studies addressing the influence of one or 
two extracts on absorption of their phytopharmaceutical compounds.  
Paclitaxel which is a potent anticancer drug of Taxus yunnanensis is poorly bioavailable in vivo due to 
being substrate of P-gp and CYP3A. The Caco-2 study showed that the extract increased absorption of 
paclitaxel and had a similar effect on P-gp as the commonly used inhibitor verapamil.58 Echinacea 
saguinea and Echinacea pallida are used to prevent upper respiratory tract infections associated with a 
cold and influenza. Bauer alkamide 8, 10, and 1, and ketone 24 were assumed to be active compounds 
of the extracts whereas alkamide 8 and 10 showed poor bioavailability in vivo. They were absorbed in 
the Caco-2 model by passive diffusion and metabolized to glucuronides. The extract did not have an 
effect on the absorption of the compounds but stimulated glucuronidation and increased basal transfer, 
apart from alkamide 11 glucuronide, which was proposed to be due to regulation of transporter proteins 
expression.59 The three alkaloids aconitine, mesaconitine, and hypaconitine are active compounds of 
Aconitum species. Their absorption was increased by the plant extract which was assumed to be due to 
P-gp inhibition.60 Prunella vulgaris and Salvia officinalis are traditionally used against inflammation in the 
mouth. Rosmarinic acid present in Prunella vulgaris and ursulic acid in Salvia officinalis were reported to 
be poorly absorbed in vivo in combination with other plant extracts. In the Caco-2 study both 
compounds crossed the monolayer by passive diffusion and were metabolized to glucuronides and 
sulfates. The extract of Salvia officinalis and Prunella vulgaris did not influence their absorption and 
metabolism.61 However, inhibition of the apical efflux of rosmarinic acid was suggested with the extract 
of Plectranthus barbatus in the Caco-2 model.62 Artemisia afra is used against respiratory illnesses and 
contains luteolin which showed an increased bioavailability in monkeys when administered as extract. It 
was proposed that luteolin was absorbed by passive diffusion and also influx and efflux transporters 
could be involved in Caco-2 cells. Luteolin was extensively metabolized in the cells to luteolin 
monoglucuronide, sulfate, monoglucuronide sulfate, and methylated luteolin sulfate which were 
substrates of MRPs. Additionally, the study suggested that glycosylated luteolin (luteolin-7-O-glucoside) 
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was transported by SGLT into the cell where it was either hydrolyzed to luteolin which was further 
metabolized to the four metabolites or it crossed the basal membrane by an unknown transport 
process. Interestingly, the extract increased the uptake of luteolin and luteolin-7-O-glucoside and the 
metabolism in the cell to luteolin monoglucuronide, sulfate, and monoglucuronide sulfate whereas no 
luteolin and luteolin-7-O-glucoside was found in the basal compartment. The same observation was 
made with an acid-hydrolyzed extract of Artemisia afra containing only luteolin.63 Mulberry (Morbus 
alba L.) contains 1-deoxynojirimycin which is an α-glucosidase inhibitor. It crossed the Caco-2 monolayer 
in its intact form whereas in presence of the extract a slower permeation was observed.64 Red clover 
(Trifolium pratense) is used, for example, as menopausal hormone replacement therapy. Its ingredients 
formononetin and biochanin A are absorbed and metabolized to glucuronides and to a smaller amount 
to sulfates which were excreted to both compartments whereas more formononetin was detected in 
the basal compartment and to a similar amount in the apical compartment compared to biochanin A. In 
presence of the extract no formononetin conjugates were found, the apical excretion of biochanin A was 
increased, and no sulfates were formed but these observations did not have an effect on absorption.65 
Danggui Buxue Tang is a combination of Astragali radix and Angelicae sinensis radix in traditional 
Chinese medicine to treat menopausal symptoms. The absorption of formononetin and calycosin 
compounds of Astragali radix was not increased by the extract of this plant whereas in combination with 
Angelicae sinensis radix extract an improvement was observed which was proposed amongst other to 
be due to reduced efflux in the Caco-2 model.66  
Several commercial products of Hypericum perforatum are available to treat mild to moderate 
symptoms of depression. Rutin, hyeroside, and isoquercitrin are phenolic glycoside of Hypericum 
perforatum which are transported in the Caco-2 model mainly from the apical-to-basal (rutin and 
hyperoside) or basal-to-apical (isoquercitrin) direction. The commercial products increased the transport 
from rutin and hyperoside form basal-to-apical. This observation was attributed to an increased apical 
efflux by MRP2 due to ingredients of the products. Interestingly, the three used products alternated the 
transport differently which was probably a result of the different composition of ingredients.67 A similar 
observation was made for daizein, genistein, formononetin, and biochanin A in 6 products of red clover 
(Trifolium pratense). The absorption rate of the four isoflavones, the glucuronidation of biochanin A, and 
the efflux of its metabolites was differently affected by the 6 products which was also supposed to be a 
result of the different compositions of the products.68   
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Table 1: Influence of plant extracts on absorption of phytopharmaceutical compounds in the Caco-2 model. 
Plant extracts Compounds Effects of the extract in Caco-2 model Year published 
One extract    
Taxus yunnanensis paclitaxel apical efflux  ↓ 
absorption ↑ 
2013
58
 
Echinacea saguinea  Bauer alkamide 8 
Bauer alkamide 10 
Bauer alkamide 11 
Bauer ketone 24 
glucuronidation ↑ 
basal transfer of glucuronides ↑ 
  (apart from alkamide 11 glucuronide) 
absorption = 
2013
59
 
Echinacea pallida Bauer alkamide 8 
Bauer alkamide 10 
Bauer alkamide 11 
Bauer ketone 24 
glucuronidation ↑ 
basal transfer of glucuronides ↑ 
  (apart from alkamide 11 glucuronide) 
absorption = 
2013
59
 
Aconitum species aconitine 
mesaconitine 
hypaconitine 
apical efflux  ↓ 
absorption ↑ 
2012
60
 
Prunella vulgaris rosmarinic acid metabolism = 
absorption = 
2011
61
 
Plectranthus barbatus rosmarinic acid 
 
apical efflux ↓  
absorption ↑ 
2012
62
 
Salvia officinalis ursolic acid metabolism = 
absorption = 
2011
61
 
Artemisia afra luteolin uptake into the cell ↑ 
metabolism ↑ 
absorption ↓ 
2010
63
 
Morbus alba L. 1-deoxynojirimycin absorption ↓ 2010
64
 
Trifolium pratense L. formononetin 
biochanin A 
glucuronidation ↓ (formononetin) 
apical excreation of glucuronides ↑ 
(biochanin A) 
sulfonation ↓ 
absorption = 
2004
65
 
Two extracts    
Astragalus membranaceus 
var.mongholicus and     
Angelicae sinensis  
formononetin 
calycosin 
absorption ↑ 
  (with Angelicae sinensis) 
2012
66
 
Commercial products    
Hypericum perforatum rutin 
hyperoside 
apical efflux  ↑ 
absorption ↓ 
2010
67
 
Trifolium pratense L. daizein  
genistein 
formononetin 
biochanin A 
absorption  ↑ ↓ 2008
68
 
↑: increasing effect, ↓: decreasing effect, = no effect 
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2.1.2.3   Influence of plant ingredients on absorption of phytopharmaceutical compounds 
There is a great interest in elucidating interactions between specific phytopharmaceutical compounds of 
one plant or two different plants which is supported by the large number of reported Caco-2 studies on 
this topic. Some examples are given in Table 2. 
The first four examples, in Table 2, show the influence of one or more phytopharmaceutical compounds 
on the absorption of another compound of the same plant. The apical efflux of curcumin was inhibited 
by the combination of α-tumerone and aromatic tumerone. This effect was attributed to α-tumerone 
which inhibited P-gp and possibly also other efflux transporters.69 Influence of 9 different flavonoids on 
hesperetin metabolism (glucuronidation, sulfonation) and efflux of its conjugates decreased metabolism 
in the cell and apical efflux of metabolites probably due to BCRP inhibition, and increased the basal 
transport of metabolites. Further, in combination with quercetin it was shown that the total amount of 
hesperetin was increased. It was suggested that by reduction of metabolism absorption of hesperetin 
could be increased.70 Also the transport of rosmarinic acid was influenced by flavonoids. It was proposed 
that the combination of luteolin and apigenin reduced the apical uptake by MCT and the apical efflux of 
rosmarinic acid by ABC transporters in a concentration dependent manner of the flavonoid composition 
which resulted in an increased absorption.62 Involvement of apical efflux inhibition of hypericin of 
Hypericum perforatum by seven different polyphenolic compounds of Hypericum perforatum was also 
suggested for the increased absorption of hypericin.13,71   
The second group in Table 2 deals with the influence of mixtures of compounds of one plant on each 
other’s absorption. Increased absorption was reported for all three flavones baicalein, wogonin, and 
oroxylin A by administering them as a mixture which was attributed to a metabolic competition 
(glucuronidation and sulfonation).72 The co-administration of the three alkaloids aconitine, 
mesaconitine, and hypaconitine resulted in the inhibition of their own apical efflux by P-gp and 
therefore showed an increased absorption. Interestingly, the effect was not as strong as with the 
extract.60 Quercetin and isorhamentin (3'-O-methylquercetin) are compounds of Hippophae rhamnoides 
or Gingko biloba whereas the latter is a metabolite of quercetin formed in plants and humans by 
catechol-O-methyltransferase (COMT). The combination of those compounds increased absorption of 
each other which was ascribed to inhibitory effects of them on efflux transporters such as P-gp whereas 
other transporters might be involved as well. Reduced methylation of quercetin in the presence of the 
metabolite isorhamentin was also discussed and was assumed to play a negligible role.73  
Finally, the last group shows that a compound of one plant can influence absorption of a substance of 
another plant. The given examples indicate that this interaction is of great interest in the field of 
traditional Chinese medicine. Puerarin is an active compound of Pueraria labota and is often prescribed 
as a drug pair with Angelicae dahuricae in traditional Chinese medicine. The combination of puerarin in 
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the extract with total cumarine and/or essential oil of Angelicae dahuricae increased absorption of 
puerarin which was probably due to decreased activity or expression of P-gp and/or MRP.74 A similar 
effect of total cumarine and/or essential oil of Angelicae dahuricae was observed on the absorption of 
baicalin in Radix scutellariae extract. It was improved as an effect of opening tight junctions and 
inhibition of function and expression of MRP.75 The absorption of formononetin and calycosin in the 
extract of Astragalus membranaceus var. mongholicus was described above to be improved by the 
extract of Angelicae sinensis. The combination of Astragalus membranaceus var. mongholicus extract 
with two compounds of Angelicae sinensis extract showed that ferulic acid increased absorption of 
formononetin and calycosin, and ligustilide decreased it. It was assumed that ferulic acid inhibited apical 
efflux transport and ligustilide induced it.66 The transport of the saponines notoginsenoside R1, 
ginsenoside Rg1, and ginsenoside Re was increased in both directions by co-administering each of them 
with borneol. This effect was explained by loosening the tight junctions.76 A reduced absorption of 
baicalein was observed in the presence of berberine. The apical-to-basal transport was reduced by 
bernerine and decreased baicalein and baicalin (glucuronide of baicalein) concentrations were detected 
in the basal compartment which suggested inhibition of the uptake into the cell.77  
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Table 2: Influence of plant ingredients on absorption of phytopharmaceutical compounds in the Caco-2 model. 
One plant Influenced 
compound 
Influencing 
compound 
Effects in Caco-2 model year  
published 
Curcuma longa  curcumin α-tumerone 
ar-tumerone 
apical efflux  ↓ 
absorption ↑ 
  (in combination and with 
  α-tumerone)  
2012
69
 
Not mentioned hesperetin 9 flavonoids 
 
apical efflux ↓ 
  (of metabolites) 
metabolism ↓ 
total amount ↑ 
2010
70
 
Plectranthus barbatus rosmarinic acid luteolin 
apigenin 
apical efflux/influx  ↓  
absorption ↑ 
2012
62
 
Hypericum perforatum hypericin 7 phenolics  apical efflux  ↓ 
absorption ↑ 
2006
13
/2010
71
 
 Mixture of compounds   
Scutellariae baicalensis baicalein 
wogonin 
oroxylin A 
 metabolism ↓ 
absorption ↑ 
  (of every compound) 
2012
72
 
Aconitum species aconitine 
mesaconitine 
hypaconitine 
 apical efflux  ↓ 
absorption ↑ 
  (of every compound) 
2012
60
 
Hippophae rhamnoides 
or Gingko biloba 
quercetin 
isorhamentin (3'-O-methylquercetin) 
apical efflux  ↓ 
absorption ↑ 
  (of both compounds) 
2008
73
 
Two plants 
(plant 1 and plant 2) 
Influenced 
compound plant 1 
Influencing 
compound plant 2 
  
Pueraria labota and 
Angelicae Dahurica 
puerarin 
  (in extract) 
coumarins  
essential oil 
apical efflux  ↓ 
absorption ↑ 
  (in combination and with 
the single compounds) 
2012
74
 
Scutellariae baicalensis 
and Angelicae 
dahurica  
baicalin 
  (in extract) 
coumarins  
essential oil 
apical efflux ↓ 
tight junctions ↓ 
absorption↑ 
  (in combination and with 
the single compounds) 
2013
75
 
Astragalus 
membranaceus var. 
mongholicus and     
Angelicae sinensis  
formononetin 
calycosin 
  (in extract) 
ligustilide 
ferulic acid 
absorption ↓ 
  (with ligustilide) 
absorption ↑ 
  (with ferulic acid) 
2012
66
 
Panax notoginseng 
and Blumea 
martiniana 
notoginsenoside R1 
ginsenoside Rg1 
ginsenoside Re 
borneol tight junction ↓ 
absorption ↑ 
 
2013
76
 
Scutellariae baicalensis 
and Coptis chinesis 
baicalein berberine absorption ↓ 
 
2009
77
 
↑: increasing effect, ↓: decreasing effect, = no effect 
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2.1.2.4   Advantages and difficulties in determining absorption of pharmaceuticals with the Caco-2  
               model 
The above mentioned examples show that the extract has often an effect on absorption but it is very 
difficult to elucidate the mechanism and to determine the compounds which are responsible. There are 
mainly two reasons for this problem. Firstly, many compounds of the extract show a complex absorption 
behavior which is due to a complex transport mechanism by diffusion and carriers, metabolism, and 
being inhibitors and inductors of carriers and metabolizing enzymes. These properties bear a high 
potential of interaction with other compounds. The second problem is the extract itself. It is a mixture of 
many phytochemicals which are not all fully identified. Therefore, it is very difficult to discover the 
compounds which have an effect on absorption. Regularly single compounds, mixtures of substances 
like flavonoids, or ingredients such as essential oils are used to identify the compounds which affect 
absorption. Often these results give only a suggestion but do not fully explain the effect of the extract. 
Mostly the combination of all ingredients is proposed to elicit the effect of an extract. Additionally, it has 
to be noted that the phytochemical profile of one plant can differ, for example, between batches of this 
plant or different extraction techniques. Therefore it is not surprising that different extracts of one plant 
can have diverse effects on absorption as it was discussed above for Hypericum perforatum.  
To predict intestinal absorption governed by several processes, a model which comprises these 
processes has to be used. Caco-2 cells fulfill this requirement by expressing similar metabolizing 
enzymes and carriers as the human intestine.78-80 However, it is difficult to distinguish between all those 
processes and how much they contribute to absorption with the Caco-2 model. Inhibitors, especially of 
transporters, can help to provide clarification, particularly in the elucidation of the absorption process of 
a single compound. It becomes more difficult in the presence of multi-component systems like the 
above mentioned extracts and mixtures of compounds or combinations of compounds especially if they 
show a complex absorption behavior. Often the underlying mechanisms are guessed or assumed due to 
multiple interaction possibilities and lack of knowledge of the composition of the extract. Nevertheless, 
the Caco-2 model reflects reality very well and is therefore one of the best in vitro model to detect and 
predict effects of extracts on absorption due to inter- and intra-herb interactions. 
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2.2  CARRIER MEDIATED TRANSPORT AND METABOLISM IN THE CACO-2 MODEL 
2.2.1   Carrier mediated transport in the Caco-2 model 
2.2.1.1   Human enterocytes vs. Caco-2 cells 
Enterocytes 
The enterocytes in the gastrointestinal tract express different efflux and influx transporter proteins 
which carry a drug in or out of the cells. They are asymmetrically located at the apical or basal 
membrane and divided into two superfamilies ATP-binding cassette (ABC) for efflux transporters and 
solute carrier (SLC) for influx transporters (Scheme 1). The transporters, which are considered as the 
clinically most important from the international consortium of transporters, are at the apical side P-gp 
(P-glycoprotein, MDR1, ABCB1), BCRP (breast cancer resistance protein, ABCG2), MRP2 (multidrug 
resistance protein 2, ABCC2) and at the basal side MRP3 (ABCC3). Influx transporters are at the apical 
membrane one or more members of the organic anion transporting polypeptide (OATP) family, PEPT1 
(peptide transporter 1, SLC15A1), ASBT (ileal apical sodium/bile acid co-transporter, SLC10A2), and 
MCT1 (monocarboxylic acid transporter 1, SLC16A1) and at the basal membrane OCT1 (organic cation 
transporter 1, SLC22A1) and the heteromeric organic solute transporter (OSTα-OSTβ).81 Interestingly, a 
recent study showed that OCT1 is localized at the apical membrane of Caco-2 cells and enterocytes and 
not at the basal membrane as assumed since 2001.82 This finding is important for the reason that 
different reviews and also the FDA guidance for the industry state that OCT1 is located at the basal 
membrane.81-84 
 
 
Scheme 1: Transporters of the intestinal epithelia are P-gp (P-glycoprotein, ABCB1), BCRP (breast cancer resistance protein, 
ABCG2), MRP2 (multidrug resistance protein, ABCC2), MRP3 (ABCC3), one or more members of the organic anion transporting 
polypeptide (OATP) family, PEPT1 (peptide transporter 1, SLC15A1), ASBT (ileal apical sodium/bile acid co-transporter, 
SLC10A2), MCT1 (monocarboxylic acid transporter 1, SLC16A1), OCT1 (organic cation transporter 1, SLC22A1), and the 
heteromeric organic solute transporter (OSTα-OSTβ).
81 
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These transporters show different but also overlapping substrate specificities. P-gp transports mainly 
hydrophobic molecules which are often cationic. BCRP is proposed to transport molecules with one 
amine bonded to one carbon of a heterocyclic ring, molecules with fused heterocyclic ring(s) and two 
substituents on a carbocyclic ring of the fused heterocyclic ring(s) such as protein kinase inhibitors, for 
example, imatinib or phytoestrogens like genistein, and phase II metabolites such as glucuronides, 
glutathione conjugates, and sulfates.81,85 MRPs were reported to transport hydrophilic compounds 
including phase II metabolites like glucuronides, glutathione conjugates, and sulfates.85 OATPs show a 
wide substrate specificity of amphiphilic organic compounds such as glucuronides, bile acids, sulfates, 
and anionic peptides.81 PEPT1 transports small peptides and drugs with peptide like structures such as  
β-lactam antibiotics.86 MCT transports monocarboxylates, for example, salicylic acid.87,88 ASBT is 
responsible for the uptake of bile acids and sterols and OSTα-OSTβ for the efflux of them at the basal 
membrane.86,89 OCTs transport relatively hydrophilic cations with a low molecular mass like metformin.81 
Caco-2 cells 
Caco-2 cells show a similar expression pattern of transporters as the human intestinal cells.78,80,90-92 
Figure 1 illustrates that mainly the ABC transporters P-gp (MDR1), BCRP, MRP2, and MRP3 and the SLC 
transporters HPT1, PEPT1, MCT1, MCT5, OCTN2, IBAT (Ileal sodium/bile acid co-transporter, SLC10A2), 
and OATP2B1 (OATP-B) were expressed in Caco-2 cells. Compared to human jejunum the expression 
level especially of P-gp, MRP2, BCRP, and PEPT1 was lower and that of HPT1 (human peptide transporter 
1, CDH17) and OATP2B1 increased.78 In a study involving Caco-2 cells of 10 different laboratories it was 
shown that the important transporters represented in Scheme 1 were expressed in the following order: 
MRP2, OATP2B1, ASBT > P-gp, MRP3, BCRP, OSTα, PEPT1, MCT1, > OSTβ, OCT. Furthermore, high levels 
of HPT1, GLUT3 (facilitated glucose transporter, SLC2A3), and GLUT5 (SLC2A5) were expressed.28 
 
 
Figure 1: Relative transporter gene expression levels of ABC (left panel) and SLC (right panel) transporters in 16 day old Caco-2 
cells (light grey bars), human tissues isolated from jejunum mucosa (dark grey bars). * absence of gene expression.
78
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Transporter expression in Caco-2 cells depends on the culture time and passage number. An increase in 
P-gp, BCRP, MRP2, OATP2B1, and PEPT1 was observed during culture time which reached a plateau 
after 21 days post seeding.80,93 The effect of passage number was mainly investigated on nutrient 
transporters such as glucose transporter and only little is known about xenobiotic transporters. Cells 
which were treated with the P-gp inducer vinblastine showed that P-gp expression and function was 
reduced between passages 29 through 49.94 Also BCRP was observed to be expressed in a lower level 
between passages 36 through 56.95 Therefore, it was proposed to carry out transport experiments 
around 21 days post seeding with cells within 10 passage numbers.26 
2.2.1.2   Experimental approach to study carrier mediated transport 
In vitro absorption studies with Caco-2 cells are carried out in transwell™ plates with polycarbonate 
membranes on which the cells grow. The substance of interest is either added to the apical or basal 
compartment corresponding to the transport direction from apical-to-basal (absorptive transport) or 
from basal-to-apical (secretory transport). The change of concentration in the compartments is 
observed as a function of time.96  
 
 
Scheme 2: A) Unidirectional single barrier model: Transport process is modeled as a unidirectional process from the apical to 
the basal or from the basal to the apical compartment across a single barrier (arrows indicate the transport direction).               
B) Compartment modeling: Transport process is modeled as a combination of different processes from the apical to the basal 
or from basal to the apical compartment whereas the monolayer is considered as a compartment (arrows indicate an example 
of different processes during both transport directions).
97
 
 A common approach to analyze permeation data is the "unidirectional single barrier model"        
(Scheme 2).97 The concentration of the drug is measured in the receiver compartment as a function of 
time and an apparent permeability coefficient Papp is calculated by the following equation which is based 
on the Fick's first law of diffusion. 
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where, J is the flux, X is the measured mass, C0 is the initial concentration, A is the surface area, and t is 
time. Papp values are typically calculated for both transport directions. The first indication of involved 
transporter proteins or metabolism might be indicated by a change of Papp values by using different 
initial concentrations. A common method to elucidate the contribution of transporters is by calculating 
the efflux ratio (ER). 
 
   
      
      
                                                                                                                                                           
 
where, Papp,AB is the permeability coefficient for the transport direction from apical-to-basal and Papp,BA 
from basal-to-apical. A calculated ER of > 2 shows that a drug is substrate of an efflux transporter.26,96,97 
To evaluate which transporters are involved and if a transport is increased or reduced in one direction 
inhibitors of specific transporters are used and the absorptive quotient (AQ) was proposed. 
 
   
            
     
                                                                                                                                           
 
where, PPD,AB is the permeability coefficient in presence of an inhibitor.
98 The AQ values reach from 0 
through 1 which denotes no transport by efflux carriers up to complete transport by efflux transporters. 
A drug with AQ > 0.3 is suggested to be a substrate of an efflux transporter.99 
To elucidate different parallel processes, compartment modeling was introduced for analyzing 
permeation data of Caco-2 experiments several years ago which leads to a better mechanistic 
understanding of the absorption process (Scheme 2). Parameters of the different processes can be 
defined and values deduced which allow a quantitative evaluation of the involved mechanisms during 
absorption.97 One of the first compartment model which was reported included passive diffusion and 
apical efflux by P-gp of digoxin and vinblastine across MDCK cell monolayer.100 It considered three 
compartments and explained the data better than the "unidirectional single barrier model". Other 
models are similar or more complex including possible location and binding site, Michaelis-Menten type 
concentration-dependent function or distinguish between the binding, transport, and dissociation rate 
of the P-gp mediated carrier.101-104 Furthermore, there are also models taking into account, for example, 
different transporters, metabolism, paracellular transport, intracellular compartments such as 
lysosomes, lipids, and mitochondria, adsorption to the plastic of the transwell™ plate, and different 
compositions of solutions in the apical and basal compartments.105-114   
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2.2.1.3   Reported transport studies 
Numerous substances were investigated in the Caco-2 model and found to be substrates of the 
important intestinal transporters shown in Scheme 1. Table 3 shows examples of elucidated transport 
processes. Most studies consider the well characterized P-gp. In recent years also other transporters 
were taken into account. 
Table 3: Substrates of carrier mediated transport, investigated in the Caco-2 model.  
Transporter Substrate Reference 
P-gp saquinavir, indinavir, nelfinavir, digoxin, verapamil, paclitaxel, 
talinolol, fexofenadine, atorvastatin, cyclosportin A, digoxin, 
doxorubicin, rhodamine 123, vinblastine, colchicine, grepofloxacin 
58,98,111,115-118 
BCRP ochratoxin A, methotrexate, rosuvastatin, estrone-3-sulfate 95,119-121 
MRP2 methotrexate, fexofenadine, grepofloxacin 95,116,118 
MRP3 fexofenadine 116 
OATPB fexofenadine, estone-3-sulfate, salicylic acid 88,116,122 
PEPT1 cephalexin, cefixime, levovirin produrgs, midodrine, amino acid ester 
prodrugs of acyclovir and zidovudine 
123-127 
MCT1 atorvastatin, butyrate, salicylic acid 88,117,128 
ASBT taurocholic acid, ceftriaxone with an oral drug carrier derived from 
deoxycholic acid  
121,129 
OCT1 ranitidine, metformin, pentamidine 82,108,130 
OSTα-OSTβ taurocholic acid, estrone-3-sulfate  121 
 
2.2.2   Metabolism in the Caco-2 model 
2.2.2.1   Human enterocytes vs. Caco-2 cells 
Enterocytes 
The human intestine plays an important role in the first-pass metabolism of a drug. Enterocytes 
comprise enzymes that mediate phase I and phase II reactions.131   
Phase I 
Phase I metabolizing enzymes catalyze redox reactions and hydrolysis.132 
Cytochrome P450 (CYP): 
The most important metabolizing enzymes of phase I reactions are those of the cytochrome P450 (CYP) 
superfamily. They are haem proteins localized in the membrane of the endoplasmic reticulum and in the 
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inner membrane of mitochondria and catalyze mainly oxidation reactions of drugs. The subfamilies 
which are involved in drug metabolism are CYP1, CYP2, and CYP3. The CYP3A is the most abundant 
subfamily with 70-80% of total CYP content in the small intestine. Its major isoenzyme is CYP3A4 
followed by CYP3A5. The second most abundant family is CYP2C with about 18% of the total CYP 
content in the intestine. Major isoenzymes are CYP2C9 and CYP2C19. Furthermore, the isoenzyme 
CYP2J2, CYP2D6, CYP1A1, and CYP2E1 are reported to be expressed in small amounts only and are thus 
not considered to play a significant role in the metabolism of drugs in the small intestine.133   
Other phase I metabolizing enzymes: 
The intestine contains besides CYPs amine oxidases, xanthine oxidoreductase, peroxidases, 
dehydrogenases, reductases, and hydrolases such as carboxylesterases, β-glucuronidase, β-glucosidase, 
lactase phloridizin hydrolase (LPH).5,131,132,134-136  
One important hydrolase for drug metabolism especially for ester-containing drugs and prodrugs is the 
carboxylesterase (CES). CESs are localized in the endoplasmatic reticulum and catalyze ester cleavage 
using the co-reactant water. The CESs isozymes are classified into four groups CES1, CES2, CES3, and 
CES4 and several subgroups. The hCE-1 (CES1A1, HU1) is an isozyme of CES1 and hCE-2 (hiCE, HU3) one 
of CES2, which are the major groups of CES. hCE-2 is present in the small intestine whereas hCE-1 is 
expressed in low levels. Interestingly, hCE-1 can carry out also transesterification reactions beside 
hydrolysis of esters. Furthermore, they show different substrate specificities. hCE-1 prefers compounds 
with large acyl groups and small esterified alcohol groups whereas hCE-2 prefers small acyl groups and 
large alcohol groups.134  
Phase II 
Phase II metabolizing enzymes conjugate parent drugs or their phase I metabolites with an endogenous 
substrate to form generally better water soluble compounds with an increased molecular weight.131,137 
The three major conjugation enzymes are UDP-glucuronosyltransferase, glutathione S-transferase, and 
sulfotransferases.  
UDP-glucuronosyltransferase (UDP-glucuronyltransferase, UGT): 
UDP-glucuronosyltransferase is beside glutathione S-transferase one of the most important conjugation 
enzyme which is indicated by its broad substrate specificity such as hydroxyl groups, amines, thiols, and 
enolic acids. It is a membrane bound enzyme localized in the smooth endoplasmatic reticulum and 
catalyzes glucuronidation which includes the transfer of glucuronic acid from the co-factor uridin-5'-
diphospho-α-D-glucuronic acid (UDPGA) to the substrate. UDPGA is formed endogenously by oxidation 
of UDP-α-glucose and is present in (1α)-conformation. Due to the reaction mechanism the products are 
β-glucuronides and depending on the site of glucuronidation termed as O-, N-, S-, and C-glucuronides. 
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Glucuronosyltransferases are low affinity enzymes compared to sulfotransferases which indicates that 
glucuronidation is slower at low substrate concentration than sulfonation.137 Besides glucuronidation 
glucuronosyltransferases can also catalyze conjugation reactions with glucose and other hexoses.137 
There are four gene families UGT1, UGT2, UGT3, and UGT8 whereas UGT1 and UGT2 are involved in 
glucuronidation of drugs and showing numerous polymorphisms. UGT2 is further divided in two 
subfamilies UGT2A and UGT2B.138,139 Different UGT forms are expressed in the small intestine such as 
UGT1A1, 1A3, 1A4, 1A5, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B10, 2B11, 2B15, 2B17, and 2B28.138-140 
The expression pattern of UGT in the small intestine is similar to that of the liver apart from the main 
difference that UGT1A7, 1A8, and 1A10 are absent in the liver.138,139  
Glutathione S-transferase (GST): 
As mentioned above, glutathione S-transferase is beside UDP-glucuronosyltransferase one of the most 
important conjugation enzyme. It catalyzes the conjugation with the tripeptide glutathione (GSH) 
containing L-glutamic acid, L-cysteine, and glyzine. There are two superfamilies of glutathione  
S-transferase the microsomal GST (MGST) which are homotrimers and the cytoplasmic GST (GST) which 
are mainly homodimers with a few heterodimers. The GST is the largest family and is divided into 8 
classes: Alpha (GSTA), kappa (GSTK) (which is located in mitochondria and peroxisomes), mu (GSTM), 
omega (GSTO), pi (GSTP), sigma (GSTS), theta (GSTT), and zeta (GSTZ). 137 In the intestine mainly GSTA1, 
GSTA2, and GSTP1 are expressed and to a lower extent, also GSTM1 and GSTM3.141,142    
Sulfotransferase (SULT): 
Sulfotransferase is a cytosolic enzyme which catalyzes sulfonation (commonly termed sulfatation) of a 
substrate with a solfonate groupe (-SO3
-) by the cofactor 3'-phosphoadenylyl sulfate  
(3'-phosphoadenosine 5'posphosulfate, PAPS) to sulfates (R-O-SO3
-) or sulfamates (R-NR'-SO3
-). Around 
50 gene superfamilies of sulfotransferases are known whose products are classified into different 
families and subfamilies. The most important sulfotransferases in drug metabolism are the phenol 
sulfotransferases (SULT1), alcohol sulfotransferases (SULT2), and amine sulfotransferases (SULT3) that 
show also substrate overlaps.137 The human intestine expresses the subfamilies SULT1B1 by 36% 
(thyroid hormone sulfotransferase), SULT1A3 by 31% (monoamine-sulfating phenol transferase), 
SULT1A1 by 19% (aryl sulfotransferase 1), SULT1E1 by 8% (estrogen sulfotransferase), and SULT2A1 by 
6% (alcohol/hydrosysteroid sulfotransferase) which are considered as the most important SULTs. 
SULT1A3 is not expressed and SULT1B1 is significantly lower expressed in the liver.143-145    
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Other phase II metabolizing enzymes: 
In addition to the above mentioned enzymes methyltransferases and acetyltransferases (N- and  
O-acetyltransferases) are also found in the intestine.131,137 
Caco-2 cells 
Caco-2 cells show a similar expression pattern of drug metabolizing enzymes as the intestinal cells with 
some exceptions.  
Phase I 
Cytochrome P450 (CYP): 
Cytochrome P450 is poorly expressed in the Caco-2 model.28,79 A cross laboratory study showed that the 
major isoenzyme of the intestine CYP3A4 of the subfamily of CYP3A was not or only poorly expressed.28 
Also the isoenzyme CYP3A5 was only expressed in low levels.28 CYP2C9 and CYP2C19 of the subfamily 
CYP2C showed low to moderate expression levels whereas CYP1A2 and CYP2D6 were not found.28 
Interestingly, the isoenzyme CYP2A6 was reported to be expressed at low level whereas it is absent or 
only faintly detected in the small intestine.28,133 Also the isoenzymes CYP1A1 and CYP2E1 were reported 
to be present in the Caco-2 cells.146,147 
The expression of CYP3A4 in the Caco-2 cells can be induced by vitamin D3 (1α,25-dihydroxyvitamin D3) 
or it can by expressed through transfection of the CYP3A4 gene which allows studies involving 
metabolism by this important intestinal enzyme.148-150 
Other phase I metabolizing enzymes: 
Caco-2 cells contain other enzymes such as different hydrolases, including carboxylesterases,                  
β-glucuronidase, and lactase phloridizin hydrolase (LPH).50,151-154  
Interestingly, the cells express the hydrolases carboxylesterases hCE-1 and hCE-2 in significantly lower 
levels than the intestine. The hCE-1 is further higher expressed than hCE-2 which is exactly the opposite 
of the human intestine and similar to the expression pattern of the liver.134,155 
Phase II 
UDP-glucuronosyltransferase (UGT): 
UDP-glucuronosyltransferases activity in Caco-2 cells was found comparable to that in the intestine, 
particularly the colon.79 The cells express UGT1A1, 1A3, 1A4, 1A5, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 
2B10, 2B11, 2B15, 2B17, and 2B28, whereas the major UGTs are 1A6, 1A8, and 2B17.28,156-158  
 
Chapter 2. Theoretical section: An overview  28 
    
 
 
 
 
Glutathione S-transferase (GST): 
The activity of glutathione S-transferase is higher in the Caco-2 cells compared to the intestinal cells.79 In 
differentiated Caco-2 cells mainly GSTPA1, A2, A3, A4 and GSTP1 and GSTO1 were detected in high 
levels whereas GSTM were not or marginally expressed.28,159,160 
Sulfotransferase (SULT): 
The sulfotransferases which were found in the Caco-2 cells are SULT1A1, SULT1A2, SULT1A3, SULT1B1, 
SULT1C1, SULT1C2 and SULT2A1.28,161 The expression pattern is similar to that in the intestine, although, 
SULT1A1 and SULT1B1 were lower, SULT1C1 higher expressed, and SULT1E1 was absent in one report 
and found in another.161,162 
Other phase II metabolizing enzymes: 
N-acetyltransferase activity for Caco-2 cells was reported to be in agreement with observations in the 
human small and large intestine.79 
It was discussed above that culture time and passage number influence expression of transporter 
proteins. This is also true for metabolizing enzymes. The UGTs expression in differentiated cells (21 days 
post seeding) was increased compared to undifferentiated cells.156,157,163 Interestingly, UGT1A6 was the 
only glucuronosyltransferase which was also found in high levels in undifferentiated cells.156 Passage 
number affected UGT expression in differentiated cells and was increased at higher passages whereas 
the passage numbers varied between 43 and 130.156,164 Expression of glutathione S-transferase 
increased during culture time (between 14 and 32 days post seeding) especially of GSTAs whereas 
GSTO1 and GSTP1 remained the same.159,160 Also sulfotransferases were increasingly expressed during 
differentiation (20 days post seeding).161 No report describing the effect of passage number on GST and 
SULT expression could be found in the literature. As discussed above for carriers, these reported 
observations confirm that it is important to keep culture time and passage number constant for the 
experiment not only to assure a reproducible expression pattern of carriers but also of metabolizing 
enzymes.  
2.2.2.2   Reported studies 
Table 4 summarizes reported studies which were carried out with Caco-2 cells. They were either used as 
monolayer, for example, in a transport experiment or as cell homogenate, cell lysate, or microsomes 
made of Caco-2 cells to study the metabolism of a compound.  
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Table 4: Reported studies of metabolism in Caco-2 cells. 
Enzymes Substrate Reference 
Phase I   
CYP sirolimusa, midazolam a,b, benzo[a]pyrenea, testosteronea, K77a, 
felodipinea, b, carvedilola, b 
148-150,165-170 
esterases acetylsalicylic acidb, p-nitorophenol acetateb, temocaprila, b, 
carindacillina, phenylmethyl sulfonylfluoridea,  
2'-benzoyloxycinnamaldehydea, praeruptorin Aa, lovastatina, 
enalaprila 
49,79,171-174 
Phase II   
UGT 1-naphthola, b, raloxifeneb, carvedilola, scutellareina, apigenina, b, 
estradiolb, testosteroneb, diclofenacb, indomethacinb, oxazepamb, 
propranololb, zidivudineb, trifluoperazineb, propofolb,  
biochanin Aa, formononetina, emodina,b, benzo[a]pyrenea 
33,34,65,79,156,163,
164,175-178 
GST curcumina, benzo[a]pyrenea, 9-norbornyl-6-chloropurinea 179-181 
SULT 1-naphthola, apigenina, b, benzo[a]pyrenea, 1-cloro-2,4-
dinitrobenzeneb, raloxifenea ,b 
33,46,79,165,175,178 
acetlytransferase sulfamethazineb 79 
a
 cell monolayer , 
b
 cell homogenate, lysate, microsomes of Caco-2 cells 
 
2.2.3   Interplay between transporters and metabolizing enzymes 
As mentioned above, the formed metabolites are often substrates of efflux transporter proteins. 
Metabolites of verapamil are transported by P-gp, apigenin glucuronide and sulfates are substrates of 
MRPs and/or BCRP, and glutathione conjugates such as the endogenous leukotriene C4 are transported 
by MRPs.33,182-184 Interestingly, some cases of functional interplay between metabolizing enzymes and 
transporter proteins were observed in recent years and can be divided into two different types 
(Scheme 3).185,186 The first type can be termed parallel-metabolism interplay between transporter and 
enzyme.185 Transporter and enzyme have overlapping substrate specificity which was observed and 
extensively discussed especially for P-gp and CYPs.185,187,188 This interplay results in a larger extent of 
metabolism and a poor absorption of the substrate.185,186 Mechanistically the efflux transporter prevents 
saturation of the metabolizing enzyme leading to a prolonged exposure to the enzyme by re-permeation 
of the substrate into the cell. The second type of interplay can be termed concatenated interplay 
between transporter and enzyme.185 In this interplay, the formed metabolite is substrate of the 
transporter. The efflux transporter prevents the enzyme from substrate/product inhibition which also 
results in a poor absorption of the substrate.185,186 These interplays show a new aspect in drug 
absorption and might play an essential role whereas the impact of these interplays on in vivo intestinal 
drug absorption and therefore on bioavailability is not known at the moment.185,186  
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Scheme 3: A) Parallel interplay: The parent compound is substrate of both a metabolic enzyme and an efflux transporter. They 
both decrease the exposure to these proteins, which can prevent saturation. B) Concatenated interplay: Metabolite is an efflux 
transporter substrate and metabolism inhibitor. Efflux increases the contribution of metabolism by preventing the 
accumulation of the metabolite, thus reducing the product inhibition of metabolism.
185
 
The Caco-2 cells are a good model to study interplay between transporter and enzyme as they express 
both of them. For instance, metabolism of K77 and sirolimus, which are substrates of cytochrome P450 
and P-gp, was decreased by inhibition of the efflux transporter in the Caco-2 model whereas the 
inhibition did not reduce metabolism of the non P-gp substrates midazolam and felodipine.166,167 Also, 
concatenated interplays between phase II metabolism and transporters was observed in Caco-2 cells 
such as for the glucuronidation of apigenin, raloxifene, emodin, biochanin A , formononetin, and 
sulfonation of apigenin, and raloxifene with MRPs.33,34,65,175,186 
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2.3  ANTHEMIS NOBILIS L. 
Synonym: Anthemis chamomilla-romaona CRANTZ, Anthemis odorata LAM., Chamaemelum nobilie (L.) 
All., Chamaemelum odoratum DOD., Chamomilla nobilis GOD., Leucanthemum odoratum EID. AP., 
Lyonnetia abrotanifolia WEBB., Matricaria nobilis BAILL., Ormenis aurea R. LOWE., Ormenis nobilis J. 
GAY.189 
Anthemis nobilis L. belongs to the family of Asteraceae. It is a low growing, of about 20 to 50 cm herb 
with 2-3 pinnately divided leaves. The wild form has similar flowers as Chamomilla recutita (L.) 
RAUSCHERT, however, the flowers are bigger. The cultivated double variety of Chamaemelum nobile (L.) 
All. (Anthemis nobilis (L.)), which is used in medicine, differs in its flowers which are up to 3 cm wide, 
consisting almost exclusively of white ligulate florets (Figure 2). It is cultivated in Belgium, France, 
England, Italy, Poland, Czech Republic, northern USA, and Argentina. It originates from southern and 
western Europe (England, Belgium, France, Germany, Italy, Spain) and northern Africa (Marocco, 
Algeria) and the Azores.189,190  
 
 
Figure 2: Anthemis nobilis L. (left picture) and dried flowers of Anthemis nobilis L. (Chamomillae romanae flos) (right picture).
190
   
2.3.1   Chamomillae romanae flos (PhEur 6) 
The European pharmacopoeia describes Chamomillae romanae flos as "white or yellowish-grey, 
composed of solitary hemispherical capitula, made up of a solid conical receptacle bearing the florets, 
each subtended by a transparent small palea" (Figure 2). It has a "strong and characteristic odor" and 
should contain "minimum 7 ml/kg of essential oil (dried drug)".191 
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2.3.1.1   Chemical composition of Chamomillae romanae flos 
The chemical composition of the flowers is summarized in Table 5. Normally Chamomillae romanae flos 
contains 0.6-2.5% essential oil. It is blue after distillation and becomes brown during storage. 
Furthermore, it contains sesquiterpene lactones, organic peroxides, polyphenols, polyynes, terpenes, 
and steroids.189  
Table 5: Chemical composition of Chamomillae romanae flos.
189,190
 
Substances Ingredients 
essential oil mainly esters of angelic acid, tiglic acid, methacryl- and isobutyric acid 
with aliphatic C3-C6 alcohols like n-butanol, isobutanol, isoamylalcohol, 
and 3 methyl-pentan-1-ol 
terpenes such as α-pinen, β-pinen, α-caryophyllene β-caryophyllene, 
chamazulene, farnesene, bisabolene, cadinene, bisabolol 
sesquiterpene lactones sesquiterpene lactones of the germacranolide such as nobilin,  
3-epinobilin, 1,10-epoxynobilin, 3-dehydronobilin 
organic peroxides 1β-hydroperoxyisonobilin (germacranolide type sesquiterpene lactone), 
proazulene 4α-hydroperoxyromanolide (guaianolide type sesquiterpene 
lactone), allyl hydroperoxide 
phenolics flavonoides such as chamaemeloside and anthemoside (acylglucoside 
derivatives of flavonoid-7-glucoside with 3-hydroxy-3-methylglutaric and 
2,4-dihydroxycinnamic acid components, respectively), cosmosioside 
(apigenin-7-glucoside), luteolin-7-glucoside, and also aglycones, apiin 
(apigenin-7-apiosylglucoside), kaempferol, and several methylated 
flavonoid aglycones 
scopolin (scopoletin-7β-glucoside), scopoletin 
catechin 
glucose esters of caffeic acid  
polyynes cis-dehydro matricaria ester, trans-dehydro matricaria ester, two cis-trans-
isomeres of thiophen ester 
terpenes and steroids pentacyclic triterpenes β-amyrin and pseudo taraxasterol, β-sitosterol 
 
2.3.1.2   Use of Chamomillae romanae flos  
Chamomillae romanae flos is used in pharmacy as a herbal drug in tea mixtures especially as a 
decorative drug.189 It is used in France, England, and Germany against menstrual disorders and as 
carminative.190 Furthermore it is applied as aromatic bitter to stimulate appetite and digestion which 
was suggested to be attributed to sesquiterpenes.189,190 It can be also helpful against nervousness, 
hysteria and general weakness.189 Externally, it is applied as wound and mouth rinse, or as a lotion for 
toothaches, headaches, and pains encountered during a flu.189,190  
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A few pharmacological activities were found for Chamomillae romanae flos. The essential oil is active 
against gram-positive bacteria (Enterococcus faecalis, methicillin-resistant Staphylococcus aureus), 
gram-negative bacteria (Escherichia coli, Pseudomonas aeruginosa, Porphyromonas gingivalis), yeast 
(Candida albicans), and dermatophytes (Trichophyton mentagrophytes).189,192-195 Antimicrobial activities 
were also proposed for sesquiterpene lactones which are possibly also active against protozoa.189 
Furthermore, cytostatic effect of sesquiterpene lactones such as nobilin, 1,10-epoxynobilin, and  
3-dehydronobilin on human HeLa (cervical carcinoma cells) and KB (nasopharynx carcinoma cells) were 
reported.196-199 Also an antiagressive effect in aggressive mice, hypoglycemic activity which was 
attributed to the 3-hydroxy-3-methylglutaric acid containing flavonoids, an in vitro vasorelaxant effect 
of the aerial parts of Anthemis nobilis L., and preventive effects against sunburn and curative effects by 
regeneration of erythematous skin were observed.189,200-202  
The flowers are further used in the cosmetic industry such as to brighten of colored blond hair, as 
repellent against mosquitos and other insects, against weeds, plant pests, and plant pathogens, and as 
aroma in liqueur industry and cigarette industry.189,203-205   
2.3.2   Nobilin (CAS: 31824-11-0)206 
Nobilin (C20 H26 O5), a sesquiterpene lactone with Mr 346 and a calculated clogP of 2.572 (± 0.601)
206 is a 
marker compound of the flowers of Anthemis nobilis L. as mentioned above. It was first isolated and 
mentioned 1964 and the chemical structure was revised 1970 and 1977.196,207,208 The absolute 
configuration of nobilin was elucidated 2013, in connection with this thesis, and the proposed 
configuration from 1977 was confirmed (Figure 3).     
 
 
Figure 3: Chemical structure of nobilin with absolute configuration.
196
 
Only few studies were carried out with nobilin. Nobilin was reported 1977 to show cytostatic activity in 
HeLa and KB cells, as mentioned above.196 Recently, it was shown that sesquiterpene lactones, also 
nobilin, inhibit the c-Myb-dependent gene expression. The c-Myb is a transcription factor that regulates 
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gene expressions which are involved in proliferation, cell survival, and differentiation. Deregulation of  
c-Myb expression results in tumors such as of leukemia, breast, and colon cancer.209 Another study 
reported that a mixture of six sesquiterpene lactones, one of them was nobilin, is a useful tool to 
diagnose Asteraceae allergic contact dermatitis.210 Also the sensory property of nobilin was investigated 
by identifying nobilin as agonist of the bitter taste receptor hTAS2R46.211   
  
Chapter 2. Theoretical section: An overview  35 
    
 
 
 
 
2.4  REFERENCES 
1. He SM, Li CG, Liu JP, Chan E, Duan W, Zhou SF 2010. Disposition pathways and pharmacokinetics 
of herbal medicines in humans. Current Medicinal Chemistry  17(33):4072-4113. 
2. Mohanty C, Sahoo SK 2010. The in vitro stability and in vivo pharmacokinetics of curcumin 
prepared as an aqueous nanoparticulate formulation. Biomaterials  31(25):6597-6611. 
3. Butterweck V, Petereit F, Winterhoff H, Nahrstedt A 1998. Solubilized hypericin and 
pseudohypericin from Hypericum perforatum exert antidepressant activity in the forced swimming test. 
Planta Medica  64(4):291-294. 
4. Metzler M, Pfeiffer E, Schulz SI, Dempe JS 2013. Curcumin uptake and metabolism. Biofactors  
39(1):14-20. 
5. D'Archivio M, Filesi C, Vari R, Scazzocchio B, Masella R 2010. Bioavailability of the polyphenols: 
Status and controversies. International Journal of Molecular Sciences  11(4):1321-1342. 
6. Manach C, Williamson G, Morand C, Scalbert A, Remesy C 2005. Bioavailability and bioefficacy of 
polyphenols in humans. I. Review of 97 bioavailability studies. American Journal of Clinical Nutrition  
81(1):230S-242S. 
7. Wu BJ, Kulkarni K, Basu S, Zhang SX, Hu M 2011. First-pass metabolism via UDP-
glucuronosyltransferase: A barrier to oral bioavailability of phenolics. Journal of Pharmaceutical Sciences  
100(9):3655-3681. 
8. Liu YT, Hao HP, Xie HG, Lai L, Wang QO, Liu CX, Wang GJ 2010. Extensive intestinal first-pass 
elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats. Drug 
Metabolism and Disposition  38(10):1779-1784. 
9. Nies AT, Herrmann E, Brom M, Keppler D 2008. Vectorial transport of the plant alkaloid 
berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, 
SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1). Naunyn-Schmiedebergs Archives of 
Pharmacology  376(6):449-461. 
10. Pan GY, Wang GJ, Liu XD, Fawcett JP, Xie YY 2002. The involvement of P-glycoprotein in 
berberine absorption. Pharmacology & Toxicology  91(4):193-197. 
11. Jiang W, Hu M 2012. Mutual interactions between flavonoids and enzymatic and transporter 
elements responsible for flavonoid disposition via phase II metabolic pathways. Rsc Advances  
2(21):7948-7963. 
12. Li Y, Paxton JW 2013. The effects of flavonoids on the ABC transporters: Consequences for the 
pharmacokinetics of substrate drugs. Expert Opinion on Drug Metabolism & Toxicology  9(3):267-285. 
13. Sieger R, Nahrstedt A 2006. Effects of phenolic compounds from Hypericum perforatum L. on 
the solubility and permeation of hypericin in vitro. Planta Medica  72(11):1073-1073. 
Chapter 2. Theoretical section: An overview  36 
    
 
 
 
 
14. Butterweck V, Lieflander-Wulf U, Winterhoff H, Nahrstedt A 2003. Plasma levels of hypericin in 
presence of procyanidin B2 and hyperoside: A pharmacokinetic study in rats. Planta Medica  69(3):189-
192. 
15. Eder M, Mehnert W 2000. Plant excipients-valuable pharmaceutical aids or superfluous ballast? 
Pharmazie in unserer Zeit  29(6):377-384. 
16. Bailey DG, Malcolm J, Arnold O, Spence JD 1998. Grapefruit juice-drug interactions. British 
Journal of Clinical Pharmacology  46(2):101-110. 
17. Parker RB, Yates CR, Soberman JE, Laizure SC 2003. Effects of grapefruit juice on intestinal P-
glycoprotein: Evaluation using digoxin in humans. Pharmacotherapy  23(8):979-987. 
18. Schwarz UI, Seemann D, Oertel R, Miehlke S, Kuhlisch E, Fromm MF, Kim RB, Bailey DG, Kirch W 
2005. Grapefruit juice ingestion significantly reduces talinolol bioavailability. Clinical Pharmacology & 
Therapeutics  77(4):291-301. 
19. Madabushi R, Frank B, Drewelow B, Derendorf H, Butterweck V 2006. Hyperforin in St. John's 
wort drug interactions. European Journal of Clinical Pharmacology  62(3):225-233. 
20. Unger M 2010. Pharmacokinetic drug interactions by herbal drugs: Critical evaluation and 
clinical relevance. Wiener medizinische Wochenschrift (1946)  160(21-22):571-577. 
21. Rahimi R, Abdollahi M 2012. An update on the ability of St. John's wort to affect the metabolism 
of other drugs. Expert Opinion on Drug Metabolism & Toxicology  8(6):691-708. 
22. Fugh-Berman A 2000. Herb-drug interactions. Lancet  355(9198):134-138. 
23. Zhou SF, Lim LY, Chowbay B 2004. Herbal modulation of P-glycoprotein. Drug Metabolism 
Reviews  36(1):57-104. 
24. Che CT, Wang ZJ, Chow MSS, Lam CWK 2013. Herb-herb combination for therapeutic 
enhancement and advancement: Theory, practice and future perspectives. Molecules  18(5):5125-5141. 
25. Artursson P, Borchardt RT 1997. Intestinal drug absorption and metabolism in cell cultures: 
Caco-2 and beyond. Pharmaceutical Research  14(12):1655-1658. 
26. Hubatsch I, Ragnarsson EGE, Artursson P 2007. Determination of drug permeability and 
prediction of drug absorption in Caco-2 monolayers. Nature Protocols  2(9):2111-2119. 
27. Sugano K, Kansy M, Artursson P, Avdeef A, Bendels S, Di L, Ecker GF, Faller B, Fischer H, 
Gerebtzoff G, Lennernaes H, Senner F 2010. Coexistence of passive and carrier-mediated processes in 
drug transport. Nature Reviews Drug Discovery  9(8):597-614. 
28. Hayeshi R, Hilgendorf C, Artursson P, Augustijns P, Brodin B, Dehertogh P, Fisher K, Fossati L, 
Hovenkamp E, Korjamo T, Masungi C, Maubon N, Mols R, Mullertz A, Monkkonen J, O'Driscoll C, Oppers-
Tiemissen HM, Ragnarsson EGE, Rooseboom M, Ungell AL 2008. Comparison of drug transporter gene 
expression and functionality in Caco-2 cells from 10 different laboratories. European Journal of 
Pharmaceutical Sciences  35(5):383-396. 
Chapter 2. Theoretical section: An overview  37 
    
 
 
 
 
29. Sumantran VN 2007. Experimental approaches for studying uptake and action of herbal 
medicines. Phytotherapy Research  21(3):210-214. 
30. Tian XJ, Yang XW, Yang XD, Wang K 2009. Studies of intestinal permeability of 36 flavonoids 
using Caco-2 cell monolayer model. International Journal of Pharmaceutics  367(1-2):58-64. 
31. Tourniaire F, Hassan M, Andre M, Ghiringhelli O, Alquier C, Amiot MJ 2005. Molecular 
mechanisms of the naringin low uptake by intestinal Caco-2 cells. Molecular Nutrition & Food Research  
49(10):957-962. 
32. Tian XJ, Yang XD, Wang K, Yang XW 2006. The efflux of flavonoids morin, isorhamnetin-3-O-
rutinoside and diosmetin-7-O-beta-D-xylopyranosyl-(1-6)-beta-D-glucopyranoside in the human 
intestinal cell line Caco-2. Pharmaceutical Research  23(8):1721-1728. 
33. Hu M, Chen J, Lin HM 2003. Metabolism of flavonoids via enteric recycling: Mechanistic studies 
of disposition of apigenin in the Caco-2 cell culture model. Journal of Pharmacology and Experimental 
Therapeutics  307(1):314-321. 
34. Liu W, Feng Q, Li Y, Ye L, Hu M, Liu ZQ 2012. Coupling of UDP-glucuronosyltransferases and 
multidrug resistance-associated proteins is responsible for the intestinal disposition and poor 
bioavailability of emodin. Toxicology and Applied Pharmacology  265(3):316-324. 
35. Schutte ME, Boersma MG, Verhallen DAM, Groten JP, Rietjens I 2008. Effects of flavonoid 
mixtures on the transport of 2-amino-1-methyl-6-phenylimidazo 4,5-b pyridine (PhIP) through Caco-2 
monolayers: An in vitro and kinetic modeling approach to predict the combined effects on transporter 
inhibition. Food and Chemical Toxicology  46(2):557-566. 
36. Schutte ME, van de Sandt JJM, Alink GM, Groten JP, Rietjens I 2006. Myricetin stimulates the 
absorption of the pro-carcinogen PhIP. Cancer Letters  231(1):36-42. 
37. Schutte ME, Freidig AP, van de Sandt JJM, Alink GM, Rietjens I, Groten JP 2006. An in vitro and in 
silico study on the flavonold-mediated modulation of the transport of 2-amino-1-methyl-6-
phenylimidazo 4,5-b pyridine (PhIP) through Caco-2 monolayers. Toxicology and Applied Pharmacology  
217(2):204-215. 
38. Bothe H, Gotz C, Stobbe-Maicherski N, Fritsche E, Abel J, Haarmann-Stemmann T 2010. Luteolin 
enhances the bioavailability of benzo[a]pyrene in human colon carcinoma cells. Archives of Biochemistry 
and Biophysics  498(2):111-118. 
39. Kamishikiryo J, Matsumura R, Takamori T, Sugihara N 2013. Effect of quercetin on the transport 
of N-acetyl 5-aminosalicylic acid. Journal of Pharmacy and Pharmacology  65(7):1037-1043. 
40. Taur JS, Rodriguez-Proteau R 2008. Effects of dietary flavonoids on the transport of cimetidine 
via P-glycoprotein and cationic transporters in Caco-2 and LLC-PK1 cell models. Xenobiotica  
38(12):1536-1550. 
Chapter 2. Theoretical section: An overview  38 
    
 
 
 
 
41. Shim CK, Cheon EP, Kang KW, Seo KS, Han HK 2007. Inhibition effect of flavonoids on 
monocarboxylate transporter 1 (MCT1) in Caco-2 cells. Journal of Pharmacy and Pharmacology  
59(11):1515-1519. 
42. Ebert B, Seidel A, Lampen A 2007. Phytochemicals induce breast cancer resistance protein in 
Caco-2 cells and enhance the transport of benzo[a]pyrene-3-sulfate. Toxicological Sciences  96(2):227-
236. 
43. Lies B, Martens S, Schmidt S, Boll M, Wenzel U 2012. Flavone potently stimulates an apical 
transporter for flavonoids in human intestinal Caco-2 cells. Molecular Nutrition & Food Research  
56(11):1627-1635. 
44. Lohner K, Schnabele K, Daniel H, Oesterle D, Rechkemmer G, Gottlicher M, Wenzel U 2007. 
Flavonoids alter P-gp expression in intestinal epithelial cells in vitro and in vivo. Molecular Nutrition & 
Food Research  51(3):293-300. 
45. Bock KW, Eckle T, Ouzzine M, Fournel-Gigleux S 2000. Coordinate induction by antioxidants of 
UDP-glucuronosyltransferase UGT1A6 and the apical conjugate export pump MRP2 (multidrug 
resistance protein 2) in Caco-2 cells. Biochemical Pharmacology  59(5):467-470. 
46. Isozaki T, Tamura H 2001. Epigallocatechin gallate (EGCG) inhibits the sulfation of 1-naphthol in 
a human colon carcinoma cell line, Caco-2. Biological & Pharmaceutical Bulletin  24(9):1076-1078. 
47. Tamura H, Matsui M 2000. Inhibitory effects of green tea and grape juice on the phenol 
sulfotransferase activity of mouse intestines and human colon carcinoma cell line, Caco-2. Biological & 
Pharmaceutical Bulletin  23(6):695-699. 
48. Pohl C, Will F, Dietrich H, Schrenk D 2006. Cytochrome p450 1A1 expression and activity in Caco-
2 cells: Modulation by apple juice extract and certain apple polyphenols. Journal of Agricultural and 
Food Chemistry  54(26):10262-10268. 
49. Li P, Callery PS, Gan LS, Balani SK 2007. Esterase inhibition by grapefruit juice flavonoids leading 
to a new drug interaction. Drug Metabolism and Disposition  35(7):1203-1208. 
50. Petri N, Tannergren C, Holst B, Mellon FA, Bao YP, Plumb GW, Bacon J, O'Leary KA, Kroon PA, 
Knutson L, Forsell P, Eriksson T, Lennernas H, Williamson G 2003. Absorption/metabolism of 
sulforaphane and quercetin, and regulation of phase II enzymes, in human jejunum in vivo. Drug 
Metabolism and Disposition  31(6):805-813. 
51. Ebert B, Seidel A, Lampen A 2005. Induction of phase-1 metabolizing enzymes by oltipraz, 
flavone and indole-3-carbinol enhance the formation and transport of benzo[a]pyrene sulfate 
conjugates in intestinal Caco-2 cells. Toxicology Letters  158(2):140-151. 
52. Yoshida N, Koizumi M, Adachi I, Kawakami J 2006. Inhibition of P-glycoprotein-mediated 
transport by terpenoids contained in herbal medicines and natural products. Food and Chemical 
Toxicology  44(12):2033-2039. 
Chapter 2. Theoretical section: An overview  39 
    
 
 
 
 
53. Yang Z, Gao S, Wang JR, Yin TJ, Teng Y, Wu BJ, You M, Jiang ZH, Hu M 2011. Enhancement of oral 
bioavailability of 20(S)-ginsenoside Rh2 through improved understanding of its absorption and efflux 
mechanisms. Drug Metabolism and Disposition  39(10):1866-1872. 
54. Zhang B, Zhu XM, Hu JN, Ye H, Luo T, Liu XR, Li HY, Li W, Zheng YN, Deng ZY 2012. Absorption 
mechanism of ginsenoside compound K and its butyl and octyl ester prodrugs in Caco-2 cells. Journal of 
Agricultural and Food Chemistry  60(41):10278-10284. 
55. Eid SY, El-Readi MZ, Wink M 2012. Carotenoids reverse multidrug resistance in cancer cells by 
interfering with ABC-transporters. Phytomedicine  19(11):977-987. 
56. Lu ZL, Chen WY, Viljoen A, Hamman JH 2010. Effect of sinomenine on the in vitro intestinal 
epithelial transport of selected compounds. Phytotherapy Research  24(2):211-218. 
57. Ohnishi A, Matsuo H, Yamada S, Takanaga H, Morimoto S, Shoyama Y, Ohtani H, Sawada Y 2000. 
Effect of furanocoumarin derivatives in grapefruit juice on the uptake of vinblastine by Caco-2 cells and 
on the activity of cytochrome P450 3A4. British Journal of Pharmacology  130(6):1369-1377. 
58. Jin J, Cai D, Bi H, Zhong G, Zeng H, Gu L, Huang Z, Huang M 2013. Comparative pharmacokinetics 
of paclitaxel after oral administration of Taxus yunnanensis extract and pure paclitaxel to rats. 
Fitoterapia  90:1-9. 
59. Qiang ZY, Hauck C, McCoy JA, Widrlechner MP, Reddy MB, Murphy PA, Hendrich S 2013. 
Echinacea sanguinea and Echinacea pallida extracts stimulate glucuronidation and basolateral transfer 
of Bauer alkamides 8 and 10 and ketone 24 and inhibit P-glycoprotein transporter in Caco-2 cells. Planta 
Medica  79(3-4):266-274. 
60. Li N, Tsao R, Sui ZG, Ma JW, Liu ZQ, Liu ZY 2012. Intestinal transport of pure diester-type 
alkaloids from an aconite extract across the Caco-2 cell monolayer model. Planta Medica  78(7):692-697. 
61. Qiang ZY, Ye Z, Hauck C, Murphy PA, McCoy JA, Widrlechner MP, Reddy MB, Hendrich S 2011. 
Permeability of rosmarinic acid in Prunella vulgaris and ursolic acid in Salvia officinalis extracts across 
Caco-2 cell monolayers. Journal of Ethnopharmacology  137(3):1107-1112. 
62. Fale PL, Ascensao L, Serralheiro MLM 2013. Effect of luteolin and apigenin on rosmarinic acid 
bioavailability in Caco-2 cell monolayers. Food & Function  4(3):426-431. 
63. Mukinda JT, Syce JA, Fisher D, Meyer M 2010. Effect of the plant matrix on the uptake of luteolin 
derivatives-containing Artemisia afra aqueous-extract in Caco-2 cells. Journal of Ethnopharmacology  
130(3):439-449. 
64. Kim JY, Kwon HJ, Jung JY, Kwon HY, Baek JG, Kim YS, Kwon O 2010. Comparison of absorption of 
1-deoxynojirimycin from mulberry water extract in rats. Journal of Agricultural and Food Chemistry  
58(11):6666-6671. 
Chapter 2. Theoretical section: An overview  40 
    
 
 
 
 
65. Jia XB, Chen J, Lin HM, Hu M 2004. Disposition of flavonoids via enteric recycling: Enzyme-
transporter coupling affects metabolism of biochanin A and formononetin and excretion of their phase II 
conjugates. Journal of Pharmacology and Experimental Therapeutics  310(3):1103-1113. 
66. Zheng KYZ, Choi RCY, Guo AJY, Bi CWC, Zhu KY, Du CYQ, Zhang ZX, Lau DTW, Dong TTX, Tsim 
KWK 2012. The membrane permeability of Astragali Radix-derived formononetin and calycosin is 
increased by Angelicae Sinensis Radix in Caco-2 cells: A synergistic action of an ancient herbal decoction 
Danggui Buxue Tang. Journal of Pharmaceutical and Biomedical Analysis  70:671-679. 
67. Gao S, Jiang W, Yin TJ, Hu M 2010. Highly variable contents of phenolics in St. John's Wort 
products affect their transport in the human intestinal Caco-2 cell model: Pharmaceutical and 
biopharmaceutical rationale for product standardization. Journal of Agricultural and Food Chemistry  
58(11):6650-6659. 
68. Wang SWJ, Chen Y, Joseph T, Hu M 2008. Variable isoflavone content of red clover products 
affects intestinal disposition of biochanin A, formononetin, genistein, and daidzein. Journal of 
Alternative and Complementary Medicine  14(3):287-297. 
69. Yue GGL, Cheng S-W, Yu H, Xu Z-S, Lee JKM, Hon P-M, Lee MYH, Kennelly EJ, Deng G, Yeung SK, 
Cassileth BR, Fung K-P, Leung P-C, Lau CBS 2012. The role of turmerones on curcumin transportation and 
P-glycoprotein activities in intestinal Caco-2 cells. Journal of Medicinal Food  15(3):242-252. 
70. Brand W, Padilla B, van Bladeren PJ, Williamson G, Rietjens I 2010. The effect of co-administered 
flavonoids on the metabolism of hesperetin and the disposition of its metabolites in Caco-2 cell 
monolayers. Molecular Nutrition & Food Research  54(6):851-860. 
71. Nahrstedt A, Butterweck V 2010. Lessons learned from herbal medicinal products: The example 
of St. John's Wort. Journal of Natural Products  73(5):1015-1021. 
72. Li CR, Zhang L, Wo SK, Zhou LM, Lin G, Zuo Z 2012. Pharmacokinetic interactions among major 
bioactive components in Radix scutellariae via metabolic competition. Biopharmaceutics & Drug 
Disposition  33(9):487-500. 
73. Lan K, He JL, Tian Y, Tan F, Jiang XH, Wang L, Ye LM 2008. Intra-herb pharmacokinetics 
interaction between quercetin and isorhamentin. Acta Pharmacologica Sinica  29(11):1376-1382. 
74. Liang XL, Zhao LJ, Liao ZG, Zhao GW, Zhang J, Chao YC, Yang M, Yin RL 2012. Transport properties 
of puerarin and effect of Radix angelicae dahuricae extract on the transport of puerarin in Caco-2 cell 
model. Journal of Ethnopharmacology  144(3):677-682. 
75. Zhu ML, Liang XL, Zhao LJ, Liao ZG, Zhao GW, Cao YC, Zhang J, Luo Y 2013. Elucidation of the 
transport mechanism of baicalin and the influence of a Radix angelicae dahuricae extract on the 
absorption of baicalin in a Caco-2 cell monolayer model. Journal of Ethnopharmacology  150(2):553-559. 
Chapter 2. Theoretical section: An overview  41 
    
 
 
 
 
76. Wang S, Zang W, Zhao X, Feng W, Zhao M, He X, Liu Q, Zheng X 2013. Effects of borneol on 
pharmacokinetics and tissue distribution of notoginsenoside R1 and ginsenosides Rg1 and Re in Panax 
notoginseng in rabbits. Journal of analytical methods in chemistry  2013:706723. 
77. Shi R, Zhou H, Liu ZM, Ma YM, Wang TM, Liu YY, Wang CH 2009. Influence of Coptis chinensis on 
pharmacokinetics of flavonoids after oral administration of Radix scutellariae in rats. Biopharmaceutics 
& Drug Disposition  30(7):398-410. 
78. Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell AL, Karlsson J 2007. Expression of thirty-six 
drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metabolism 
and Disposition  35(8):1333-1340. 
79. Prueksaritanont T, Gorham LM, Hochman JH, Tran LO, Vyas KP 1996. Comparative studies of 
drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells. Drug 
Metabolism and Disposition  24(6):634-642. 
80. Englund G, Rorsman F, Ronnblom A, Karlbom U, Lazorova L, Grasjo J, Kindmark A, Artursson P 
2006. Regional levels of drug transporters along the human intestinal tract: Co-expression of ABC and 
SLC transporters and comparison with Caco-2 cells. European Journal of Pharmaceutical Sciences  29(3-
4):269-277. 
81. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KLR, Chu XY, Dahlin A, Evers R, Fischer 
V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, 
Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L, International T 2010. 
Membrane transporters in drug development. Nature Reviews Drug Discovery  9(3):215-236. 
82. Han T, Everett RS, Proctor WR, Ng CM, Costales CL, Brouwer KLR, Thakker DR 2013. Organic 
cation transporter 1 (OCT1/mOct1) is localized in the apical membrane of Caco-2 cell monolayers and 
enterocytes. Molecular Pharmacology  84(2):182-189. 
83. FDA. 2012. Guidance for Industry: Drug interaction studies — study design, data analysis, 
implications for dosing, and labeling recommendations. Rockville, MD, USA: Food and Drug 
Administration. http://www.fda.gov/downloads/Drugs/guidancecomplianceregulatoryinformation/ 
guidances/ucm292362.pdf. 
84. Estudante M, Morais JG, Soveral G, Benet LZ 2013. Intestinal drug transporters: An overview. 
Advanced Drug Delivery Reviews  64(10):1340-1356. 
85. Murakami T, Takano M 2008. Intestinal efflux transporters and drug absorption. Expert Opinion 
on Drug Metabolism & Toxicology  4(7):923-939. 
86. Fricker G. 2009. Biological membranes and drug transporters. In Mannhold R, Kubinyi H, Folkers 
G, editors. Transporters as drug carriers, 1 ed., Weinheim: WILEY-VCH Verlag GmbH & Co. KGaA. p 215-
262. 
Chapter 2. Theoretical section: An overview  42 
    
 
 
 
 
87. Neuhaus W, Noe C. 2009. Transport at the Blood-Brain Barrier. In Mannhold R, Kubinyi H, 
Folkers G, editors. Transporters as drug carriers, 1 ed., Weinheim: WILEY-VCH Verlag GmbH & Co. KGaA. 
88. Koljonen M, Rousu K, Cierny J, Kaukonen AM, Hirvonen J 2008. Transport evaluation of salicylic 
acid and structurally related compounds across Caco-2 cell monolayers and artificial PAMPA 
membranes. European Journal of Pharmaceutics and Biopharmaceutics  70(2):531-538. 
89. Dawson P. 2012. Bile formation and the enterohepatic circulation. In Johnson L, editor 
Physiology of the gastrointestinal tract, 5 ed., Amsterdam: Elisvier/Academic Press. p 1461-1484. 
90. Taipalensuu J, Tornblom H, Lindberg G, Einarsson C, Sjoqvist F, Melhus H, Garberg P, Sjostrom B, 
Lundgren B, Artursson P 2001. Correlation of gene expression of ten drug efflux proteins of the ATP-
binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 
cell monolayers. Journal of Pharmacology and Experimental Therapeutics  299(1):164-170. 
91. Sun DX, Lennernas H, Welage LS, Barnett JL, Landowski CP, Foster D, Fleisher D, Lee KD, Amidon 
GL 2002. Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene 
sequences tags and correlation with permeability of 26 drugs. Pharmaceutical Research  19(10):1400-
1416. 
92. Seithel A, Karlsson J, Hilgendorf C, Bjorquist A, Ungell AL 2006. Variability in mRNA expression of 
ABC- and SLC-transporters in human intestinal cells: Comparison between human segments and Caco-2 
cells. European Journal of Pharmaceutical Sciences  28(4):291-299. 
93. Behrens I, Kissel T 2003. Do cell culture conditions influence the carrier-mediated transport of 
peptides in Caco-2 cell monolayers? European Journal of Pharmaceutical Sciences  19(5):433-442. 
94. Siissalo S, Laitinen L, KoIjonen M, Vellonen KS, Kortejdrvi H, Urtti A, Hirvonen J, Kaukonen AM 
2007. Effect of cell differentiation and passage number on the expression of efflux proteins in wild type 
and vinblastine-induced Caco-2 cell lines. European Journal of Pharmaceutics and Biopharmaceutics  
67(2):548-554. 
95. Xia CQ, Liu N, Yang D, Miwa G, Gan LS 2005. Expression, localization, and functional 
characteristics of breast cancer resistance protein in Caco-2 cells. Drug Metabolism and Disposition  
33(5):637-643. 
96. Proctor W, Ming X, Thakker R. 2010. In vitro techniques to study drug-drug interactions involving 
transport: Caco-2 model for study of p-glycoprotein and other transporters. In Pang K, Rodrigues A, 
Peter R, editors. Enzyme- and transporter-based drug-drug interactions, 1 ed., New York, Dordrecht, 
Heidelberg, London: Springer. 
97. Heikkinen AT, Korjamo T, Monkkonen J 2010. Modelling of drug disposition kinetics in in vitro 
intestinal absorption cell models. Basic & Clinical Pharmacology & Toxicology  106(3):180-188. 
Chapter 2. Theoretical section: An overview  43 
    
 
 
 
 
98. Troutman MD, Thakker DR 2003. Novel experimental parameters to quantify the modulation of 
absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal 
epithelium. Pharmaceutical Research  20(8):1210-1224. 
99. Thiel-Demby VE, Tippin TK, Humphreys JE, Serabjit-Singh CJ, Polli JW 2004. In vitro absorption 
and secretory quotients: Practical criteria derived from a study of 331 compounds to assess for the 
impact of P-glycoprotein-mediated efflux on drug candidates. Journal of Pharmaceutical Sciences  
93(10):2567-2572. 
100. Ito S, Woodland C, Sarkadi B, Hockmann G, Walker SE, Koren G 1999. Modeling of P-
glycoprotein-involved epithelial drug transport in MDCK cells. American Journal of Physiology-Renal 
Physiology  277(1):F84-F96. 
101. Tran TT, Mittal A, Aldinger T, Polli JW, Ayrton A, Ellens H, Bentz J 2005. The elementary mass 
action rate constants of P-gp transport for a confluent monolayer of MDCKII-hMDR1 cells. Biophysical 
Journal  88(1):715-738. 
102. Gonzalez-Alvarez I, Fernandez-Teruel C, Garrigues TM, Casabo VG, Ruiz-Garcia A, Bermejo M 
2005. Kinetic modelling of passive transport and active efflux of a fluoroquinolone across Caco-2 cells 
using a compartmental approach in NONMEM. Xenobiotica  35(12):1067-1088. 
103. Korjamo T, Kemilainen H, Heikkinen AT, Monkkonen J 2007. Decrease in intracellular 
concentration causes the shift in Km value of efflux pump substrates. Drug Metabolism and Disposition  
35(9):1574-1579. 
104. Kalvass JC, Pollack GM 2007. Kinetic considerations for the quantitative assessment of efflux 
activity and inhibition: Implications for understanding and predicting the effects of efflux inhibition. 
Pharmaceutical Research  24(2):265-276. 
105. Sun HD, Pang KS 2008. Permeability, transport, and metabolism of solutes in Caco-2 cell 
monolayers: A theoretical study. Drug Metabolism and Disposition  36(1):102-123. 
106. Tam D, Sun HD, Pang KS 2003. Influence of P-glycoprotein, transfer clearances, and drug binding 
on intestinal metabolism in Caco-2 cell monolayers or membrane preparations: A theoretical analysis. 
Drug Metabolism and Disposition  31(10):1214-1226. 
107. Sun HD, Zhang L, Chow ECY, Lin G, Zuo Z, Pang KS 2008. A catenary model to study transport and 
conjugation of baicalein, a bioactive flavonoid, in the Caco-2 cell monolayer: Demonstration of substrate 
inhibition. Journal of Pharmacology and Experimental Therapeutics  326(1):117-126. 
108. Bourdet DL, Pollack GM, Thakker DR 2006. Intestinal absorptive transport of the hydrophilic 
cation ranitidine: A kinetic modeling approach to elucidate the role of uptake and efflux transporters 
and paracellular vs. transcellular transport in Caco-2 cells. Pharmaceutical Research  23(6):1178-1187. 
Chapter 2. Theoretical section: An overview  44 
    
 
 
 
 
109. Heikkinen AT, Monkkonen J, Korjamo T 2009. Kinetics of cellular retention during Caco-2 
permeation experiments: Role of lysosomal sequestration and impact on permeability estimates. 
Journal of Pharmacology and Experimental Therapeutics  328(3):882-892. 
110. Zhang X, Shedden K, Rosania GR 2006. A cell-based molecular transport simulator for 
pharmacokinetic prediction and cheminformatic exploration. Molecular pharmaceutics  3(6):704-716. 
111. Kapitza SB, Michel BR, van Hoogevest P, Leigh MLS, Imanidis G 2007. Absorption of poorly water 
soluble drugs subject to apical efflux using phospholipids as solubilizers in the Caco-2 cell model. 
European Journal of Pharmaceutics and Biopharmaceutics  66(1):146-158. 
112. Markopoulos C, Thoenen F, Preisig D, Symillides M, Vertzoni M, Parrott N, Reppas C, Imanidis G 
2013. Biorelevant media for transport experiments in the Caco-2 model to evaluate drug absorption in 
the fasted and fed state and their usefulness. European Journal of Pharmaceutics and Biopharmaceutics  
http://dx.doi.org/10.1016/j.ejpb.2013.10.017. 
113. Vertzoni M, Markopoulos C, Symillides M, Goumas C, Imanidis G, Reppas C 2012. Luminal lipid 
phases after administration of a triglyceride solution of danazol in the fed state and their contribution to 
the flux of danazol across Caco-2 cell monolayers. Molecular Pharmaceutics  9(5):1189-1198. 
114. Korzekwa K, Nagar S 2013. Compartmental models for apical efflux by P-glycoprotein: Part 2—A 
theoretical study on transporter kinetic parameters. Pharmaceutical Research  DOI 10.1007/s11095-
013-1163-8. 
115. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJJ, Roden DM, Wilkinson GR 1998. The drug 
transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. Journal of 
Clinical Investigation  101(2):289-294. 
116. Ming X, Knight BM, Thakker DR 2011. Vectorial transport of fexofenadine across Caco-2 cells: 
Involvement of apical uptake and basolateral efflux transporters. Molecular Pharmaceutics  8(5):1677-
1686. 
117. Wu XC, Whitfield LR, Stewart BH 2000. Atorvastatin transport in the Caco-2 cell model: 
Contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter. Pharmaceutical 
Research  17(2):209-215. 
118. Lowes S, Simmons NL 2002. Multiple pathways for fluoroquinolone secretion by human 
intestinal epithelial (Caco-2) cells. British Journal of Pharmacology  135(5):1263-1275. 
119. Schrickx J, Lektarau Y, Fink-Gremmels J 2006. Ochratoxin A secretion by ATP-dependent 
membrane transporters in Caco-2 cells. Archives of Toxicology  80(5):243-249. 
120. Li JB, Wang Y, Zhang W, Huang YH, Hein K, Hidalgo IJ 2012. The role of a basolateral transporter 
in rosuvastatin transport and its interplay with apical breast cancer resistance protein in polarized cell 
monolayer systems. Drug Metabolism and Disposition  40(11):2102-2108. 
Chapter 2. Theoretical section: An overview  45 
    
 
 
 
 
121. Grandvuinet AS, Steffansen B 2011. Interactions between organic anions on multiple 
transporters in Caco-2 cells. Journal of Pharmaceutical Sciences  100(9):3817-3830. 
122. Sai Y, Kaneko Y, Ito S, Mitsuoka K, Kato Y, Tamai I, Artursson P, Tsuji A 2006. Predominant 
contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone-3-
sulfate by human intestinal Caco-2 cells. Drug Metabolism and Disposition  34(8):1423-1431. 
123. Watanabe K, Jinriki T, Sato J 2004. Effects of progesterone and norethisterone on cephalexin 
uptake in the human intestinal cell line Caco-2. Biological & Pharmaceutical Bulletin  27(4):559-563. 
124. Wenzel U, Kuntz S, Diestel S, Daniel H 2002. PEPT1-mediated cefixime uptake into human 
intestinal epithelial cells is increased by Ca2+ channel blockers. Antimicrobial Agents and Chemotherapy  
46(5):1375-1380. 
125. Li FJ, Hong L, Mau CI, Chan R, Hendricks T, Dvorak C, Yee C, Harris J, Alfredson T 2006. Transport 
of levovirin prodrugs in the human intestinal Caco-2 cell. Journal of Pharmaceutical Sciences  
95(6):1318-1325. 
126. Tsuda M, Terada T, Irie M, Katsura T, Niida A, Tomita K, Fujii N, Inui K 2006. Transport 
characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its 
amino acid derivatives. Journal of Pharmacology and Experimental Therapeutics  318(1):455-460. 
127. Han HK, Oh DM, Amidon GL 1998. Cellular uptake mechanism of amino acid ester prodrugs in 
Caco-2/hPEPT1 cells overexpressing a human peptide transporter. Pharmaceutical Research  15(9):1382-
1386. 
128. Hadjiagapiou C, Schmidt L, Dudeja PK, Layden TJ, Ramaswamy K 2000. Mechanism(s) of butyrate 
transport in Caco-2 cells: Role of monocarboxylate transporter 1. American Journal of Physiology-
Gastrointestinal and Liver Physiology  279(4):G775-G780. 
129. Jeon OC, Hwang SR, Al-Hilal TA, Park JW, Moon HT, Lee S, Park JH, Byun Y 2013. Oral delivery of 
ionic complex of ceftriaxone with bile acid derivative in non-human primates. Pharmaceutical Research  
30(4):959-967. 
130. Proctor WR, Bourdet DL, Thakker DR 2008. Mechanisms underlying saturable intestinal 
absorption of metformin. Drug Metabolism and Disposition  36(8):1650-1658. 
131. Krishna DR, Klotz U 1994. Extrahepatic metabolism of drugs in humans. Clinical 
Pharmacokinetics  26(2):144-160. 
132. Testa B, Krämer S. 2008. The biochemistry of drug metabolism: Principles, redox reactions, 
hydrolyses. 1 ed., Zürich, Weinheim: VHCA, WILEY-VCH. 
133. Thelen K, Dressman JB 2009. Cytochrome P450-mediated metabolism in the human gut wall. 
Journal of Pharmacy and Pharmacology  61(5):541-558. 
134. Imai T 2006. Human carboxylesterase isozymes: Catalytic properties and rational drug design. 
Drug Metabolism and Pharmacokinetics  21(3):173-185. 
Chapter 2. Theoretical section: An overview  46 
    
 
 
 
 
135. Chiang CP, Wu CW, Lee SP, Ho JL, Lee SL, Nieh S, Yin SJ 2012. Expression pattern, ethanol-
metabolizing activities, and cellular localization of alcohol and aldehyde dehydrogenases in human small 
intestine. Alcoholism-Clinical and Experimental Research  36(12):2047-2058. 
136. Kelner MJ, Bagnell RD, Montoya MA, Lanham KA 2000. Structural organization of the human 
gastrointestinal glutathione peroxidase (GPX2) promoter and 3 '-nontranscribed region: Transcriptional 
response to exogenous redox agents. Gene  248(1-2):109-116. 
137. Testa B, Krämer S. 2010. The biochemistry of drug metabolism: Conjugations, consequences of 
metabolism, influencing factors. 1 ed., Zürich, Weinheim: VHCA, WILEY-VCH. 
138. Gregory PA, Lewinsky RH, Gardner-Stephen DA, Mackenzie PI 2004. Regulation of UDP 
glucuronosyltransferases in the gastrointestinal tract. Toxicology and Applied Pharmacology  199(3):354-
363. 
139. Rowland A, Miners JO, Mackenzie PI 2013. The UDP-glucuronosyltransferases: Their role in drug 
metabolism and detoxification. International Journal of Biochemistry & Cell Biology  45(6):1121-1132. 
140. Kaminsky LS, Zhang QY 2003. The small intestine as a xenobiotic-metabolizing organ. Drug 
Metabolism and Disposition  31(12):1520-1525. 
141. Coles BF, Chen GP, Kadlubar FF, Radominska-Pandya A 2002. Interindividual variation and organ-
specific patterns of glutathione S-transferase alpha, mu, and pi expression in gastrointestinal tract 
mucosa of normal individuals. Archives of Biochemistry and Biophysics  403(2):270-276. 
142. Pool-Zobel B, Veeriah S, Bohmer FD 2005. Modulation of xenobiotic metabolising enzymes by 
anticarcinogens - focus on glutathione S-transferases and their role as targets of dietary 
chemoprevention in colorectal carcinogenesis. Mutation Research-Fundamental and Molecular 
Mechanisms of Mutagenesis  591(1-2):74-92. 
143. Riches Z, Stanley EL, Bloomer JC, Coughtrie MWH 2009. Quantitative evaluation of the 
expression and activity of five major sulfotransferases (SULTs) in human tissues: The SULT "Pie". Drug 
Metabolism and Disposition  37(11):2255-2261. 
144. Teubner W, Meinl W, Florian S, Kretzschmar M, Glatt H 2007. Identification and localization of 
soluble sulfotransferases in the human gastrointestinal tract. Biochemical Journal  404:207-215. 
145. Chen GP, Zhang DQ, Jing N, Yin SH, Falany CN, Radominska-Pandya A 2003. Human 
gastrointestinal sulfotransferases: Identification and distribution. Toxicology and Applied Pharmacology  
187(3):186-197. 
146. Schreiber TD, Kohle C, Buckler F, Schmohl S, Braeuning A, Schmiechen A, Schwarz M, Munzel PA 
2006. Regulation of CYP1A1 gene expression by the antioxidant tert-butylhydroquinone. Drug 
Metabolism and Disposition  34(7):1096-1101. 
Chapter 2. Theoretical section: An overview  47 
    
 
 
 
 
147. Lampen A, Bader A, Bestmann T, Winkler M, Witte L, Borlak JT 1998. Catalytic activities, protein- 
and mRNA-expression of cytochrome P450 isoenzymes in intestinal cell lines. Xenobiotica  28(5):429-
441. 
148. SchmiedlinRen P, Thummel KE, Fisher JM, Paine MF, Lown KS, Watkins PB 1997. Expression of 
enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in 
the presence of 1 alpha,25-dihydroxyvitamin D-3. Molecular Pharmacology  51(5):741-754. 
149. Engman HA, Lennernas H, Taipalensuu J, Otter C, Leidvik B, Artursson P 2001. CYP3A4, CYP3A5, 
and MDR1 in human small and large intestinal cell lines suitable for drug transport studies. Journal of 
Pharmaceutical Sciences  90(11):1736-1751. 
150. Brimer C, Dalton JT, Zhu ZX, Schuetz J, Yasuda K, Vanin E, Relling MV, Lu Y, Schuetz EG 2000. 
Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-
glycoprotein. Pharmaceutical Research  17(7):803-810. 
151. Shimoi K, Nakayama T. 2005. Glucuronidase deconjugation in inflammation. In Sies H, Parker L, 
editors. Phase II conjugation enzymes and transport systems, 1 ed., San Diego, New York, Berkeley, 
Boston, London, Sydney, Tokyo, Toronto: Academic Press. p 263-272. 
152. Zhang Y, Wick DA, Haas AL, Seetharam B, Dahms NM 1995. Regulation of lysosomal and 
ubiquitin degradative pathways in differentiating human intestinal Caco-2 cells. Biochimica Et Biophysica 
Acta-Molecular Cell Research  1267(1):15-24. 
153. Artursson P 1991. Cell - cultures as models for drug absorption across the intestinal - mucosa. 
Critical Reviews in Therapeutic Drug Carrier Systems  8(4):305-330. 
154. Mizuma T, Fuseda N, Hayashi M 2005. Kinetic characterization of glycosidase activity from 
disaccharide conjugate to monosaccharide conjugate in Caco-2 cells. Journal of Pharmacy and 
Pharmacology  57(5):661-664. 
155. Imai T, Imoto M, Sakamoto H, Hashimoto M 2005. Identification of esterases expressed in Caco-
2 cells and effects of their hydrolyzing activity in predicting human intestinal absorption. Drug 
Metabolism and Disposition  33(8):1185-1190. 
156. Siissalo S, Zhang HB, Stilgenbauer E, Kaukonen AM, Hirvonen J, Finel M 2008. The expression of 
most UDP-glucuronosyltransferases (UGTs) is increased significantly during Caco-2 cell differentiation, 
whereas UGT1A6 Is highly expressed also in undifferentiated cells. Drug Metabolism and Disposition  
36(11):2331-2336. 
157. Sabolovic N, Magdalou J, Netter P, Abid A 2000. Nonsteroidal anti-inflammatory drugs and 
phenols glucuronidation in Caco-2 cells - Identification of the UDP-glucuronosyltransferases UGT1A6, 
1A3 and 2B7. Life Sciences  67(2):185-196. 
158. Jeong EJ, Liu Y, Lin HM, Hu M 2005. Species- and disposition model-dependent metabolism of 
raloxifene in gut and liver: Role of UGT1A10. Drug Metabolism and Disposition  33(6):785-794. 
Chapter 2. Theoretical section: An overview  48 
    
 
 
 
 
159. Scharmach E, Hessel S, Niemann B, Lampen A 2009. Glutathione S-transferase expression and 
isoenzyme composition during cell differentiation of Caco-2 cells. Toxicology  265(3):122-126. 
160. Peters WHN, Roelofs HMJ 1989. Time-dependent activity and expression of glutathione S-
transferases in the human-colon adenocarcinoma cell-line Caco-2. Biochemical Journal  264(2):613-616. 
161. Meinl W, Ebert B, Glatt H, Lampen A 2008. Sulfotransferase forms expressed in human intestinal 
Caco-2 and TC7 cells at varying stages of differentiation and role in benzo[a]pyrene metabolism. Drug 
Metabolism and Disposition  36(2):276-283. 
162. Tamura H, Taniguchi K, Hayashi E, Hiyoshi Y, Nagai F 2001. Expression profiling of 
sulfotransferases in human cell lines derived from extra-hepatic tissues. Biological & Pharmaceutical 
Bulletin  24(11):1258-1262. 
163. Zhang HB, Tolonen A, Rousu T, Hirvonen J, Finel M 2011. Effects of cell differentiation and assay 
conditions on the UDP-glucuronosyltransferase activity in Caco-2 cells. Drug Metabolism and Disposition  
39(3):456-464. 
164. Mizuma T, Momota R, Haga M, Hayashi M 2004. Factors affecting glucuronidation activity in 
Caco-2 cells. Drug metabolism and pharmacokinetics  19(2):130-134. 
165. Buesen R, Mock M, Seidel A, Jacob J, Lampen A 2002. Interaction between metabolism and 
transport of benzo[a]pyrene and its metabolites in enterocytes. Toxicology and Applied Pharmacology  
183(3):168-178. 
166. Cummins CL, Jacobsen W, Christians U, Benet LZ 2004. CYP3A4-transfected Caco-2 cells as a tool 
for understanding biochemical absorption barriers: Studies with sirolimus and midazolam. Journal of 
Pharmacology and Experimental Therapeutics  308(1):143-155. 
167. Cummins CL, Jacobsen W, Benet LZ 2002. Unmasking the dynamic interplay between intestinal 
P-glycoprotein and CYP3A4. Journal of Pharmacology and Experimental Therapeutics  300(3):1036-1045. 
168. Fisher JM, Wrighton SA, Watkins PB, Schmiedlin-Ren P, Calamia JC, Shen DD, Kunze KL, Thummel 
KE 1999. First-pass midazolam metabolism catalyzed by 1 alpha,25-dihydroxy vitamin D-3-modified 
Caco-2 cell monolayers. Journal of Pharmacology and Experimental Therapeutics  289(2):1134-1142. 
169. Paine MF, Leung LY, Lim HK, Liao KC, Oganesian A, Zhang MY, Thummel KE, Watkins PB 2002. 
Identification of a novel route of extraction of sirolimus in human small intestine: Roles of metabolism 
and secretion. Journal of Pharmacology and Experimental Therapeutics  301(1):174-186. 
170. Ishida K, Taguchi M, Akao T, Hashimoto Y 2009. Involvement of the CYP1A subfamily in 
stereoselective metabolism of carvedilol in beta-naphthoflavone-treated Caco-2 cells. Biological & 
Pharmaceutical Bulletin  32(3):513-516. 
171. Li YH, Ito K, Tsuda Y, Kohda R, Yamada H, Itoh T 1999. Mechanism of intestinal absorption of an 
orally active beta-lactam prodrug: Uptake and transport of carindacillin in Caco-2 cells. Journal of 
Pharmacology and Experimental Therapeutics  290(3):958-964. 
Chapter 2. Theoretical section: An overview  49 
    
 
 
 
 
172. Tantishaiyakul V, Wiwattanawongsa K, Pinsuwan S, Kasiwong S, Phadoongsombut N, 
Kaewnopparat S, Kaewnopparat N, Rojanasakul Y 2002. Characterization of mefenamic acid-guaiacol 
ester: Stability and transport across Caco-2 cell monolayers. Pharmaceutical Research  19(7):1013-1018. 
173. Lee K, Park SK, Kwon BM, Kim K, Yu HE, Ryu J, Oh SJ, Lee KS, Kang JS, Lee CW, Kwon MG, Kim HM 
2009. Transport and metabolism of the antitumour drug candidate 2 '-benzoyloxycinnamaldehyde in 
Caco-2 cells. Xenobiotica  39(12):881-888. 
174. Jing WH, Song YL, Yan R, Bi HC, Li PT, Wang YT 2011. Transport and metabolism of (+/-)-
praeruptorin A in Caco-2 cell monolayers. Xenobiotica  41(1):71-81. 
175. Jeong EJ, Lin HM, Hu M 2004. Disposition mechanisms of raloxifene in the human intestinal 
Caco-2 model. Journal of Pharmacology and Experimental Therapeutics  310(1):376-385. 
176. Ishida K, Honda M, Shimizu T, Taguchi M, Hashimoto Y 2007. Stereoselective metabolism of 
carvedilol by the beta-naphthoflavone-inducible enzyme in human intestinal epithelial Caco-2 cells. 
Biological & Pharmaceutical Bulletin  30(10):1930-1933. 
177. Wang YZ, Ao HS, Qian ZM, Zheng Y 2011. Intestinal transport of scutellarein and scutellarin and 
first-pass metabolism by UDP-glucuronosyltransferase-mediated glucuronidation of scutellarein and 
hydrolysis of scutellarin. Xenobiotica  41(7):538-548. 
178. Ebert B, Seidel A, Lampen A 2005. Identification of BCRP as transporter of benzo[a]pyrene 
conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists. 
Carcinogenesis  26(10):1754-1763. 
179. Usta M, Wortelboer HM, Vervoort J, Boersma MG, Rietjens I, van Bladeren PJ, Cnubben NHP 
2007. Human glutathione S-transferase-mediated glutathione conjugation of curcumin and efflux of 
these conjugates in Caco-2 cells. Chemical Research in Toxicology  20(12):1895-1902. 
180. Hessel S, John A, Seidel A, Lampen A 2013. Multidrug resistance-associated proteins are involved 
in the transport of the glutathione conjugates of the ultimate carcinogen of benzo[a]pyrene in human 
Caco-2 cells. Archives of Toxicology  87(2):269-280. 
181. Plackova P, Rozumova N, Hrebabecky H, Sala M, Nencka R, Elbert T, Dvorakova A, Votruba I, 
Mertlikova-Kaiserova H 2013. 9-Norbornyl-6-chloropurine is a novel antileukemic compound interacting 
with cellular GSH. Anticancer Research  33(8):3163-3168. 
182. Pauli-Magnus C, von Richter O, Burk O, Ziegler A, Mettang T, Eichelbaum M, Fromm MF 2000. 
Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. 
Journal of Pharmacology and Experimental Therapeutics  293(2):376-382. 
183. Zhou SF, Wang LL, Di YM, Xue CC, Duan W, Li CG, Li Y 2008. Substrates and inhibitors of human 
multidrug resistance associated proteins and the implications in drug development. Current Medicinal 
Chemistry  15(20):1981-2039. 
Chapter 2. Theoretical section: An overview  50 
    
 
 
 
 
184. Jiang W, Xu BB, Wu BJ, Yu R, Hu M 2012. UDP-glucuronosyltransferase (UGT) 1A9-
overexpressing HeLa cells is an appropriate tool to delineate the kinetic interplay between breast cancer 
resistance protein (BRCP) and UGT and to rapidly identify the glucuronide substrates of BCRP. Drug 
Metabolism and Disposition  40(2):336-345. 
185. Siissalo S, Heikkinen AT 2013. In vitro methods to study the interplay of drug metabolism and 
efflux in the intestine. Current Drug Metabolism  14(1):102-111. 
186. Jeong EJ, Liu X, Jia XB, Chen J, Hu M 2005. Coupling of conjugating enzymes and efflux 
transporters: Impact on bioavailability and drug interactions. Current Drug Metabolism  6(5):455-468. 
187. van Waterschoot RAB, Schinkel AH 2011. A critical analysis of the interplay between cytochrome 
P450 3A and P-glycoprotein: Recent insights from knockout and transgenic mice. Pharmacological 
Reviews  63(2):390-410. 
188. Mudra DR, Desino KE, Desai PV 2011. In silico, in vitro and in situ models to assess interplay 
between CYP3A and P-gp. Current Drug Metabolism  12(8):750-773. 
189. Otto I. 2007. Chamaemelum nobilie (L.) ALL. In Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, 
Keller K, Reichling J, Schulz V, editors. Hagers Enzyklopädie der Arzneistoffe und Drogen, 6 ed., Stuttgart: 
Wissenschaftliche Verlagsgesellschaft mbh Stuttgart. p 298-308. 
190. Willuhn G. 2004. Chamomillae romanae flos. In Wichtl M, editor Herbal drugs and 
phytopharmaceuticals, 3 ed., Stuttgart and Boca Raton, London, New York, Washington, D.C.: 
medpharm Scientific Publishers and CRC Press. 
191. 2007. Chamomillae romanae flos.  European pharmacopoeia, 6 ed., Strasbourg: Council of 
Europe. p 1487-1488. 
192. Bail S, Buchbauer G, Jirovetz L, Denkova Z, Slavchev A, Stoyanova A, Schmidt E, Geissler M 2009. 
Antimicrobial activities of roman chamomile oil from France and its main compounds. Journal of 
Essential Oil Research  21(3):283-286. 
193. Saderi H, Owlia P, Hosseini A, Semiyari H 2005. Antimicrobial effects of chamomile extract and 
essential oil on clinically isolated Porphyromonas gingivalis from periodontitis. WOCMAP III: Traditional 
Medicine and Nutraceuticals (680):145-146. 
194. Chao S, Young G, Oberg C, Nakaoka K 2008. Inhibition of methicillin-resistant Staphylococcus 
aureus (MRSA) by essential oils. Flavour and Fragrance Journal  23(6):444-449. 
195. Inouye S, Uchida K, Abe S 2006. Vapor activity of 72 essential oils against a Trichophyton 
mentagrophytes. Journal of Infection and Chemotherapy  12(4):210-216. 
196. Holub M, Samek Z 1977. Terpenes. CLXX. Isolation and structure of 3-epinobilin, 1,10-
epoxynobilin and 3-dehydronobilin - other sesquiterpenic lactones from flowers of Anthemis nobilis L. 
revision of structure of nobilin and eucannabinolide. Collection of Czechoslovak Chemical 
Communications  42(3):1053-1064. 
Chapter 2. Theoretical section: An overview  51 
    
 
 
 
 
197. Grabarczyk H, Drozdz B, Hladon B, Wojciechowska J 1977. Sesquiterpene lactones. Part XV. New 
cytostatic active sesquiterpene lactone from herb of Anthemis nobilis L. Polish Journal of Pharmacology 
and Pharmacy  29(4):419-423. 
198. Samek Z, M. H, Grabarczyk H, Herout V 1977. The structure of hydroxyisonobilin - a cytostatically 
active sesquiterpenic lactone form the leaves of Anthemis nobilis L. Collection of Czechoslovak Chemical 
Communications  42(3):1065-1067. 
199. Fernandes MB, Scotti MT, Ferreira MJP, Emerenciano VP 2008. Use of self-organizing maps and 
molecular descriptors to predict the cytotoxic activity of sesquiterpene lactones. European Journal of 
Medicinal Chemistry  43(10):2197-2205. 
200. Konig GM, Wright AD, Keller WJ, Judd RL, Bates S, Day C 1998. Hypoglycaemic activity of an 
HMG-containing flavonoid glucoside, chamaemeloside, from Chamaemelum nobile. Planta Medica  
64(7):612-614. 
201. Schrader A, Eckey H, Rohr E 1997. Die Prüfung der Wirksamkeit reizlindernder Stoffe an der 
menschlichen Haut am Beispiel verschiedener Kamillenextrakte. SÖFW Journal  123(1):3-11. 
202. Zeggwagh NA, Michel JB, Eddouks M 2013. Vascular effects of aqueous extract of Chamaemelum 
nobile: In vitro pharmacological studies in rats. Clinical and Experimental Hypertension  35(3):200-206. 
203. Feng W, Liu J, Xu S, Wei J, Yin G, Zhang H. 2012. Chamaemelum nobile extract for producing 
cigarette, is prepared by adding cleaned Chamaemelum nobile flowers with ethanol, digesting and 
filtering resultant product, collecting filtrate, adding ethanol and performing ethanol precipitation. 
A24B15/26 ed., China: YUNNAN TOBACCO SCI RES INST. 
204. Gwinn KD, Green J, Hamilton S, Green JF. 2004. Bioactive herbage composition useful for 
controlling weeds, plant pests or plant pathogens, comprises herbage obtained from Monarda, 
Chamaemelum, Matricaria and/or Chenopodium. A01N65/00 ed.: UNIV TENNESSEE RES FOUNDATION 
[US], GWINN KIMBERLY D [US], GREEN JAMES E [US], HAMILTON SUSAN [US]. p 1-34. 
205. Magro A, Carolino M, Bastos M, Mexia A 2006. Efficacy of plant extracts against stored products 
fungi. Revista Iberoamericana de Micologia  23(3):176-178. 
206. Advanced Chemistry Development (ACD/Labs) Software V11.02 (© 1994-2012 ACD/Labs), 
https://scifinder.cas.org. 
207. Benesova V, Herout V, Sorm F 1964. On terpenes. CLXX. Isolation and sturcture of nobilin 
sesquiterpenic lactone with 10-membered ring. Collection of Czechoslovak Chemical Communications  
29(12):3096-3101. 
208. Benesova V, Samek Z, Herout V, Sorm F 1970. Structure of nobilin. Tetrahedron Letters 
(57):5017-5020. 
Chapter 2. Theoretical section: An overview  52 
    
 
 
 
 
209. Schomburg C, Schuehly W, Da Costa FB, Klempnauer KH, Schmidt TJ 2013. Natural sesquiterpene 
lactones as inhibitors of Myb-dependent gene expression: Structure-activity relationships. European 
Journal of Medicinal Chemistry  63:313-320. 
210. Jacob M, Brinkmann J, Schmidt TJ 2012. Sesquiterpene lactone mix as a diagnostic tool for 
Asteraceae allergic contact dermatitis: Chemical explanation for its poor performance and 
sesquiterpene lactone mix II as a proposed improvement. Contact Dermatitis  66(5):233-240. 
211. Brockhoff A, Behrens M, Massarotti A, Appendino G, Meyerhof W 2007. Broad tuning of the 
human bitter taste receptor hTAS2R46 to various sesquiterpene lactones, clerodane and labdane 
diterpenoids, strychnine, and denatonium. Journal of Agricultural and Food Chemistry  55(15):6236-
6243. 
 
 
 
 
 
 
 
 
Thormann U. et al. 2014. Mechanism of chemical degradation and determination of solubility by kinetic modeling of the highly 
unstable sesquiterpene lactone nobilin in different media. Journal of Pharmaceutical Sciences, to be submitted 
 
   53 
 
Chapter 3 
 
Mechanism of chemical degradation and determination 
of solubility by kinetic modeling of the highly unstable 
sesquiterpene lactone nobilin in different media 
 
3.1  ABSTRACT  
The objective of this work was firstly to investigate the chemical degradation of the sesquiterpene 
lactone nobilin and determine its solubility under conditions of concurrent degradation; secondly, to 
study the effect of biorelevant media used in the in vitro measurement of intestinal absorption on 
degradation and solubility of nobilin. Purely aqueous medium (aq-TMCaco), fasted and fed state 
simulated intestinal fluid (FaSSIF-TMCaco and FeSSIF-TMCaco), and two liposomal formulations 
(LiposomesFaSSIF and LiposomesFeSSIF) with the same lipid concentration as FaSSIF-TMCaco and  
FeSSIF-TMCaco were used. Degradation products were identified by NMR and X-ray crystallography and 
the order of reaction kinetics was determined. Solubility was deduced with a mathematical model 
encompassing dissolution and degradation kinetics that took into account particle size distribution of 
the solid material. Degradation mechanism of nobilin involved water catalyzed opening of the lactone 
ring and transannular cyclization resulting in five degradation products. Degradation followed first order 
kinetics in aq-TMCaco and FaSSIF-TMCaco and higher order kinetics in FeSSIF-TMCaco and the two liposomal 
formulations, while degradation in the latter media was reduced. Solubility of purified nobilin increased 
in the order: aq-TMCaco < FaSSIF-TMCaco < LiposomesFaSSIF < FeSSIF-TMCaco < LiposomesFeSSIF. Improvement 
of stability and solubility of nobilin was consistent with incorporation of the molecule into colloidal lipid 
particles. The developed kinetic model is proposed to be a useful tool for deducing solubility of a highly 
unstable compound with a wide particle size distribution.
 
Chapter 3. Chemical degradation and stability of nobilin 54 
    
 
 
 
 
3.2  INTRODUCTION 
Physicochemical properties such as stability and solubility play an important role in the absorption 
process of a drug. Therefore, these properties are integral part of drug profiling programs. Factors which 
potentially influence stability and solubility in the gastrointestinal tract are the aqueous environment, a 
pH range from 1 to 8 and ingredients such as bile salts, phospholipids, digestive enzymes, and lipolysis 
products.1,2 The biopharmaceutics classification system (BCS) classifies compounds with respect to 
intestinal absorption based on their intestinal permeability and their solubility3 whereas solubility of the 
largest dose strength in 250 mL or less of aqueous media over the pH range of 1 to 7.5 defines a highly 
soluble compound.4 Compounds which reportedly do not fulfill this requirement include danazol, 
mefenamic acid, ketoconazole, glyburide, troglitazone, atovaquone, sanfetrinem cilexetil, dantrolene, 
indinavir, saquinavir, sirolimus, albendazole, 9-nitrocamptothecin, and curcumin.5-20 Additionally, 
chemical instability in the gastrointestinal tract has been reported to compromise absorption such as for 
curcumin or sirolimus.13,14 Furthermore, penicillins were shown to hydrolyze in aqueous solution. The 
half-life of penicillin G at pH 2, 35°C, and ionic strength of 0.5 is 7 min. It could be increased to 15-20 min 
with semisynthetic penicillins such as amoxicillin. Issues of poor stability of a compound are frequently 
accompanied by low solubility. All these penicillins, for instance, show pH dependent degradation and 
solubility with a maximum stability and lowest solubility at pH 6-7.21,22 Other examples of pH dependent 
stability and insufficient solubility are prodrugs of 9-β-D-arabinofuranosyladenine against herpes 
viruses, different HIV protease inhibitors such as 2',3'-dideoxypurine nucleosides, carbovir, or oxathiin 
carboxanilide.23-26  
In recent years, further components of the gastrointestinal tract were considered in connection with 
studying food effect on absorption. The bioavailability of the poorly-water soluble drug danazol, for 
example, was found to be increased by food whereas its solubility was increased by micelles of bile salts, 
phospholipids, and lipolysis products.9,10,15,19 Food effect has become the subject of a guidance for the 
industry issued by the FDA.27 Therefore, several attempts have been made to develop biorelevant media 
to simulate the conditions in the intestine in fasted and fed state.1,5,6,15,28,29 A quite good in vitro-in vivo 
correlation between in vivo bioavailability and in vitro dissolution was seen.6-8,15-17,28,30 Recently, 
biorelevant transport media for in vitro absorption studies with the Caco-2 cell model simulating 
intestinal fluid in the fasted and the fed state, FaSSIF-TMCaco and FeSSIF-TMCaco, respectively, were 
developed.11 The influence of these media on solubility and stability is essential for their role in drug 
absorption.  
Solubility is commonly determined experimentally by adding drug in excess to a medium and directly 
measuring drug concentration at equilibrium.31 This methodology has also been used in the literature 
for determining solubility of unstable compounds whereas sampling was performed typically at a 
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predefined time point.18,21,32-34 No method to determine solubility of an unstable compound taking into 
account chemical degradation has been reported to the best of the authors’ knowledge. 
Nobilin, a sesquiterpene lactone of the germacranolide type which is a marker compound isolated from 
the flowers of Anthemis nobilis L. was used in this study.35 No reports about the chemical stability or the 
solubility of this compound exist in the literature. The aim of the work was to study the mechanism and 
the kinetics of degradation of purified nobilin and identify its degradation products and, further, to 
determine the solubility of nobilin under conditions of concurrent rapid chemical degradation. To 
accomplish the latter goal, the use of a kinetic model is proposed. Moreover, the effect of media 
simulating the environment of the intestinal tract and of vehicles used in in vitro Caco-2 absorption 
studies on stability and solubility of purified nobilin was investigated. The ultimate objective was to 
derive a basic understanding of the effect of the media on stability and solubility and its consequence 
for the bioavailability of nobilin.  
3.3  MATERIALS AND METHODS 
3.3.1   Chemicals 
D-glucose, L-glutamine, 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), sodium chloride 
(NaCl), sodium hydroxide (NaOH), maleic acid, dimethyl sulfoxide (DMSO), Dulbecco’s Modified Eagle’s 
Medium (DMEM) base powder (without D-glucose, L-glutamine, phenol red, sodium pyruvate, and 
sodium bicarbonate),36 and sodium oleate were purchased from SIGMA-Aldrich Chemie GmbH (Buchs, 
Switzerland). Lipoid E PC S and Lipoid S 100 were kindly provided by Lipoid GmbH (Ludwigshafen, 
Germany). Glycerol monooleate was purchased from Danisco (Copenhagen, Denmark). Sodium 
taurocholate was purchased from Prodotti Chimici e di Alimenttari s. p. a. (Basaluzzo, Italy). Methanol 
(MeOH) and ethanol (EtOH) from J.T.Baker (Deventer, Nederland), sodium acetate and formic acid from 
SIGMA-Aldrich Chemie GmbH (Buchs, Switzerland) were of HPLC grade. Water was purified by reversed 
osmosis with the water purification system arium® 61215 from Sartorius (Goettingen, Germany). CD3OD 
was purchased from Armar Chemicals (Döttingen, Switzerland). 
3.3.2   Purified nobilin 
Purified nobilin was kindly provided by Alpinia Laudanum Institute of Phytopharmaceutical Sciences AG 
(ALIPS) (Walenstadt, Switzerland). Nobilin was purified from an ethanolic extract of Chamomillae 
romanae flos (Hänseler AG, Herisau, Switzerland). Fatty acids, phenols, and chlorophyll were 
precipitated with a 5% (w/v) lead(II)acetate solution, filtered over a Celite® 500 fine bed and ethanol 
was evaporated. The remaining water phase was extracted with dichloromethane, the organic phase 
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was dried with magnesium sulfate, filtered, and evaporated. The received precipitate was dissolved in 
ethanol, centrifuged (5810R, Eppendorf AG, Hamburg, Germany), and the supernatant was injected in a 
MPLC (Büchi equipped with a pump manager C-615, a pump module C-605, a variable wave length 
detector C-635, and a fraction collector C-660) operated under isocratic conditions (column: Büchi glas 
column C690 36 × 460 mm pact with silica Polygoprep 100-50 C18 (Macherey Nagel, Oensingen, 
Switzerland); mobile phase: methanol:water (60:40); flow rate: 40 mL/min; detection wave length: 
218 nm). The nobilin-containing fractions were collected and combined, methanol was evaporated, 
water was lyophilized (Labconco, Freezone 2.5 liter, VWR, Switzerland), and purified nobilin was 
obtained as a yellowish white powder. Ethanol was purchased from Alcosuisse (Bern, Switzerland) and 
all other substances were obtained from SIGMA-Aldrich Chemie GmbH (Buchs, Switzerland). This 
method is based on the description of Fischer in Methods of Plant Biochemistry.37 
3.3.3   Isolation of chemical degradation products 
For the isolation and structure elucidation of degradation products, the supplied purified nobilin 
underwent an additional purification step with a preparative HPLC-UV from Varian ProStar equipped 
with a 215 binary pump, a 410 autosampler, a variable wave length detector, a 701 fraction collector 
model, and a C-18 reversed phase column (Reprosil 100 C18, 7 µm, 250 mm × 20 mm ID, Dr. Maisch 
HPLC GmbH, Ammerbuch, Germany). The mobile phases were (A) water with 0.1% (v/v) formic acid and 
(B) MeOH with 0.1% (v/v) formic acid. The composition was varied in a gradient mode: 0 min 50:50 
(A:B), 0-25 min linear change to 10:90 (A:B), 25-35 min 10:90 (A:B) with a flow rate of 25 mL/min and a 
runtime of 35 minutes. Nobilin and the degradation products were detected at 220 nm. The fractions 
were collected every 10 sec and the nobilin containing ones were pooled and lyophilized (Alpha 2-4 LD, 
Crist, Osterode am Harz, Germany). The obtained nobilin was dissolved in EtOH 1 mg/mL, added to 
water 0.05 mg/mL and stirred for 1 day at 37°C. A sample was taken and the advance of the degradation 
was checked by HPLC. The aqueous solution was lyophilized and a white powder was obtained. It was 
dissolved in MeOH:H2O (70:30) and the five different degradation products were purified with 
preparative HPLC as described above. 
3.3.4   Vehicles 
3.3.4.1   Media 
The three different TMCaco (transport media) that are compatible with the Caco-2 cell line were 
described by Markopoulos et al.11 The compositions are shown in Table 1 (purely aqueous medium    
[aq-TMCaco], fasted state simulated intestinal fluid [FaSSIF-TMCaco], and fed state simulated intestinal fluid 
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[FeSSIF-TMCaco]). The media contained DMEM base powder, L-glutamine, and D-glucose to support the 
viability of the cells.  
The DMEM base powder was dissolved in autoclaved water. It was supplemented with D-glucose,          
L-glutamine, NaCl (aq-TMCaco), and HEPES (aq-TMCaco) or maleic acid (FaSSIF-TMCaco and FeSSIF-TMCaco). 
After adjusting the pH with sodium hydroxide and sterile filtration (Supor-200, 0.2 μm pore size, Pall 
Corporation, Port Washington, NY, USA) under aseptic conditions FaSSIF-TMCaco and FeSSIF-TMCaco were 
supplemented with sodium taurocholate, lecithin, glycerol monooleate (only FeSSIF-TMCaco), and sodium 
oleate (only FeSSIF-TMCaco). Lecithin and glycerol monooleate were added to the media separately as 
dichloromethane solution and the organic solvent was evaporated with a rotary evaporator (RE 120, 
Büchi, Flawil, Switzerland) at 40°C and 100 mbar.  
Table 1: Composition of the three transport media. 
 aq-TMCaco FaSSIF-TMCaco FeSSIF-TMCaco 
DMEM base powder [g/L]a 8.3 8.3 8.3 
D-glucose [mM] 25 25 25 
L-glutamine [mM] 6 6 6 
NaCl [mM] 34 - - 
HEPES [mM] 19.98 - - 
Maleic acid [mM] - 19.12 55.02 
NaOH  qs qs qs 
Sodium taurocholate [mM] - 3 6.8 
Lecithin (Lipoid E PC S) [mM] - 0.2 6.8 
Glycerol monooleate [mM] - - 3.4 
Sodium oleate [mM] - - 0.8 
pH 7.4 6.5 5.8 
Osmolality [mOsm/kg] 350 320 390 
a
 contains amino acids, vitamins, electrolytes, trace elements;
36
 qs: sufficient 
 
3.3.4.2   Liposomal formulations 
Liposomes were prepared by the film method. Lipoid S 100 was dissolved in ethanol in a round 
bottomed flask and evaporated to dryness with a rotary evaporator at 40°C. The lipid film was 
suspended in tempered aq-TMCaco (37°C) and extruded under nitrogen pressure of 8-9 bar through 
polycarbonate filters (Nucleopore track edge membrane filters, Whatman plc, Kent, UK) pore size 
0.4 μm (3 times), 0.2 μm (5 times), and 0.1 μm (2 × 10 times).11 The two liposomal formulations in  
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aq-TMCaco had the same lipid concentrations as FaSSIF-TMCaco (3.2 mM) and FeSSIF-TMCaco (17.8 mM) and 
are termed LiposomesFaSSIF and LiposomesFeSSIF.  
3.3.5   Particle size measurement 
The particle size of the mixed micelles of FaSSIF-TMCaco and FeSSIF-TMCaco and the two liposomal 
formulations (LiposomesFaSSIF and LiposomesFeSSIF) were measured by dynamic light scattering using a 
Zetasizer (Nano ZS, Malvern Instruments, Worcestershire, UK). The solutions were equilibrated at least 
30 min at 37°C before measurement. The particle size of the lyophilized purified nobilin was determined 
by laser diffractometry (Sympatec, Helios, Clausthal-Zellerfeld, Germany). 
3.3.6   Structural elucidation of degradation products 1-5 
The structures of the degradation products 1-5 were elucidated by means of LC-MS and extensive NMR 
studies. 1D and 2D NMR spectra were recorded on a Bruker AVANCE IIITM 500 MHz spectrometer 
operating at 500.13 (1H) and 125.77 (13C) equipped with a 1 mm TXI microprobe. All the spectra were 
measured in CD3OD with the residual solvent signal as internal reference. Standard pulse sequences 
from Topspin 3.0 software package were used. 
3.3.7   Single crystal X-ray analysis of degradation product 1 
Crystal data for degradation product 1: Formula C20H28O6, M = 364.44, F(000) = 784, colorless needle, 
size 0.03 · 0.04 · 0.19 mm3, tetragonal, space group P 41, Z = 4, a = b = 10.2900(3) Å, c = 17.5267(8) Å, 
α = β = γ = 90°, V = 1855.80(11) Å3, Dcalc. = 1.304 Mg · m
-3. The crystal was measured on a Bruker Kappa 
Apex2 diffractometer at 123 K equipped with an Incoatec IS with Cu-Anode (Cu Kα-radiation with 
λ = 1.54178 Å), Θmax = 68.216°. Minimal/maximal transmission 0.97/0.98, μ = 0.785 mm
-1. The Apex2 
suite (Bruker AXS Inc., Madison (2006)) was used for data collection and integration. From a total of 
12,673 reflections, 3121 were independent (merging r = 0.039). From these, 2847 were considered as 
observed (I>2.0σ(I)) and were used to refine 236 parameters. The structure was solved by charge 
flipping methods using the program Superflip.38 Least-squares refinement against F was carried out on 
all non-hydrogen atoms using the program CRYSTALS.39 R = 0.0352 (observed data), wR = 0.0369 (all 
data), GOF = 0.9815. Minimal/maximal residual electron density = -0.16/0.29 e Å-3. Sigma weights were 
used to complete the refinement. The Flack parameter was refined using weights derived from a 
leverage analysis as described by Parsons40, and its value of 0.05(8) shows that the handedness of the 
current structural model is correct. Plots were produced using Mercury.41 Crystallographic data 
(excluding structure factors) for the structure in this paper have been deposited with the Cambridge 
Crystallographic Data Center, the deposition number is 981306. Copies of the data can be obtained, free 
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of charge, on application to the CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [fax: +44-1223-336033 or 
e-mail: deposit@ccdc.cam.ac.uk]. 
3.3.8   Kinetics of chemical degradation  
Purified nobilin was dissolved in DMSO at a concentration of 1 mg/mL and added either to purified 
water or to maleic acid / sodium maleate buffer (55.2 mM) with a pH from 4 to 7.5. The final nobilin 
concentration in purified water was 22.1 µg/mL and in maleate buffer around 50 µg/mL. DMSO solution 
of nobilin was added to all other vehicles except FeSSIF-TMCaco to a final concentration of about 3 µg/mL 
and additionally to aq-TMCaco, FaSSIF-TMCaco, and FeSSIF-TMCaco to a final concentration of around 
50 µg/mL. The highest concentration of purified nobilin for stability studies was attained by adding an 
excess of solid nobilin to the vehicles, stirring at 37°C for 30 min, centrifuging at 37°C, and 16,100 g for 
30 min (5415R, Eppendorf AG, Hamburg, Germany) and harvesting the supernatant. Degradation of 
nobilin was monitored in all preparations for 5-7 hours under magnetic stirring at 37°C. 
The following relationship was used to describe the rate of decrease of nobilin concentration: 
 
  
  
      
                                                                                                                                                        
 
where, C is concentrations, kd is rate constant of degradation, x denotes the order of reaction kinetics 
and t is time. 
The rate of nobilin degradation and the rate of formation of degradation products were described by 
the following system of differential equations: 
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where, AN is the area of the nobilin peak of the UV-chromatogram, A1 through A5 is peak area of 
degradation products 1 through 5, respectively, kd is degradation rate constant of nobilin, k1 through k5 
is rate constant of formation of degradation product 1 through 5, respectively, and x denotes the order 
of the reaction kinetics. Equation (8) was introduced to establish mass balance. 
The rate constants fulfill Equation (9). 
 
                                                                                                                                      
 
Equation (1) was employed to determine kd of nobilin in purified water and aqueous maleate buffer by 
fitting to degradation data using x = 1. Equation (1) was further fitted simultaneously to degradation 
data of two or more starting nobilin concentrations in each vehicle to determine kd and x. Equations (2) 
to (9) were fitted to data of nobilin and its degradation products at a single starting nobilin 
concentration to determine kd and k1 to k5. In this fitting, parameter x was kept constant at the value 
deduced by Equation (1). Estimation of parameter values was performed by least square regression 
analysis with the EASY-FIT® software.42   
3.3.9   Solubility study 
An accurately weighted excess of purified nobilin was added to the vehicles and stirred at 37°C. The first 
sample was taken after 30 min, centrifuged at 37°C and 16,100 g for 30 min, diluted, and injected into 
the HPLC. The change in concentration of dissolved nobilin was monitored by repeating this procedure 
every 30 or 60 min for 7-7.5 hours.   
3.3.10  Model for the estimation of solubility  
To estimate solubility, a kinetic model was developed which included the dissolution rate and the 
degradation rate. The dissolution rate is typically expressed by: 1,8,16,17,19  
 
  
  
 
 
 
                                                                                                                                                  
 
where, m is dissolved mass, D is diffusion coefficient, h is thickness of diffusion boundary layer, S is 
surface area, C is measured concentration in solution, Cs is solubility, and t is time.  
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The surface area is connected to the mass msolid of a particulate solid consisting of equally sized spherical 
particles by: 
 
  
        
   
                                                                                                                                                       
 
where, ρ is density, and d is particle diameter. 
Therefore, dissolution rate can be expressed by inserting Equation (11) into Equation (10): 
 
  
  
 
 
 
 
              
   
                                                                                                               
 
whereas, minit is the initial mass of solid material and   is shape factor accounting for deviation from 
spherical shape. 
For a solid material comprising a particle size distribution, the total dissolution rate is given by the sum 
of the contributions of the individual size fractions, i.e., 
 
(
  
  
)
     
 ∑  
             
    
 
   
                                                                                                  
 
where, i denotes size fraction and all constant terms are collected in the coefficient a. 
Taking into consideration that the dissolved nobilin is degraded, the rate of variation of measured 
concentration of intact compound in solution as a result of simultaneous dissolution and chemical 
degradation is given by: 
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where,  
 
         
  
          
                                                                                                                                 
 
with mdegr being amount of degraded compound, m(i) = C(i) V, V is volume of the solution, and ks is 
degradation rate constant. The initial mass of each size fraction was computed from the total weight of 
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the nobilin sample and the weight proportion of the fraction obtained from the particle size 
measurement; n = 27 fractions were used.  
The system of Equations (14) and (15) was fitted to the measured concentration data with the EASY-FIT® 
software.42 The least square-based regression analysis provided an estimation of solubility. In this fitting, 
ks was also treated as an adjustable parameter. The effect of sampling was neglected. 
3.3.11  HPLC  
Purified nobilin and the degradation products were analysed by a HPLC-UV-MS of Agilent series 1200 
equipped with a degaser G1379B, a binary pump G1312A, an autosampler G1367B, a thermostat 
G1330B, a column oven G1316A (series 1100), a variable wave length detector G1314B, and a 
quadrupole LC/MS detector G6130A. A C-18 reversed phase column (Agilent Eclipse XBD-C18, 5 µm, 
2 × 125 mm) and mobile phases (A) water with 0.1% (v/v) formic acid and 0.05 mM sodium acetate and 
(B) methanol with 0.1% (v/v) formic acid and 0.05 mM sodium acetate were used. The composition was 
varied in a gradient mode: 0 min 50:50 (A:B), 0-18 min linear change to 10:90 (A:B), 18-22 min 
10:90 (A:B), 22-23 min linear change to 50:50 (A:B), and 23-28 min 50:50 (A:B) with a flow rate of 
0.25 mL/min, and a runtime of 28 minutes. The samples were cooled in the autosampler to 4°C and the 
column was heated to 40°C. The ions were generated by atmospheric pressure electrospray ionisation 
and MS detector was run in scan mode (m/z 100 - 1000) at positive polarity with capillary voltage 
4000 V, fragmentor 160 V, drying gas flow 10 L/min, drying gas temperature 350°C, and nebuliser 
pressure 20 psig. Nobilin was detected at 218 nm in UV and at m/z 369 and 716 in MS corresponding to 
the sodium adduct of nobilin and the sodium adduct of the dimer of nobilin. The degradation products 
were analysed under the same conditions. The LOQ of nobilin for an injection volume of 100 µL was 
0.02 µg/mL in the UV. Linearity was fulfilled in UV for concentrations up to 100 µg/mL. Standard 
deviation of measured concentrations of the calibration curve in UV was at maximum 10%. 
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3.4  RESULTS 
3.4.1   Stability study 
Chromatograms of samples taken in the beginning and at the end of nobilin stability experiment in 
purified water (Figure 1) demonstrate that nobilin was degraded and five degradation products were 
formed. The measured m/z of the nobilin peak was 369.2 which corresponds to the adduct of nobilin 
with sodium. The 1H and 13C NMR data for degradation products 1-5 are listed in Table 2 and 3, 
respectively.  
 
 
Figure 1: Chemical structure of nobilin and UV-chromatograms of nobilin and its degradation products at time zero and 7 h 
13 min in purified water at 37°C. 
3.4.1.1   Structure elucidation of degradation products 1, 2, and 3  
Degradation products 1, 2, and 3 showed m/z of 387.2 [M+Na]+ indicating the incorporation of a 
molecule of water in the structure of nobilin. Although, on the basis of the only MS data we could have 
only proposed that the hydrolysis of the lactone or the hydration of one double bound had occurred, a 
careful analysis of the NMR data of degradation products 1, 2, and 3 revealed that nobilin rearranged 
into different structures. The 1H and 13C spectroscopic data of degradation product 1, in comparison to 
the starting material, showed upfield resonances for H-1 (δH = 1.46, δc = 50.0 ppm in 1, δH = 5.37, 
δc = 127.0 ppm in nobilin) and CH3-14 (δH = 1.26 ppm in 1, δH = 1.89 ppm in nobilin) being the latter 
bounded to an oxygenated-sp3 quaternary carbon C-10 (δc = 71.6 ppm). Moreover, the methine at C-6 
was significantly upfield shifted (δH = 2.40, δc = 40.1 ppm in 1, δH = 6.04, δc = 79.5 ppm in nobilin) thus 
1
2
3
4 5
Nobilin in H2O (37°C)
blue: 0 h
red: 7 h 13 min
Nobilin
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indicating that it was no more connected to the lactone moiety. The presence, in the COSY spectrum, of 
a strong correlation between methines H-1 and H-6, allowed us to conclude that C-1 and C-6 were 
connected through a single bond, thus leading to a decaline ring. The junction of the decaline system 
was deduced to be trans considering the coupling constants of H-1 who showed a dd, J = 11.5 and 
11.5 Hz, indicative of diaxial interactions with H-2axial and H-6. The absolute stereochemistry of the new 
cadinane structure was assigned by X-ray (Figure 2). A similar rearrangement was also revealed by the 
NMR data of compounds 2 and 3 that were diastereoisomers of 1. For compound 2 the cis-junction of 
the decaline system was established according to the value of the mutual coupling constant of the two 
angular methines 3JH, H H-1/H-6 (J = 5.0 Hz). The stereochemistry of the compound was then assigned on 
the basis of the NOESY correlations (H-8/H-6; H-1/H-6; H-1/CH3-14) and it was consistent with that 
proposed previously for simpler cadinane-type structures.43 Degradation product 3 is the 10-S epimer of 
1, being the only remarkable difference between the NMR data of the 2 compounds the δc of CH3-14 
(δc = 21.6 in 1, δc = 28.0 in 3), thus suggesting its equatorial orientation in 3. This stereochemistry was 
corroborated by the diagnostic NOESY cross peak between H-2and CH3-14. 
 
 
Figure 2: X-ray structure of degradation product 1. 
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3.4.1.2   Structure elucidation of degradation product 4 
Degradation product 4 gave a m/z 369.2, i.e., the same as nobilin. Similarly to what was mentioned 
before, the lactone opening and the formation of the decaline moiety were deduced by the resonance 
of angular methine H-6 (br d, J = 10.6 Hz, δH = 3.14, δc = 44.0 ppm). 1D and 2D NMR data of 4 showed 
that the compound conserved the unsaturation at C1-C10 as in nobilin, although H-1 was replaced by a 
quaternary carbon (δc = 124.1 ppm) due to the additional bond C-1/C-6. This structure assignment was 
corroborated by a 3JC,H HMBC correlation from H-2eq (δH = 3.05, δc = 37.3 ppm) to C-6. The 
stereochemistry of C-6 was assigned to be  by the large value of 3JH,H H-6/H7 (J = 10.6 Hz) and was 
proved by the NOESY correlations H-8/H-6. 
3.4.1.3   Structure elucidation of degradation product 5 
Degradation product 5 showed a m/z value of 351.2 for the [M+Na]+ that differed from that of nobilin by 
18 mass units. The NMR spectra of 5 displayed two ortho-coupled aromatic protons at 7.17 ppm 
(d, J = 8.0 Hz) and 6.97 ppm (dd, J = 8.0 and 1.0 Hz) assigned to H-2 and H-3, respectively, by their HMBC 
correlations. Moreover, the 1H spectrum of 5 lacked the resonances of H-1 and H-6, being C-1 and C-6 
quaternary carbons (δc = 137.5 ppm and δc = 138.7 ppm respectively), thus corroborating the formation 
of the aromatic cadinanoate structure 5. The -pseudo-equatorial orientation of CH3-14 (d, 7.0 Hz, 
δH = 1.34, δc = 22.3 ppm) was deduced on the basis of 
3JH,H H-9axial/H-10 (J = 10.3 Hz) that suggested the 
pseudo-axial orientation of H-10. 
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Table 2: 
1
H spectroscopic data (CD3OD, 500.13 MHz) for degradation products 1-5. 
Compound 
Position 
1 2 3 4 5 
1 1.46  
dd, J = 11.5, 11.5 Hz 
1.95 
ddd, J = 12.9, 4.0, 
5.0 Hz 
1.35 
dd, J = 11.0, 11.0 Hz 
- - 
2axial 1.26 
ddd, J = 12.5, 11.5, 
10.0 Hz 
1.75
a
 
m 
1.45 
ddd, J = 12.3, 11.0, 
10.5 Hz 
1.94  
dd, J = 11.6, 11.6 Hz 
7.17 
d, J = 8.0 Hz 
2equatorial 2.38 
ddd, J = 12.4, 6.0, 
1.7 Hz 
1.75
a
 
m 
2.23 
ddd, J = 12.0, 6.0,  
1.4 Hz 
3.05 
dd, J = 12.6, 5.5 Hz 
- 
3 4.12 
t, J = 8.0 Hz 
3.96 
br s  
4.14 
t, J = 8.0 Hz 
4.00 
m, W1/2 = 9.0 Hz 
6.97 
dd, J = 8.0, 1.0 Hz 
5 5.22
a
 
br s  
5.43 
d, J = 2.5 Hz 
5.22 
br s  
5.25 
br s 
6.82 
br s 
6 2.40-2.50
a
 
m  
2.70-2.87
a
 
m 
2.50-2.70
a
 
m  
3.14 
br d, J = 10.6 Hz 
- 
7 2.40-2.50
a
 
m  
2.70-2.87
a
 
m
 
 
2.50-2.70
a
 
m  
2.63 
dd, J = 11.3, 10.5 Hz 
4.02 
d, J = 8.6 Hz 
8 5.22
a
 
m  
5.36
a
 
m
 
 
5.35 
m  
5.22 
ddd, J = 11.2, 9.8,  
5.7 Hz 
5.53 
ddd, J = 10.0, 8.6, 
3.6 Hz 
9axial 1.57 
dd, J = 11.5,10.5 Hz 
1.52 
dd, J = 12.0, 11.3 Hz 
1.57 
dd, J = 12.6, 11.5 Hz 
2.11 
dd, J = 16.0, 9.8 Hz 
1.61 
ddd, J = 12.3, 10.3, 
10.3 Hz 
9equatorial 2.17 
dd, J = 11.8, 4.5 Hz 
2.00 
dd, J = 12.0, 4.0 Hz 
2.14 
dd, J = 12.8, 5.0 Hz 
2.47 
dd, J = 16.6, 5.7 Hz 
2.26 
ddd, J = 12.5, 5.5, 
3.6 Hz 
10 - - - - 3.08 
m, W1/2 = 18 Hz 
13a 5.66 br s 5.78 br s 5.70 br s 5.71 br s 5.52 
d, J = 1.3 Hz 
13b 6.34 br s 6.34 br s 6.36 br s 6.38 br s 6.31 
d, J = 1.3 Hz 
14 1.26 s 1.26 s 1.27 s 1.72 s 1.34 
d, J = 7.0 Hz 
15 1.70 s 1.73 s 1.68 s 1.70 s 2.21 br s 
18 6.00 
qq, J = 7.3, 1.3 Hz 
5.97 
br q , J = 7.3 Hz 
5.99 
qq, J = 7.3, 1.3 Hz 
6.02 
qq , J = 7.3, 1.3 Hz 
6.05 
qq, J = 7.3, 1.3 Hz 
19 1.88 
dq, J = 7.3, 1.3 Hz 
1.85 
 dq , J = 7.3, 1.3 Hz 
1.86 
dq, J = 7.3, 1.3 Hz 
1.88 
dq, J = 7.3, 1.3 Hz 
1.90 
dq, J = 7.3, 1.3 Hz 
20 1.78 
quint, J = 1.3 Hz 
1.75 
quint, J = 1.3 Hz  
1.77 
quint, J = 1.3 Hz 
1.77 
quint, J = 1.3 Hz 
1.77 
quint, J = 1.3 Hz 
s, singlet; d, doublet; t, triplet; quint, quintet; m, multiplet; dd, doublet of doublets;  
ddd, doublet of doublets of doublets; qq, quartet of quartet; dq, doublet of quartet; br, broad.  
a
 Overlapped signals 
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Table 3: 
13
C spectroscopic data (CD3OD, hsqc/hmbc, 500.13 MHz) for degradation products 1-5. 
Compound 
Position 
1 2 3 4 5 
1 50.0 40.4 48.9 124.1 137.5 
2 33.50 31.0 33.6 37.3 127.5 
3 68.7 68.7 72.0 71.2 128.2 
4 139.4 136.5 138.6 138.9 136.6 
5 126.2 128.1 126.8 126.2 129.5 
6 40.1 37.0 39.7 44.0 138.7 
7 51.6 45.1 49.5 49.3 51.2 
8 71.9 74.8 73.6 73.9 74.2 
9 48.1 40.9 46.7 39.1 37.9 
10 71.6 74.2 72.3 129.3 32.5 
11 140.0 140.3 140.1 141.8 144.2 
12 169.9 170.2 170.3 170.3 170.5 
13 129.2 127.5 126.8 126.1 129.0 
14 21.6 28.9 28.0 19.2 22.3 
15 19.6 20.7 19.5 18.3 21.0 
16 168.6 169.4 168.6 168.9 168.9 
17 129.2 129.3 129.4 128.9 129.4 
18 138.6 138.2 138.1 138.6 138.6 
19 16.0 16.0 15.9 16.0 16.0 
20 20.7 21.5 19.5 20.7 20.8 
 
3.4.1.4   Kinetics of chemical degradation  
The decrease of nobilin concentration in stability experiments in aqueous buffer solution at different pH 
values is shown in Figure 3. Similar concentration-time profiles were obtained at pH values ranging 
between 4 and 7.5. Values of the degradation rate constant kd deduced from the fit of Equation (1) are 
given in Table 4. In this calculation, first order degradation kinetics was used by setting x = 1 which 
provided adequate description of the data (r2 = 0.9991-0.9995). The use of first order kinetics is 
confirmed by the analysis of degradation kinetics in aq-TMCaco discussed below. 
The degradation of nobilin in these purely aqueous solutions took place rather quickly with a half-life of 
approximately 2 hours. There was no difference of degradation rate between purified water and 
maleate buffer. Also, degradation was found to be independent of pH. 
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Figure 3: Measured concentrations of nobilin and fitted curves at different pH values as a function of time. 
Table 4: Degradation rate constant and half-life of purified nobilin in water and maleate buffer. 
Solvent kd [h
-1]a t1/2 [h] 
purified water 0.3581 (3.10 × 10-3) 1.9 
buffer pH 4 0.3436 (3.18 × 10-3) 2.0 
buffer pH 4.5 0.3435 (3.18 × 10-3) 2.0 
buffer pH 5 0.3579 (3.44 × 10-3) 1.9 
buffer pH 5.5 0.3570 (3.28 × 10-3) 1.9 
buffer pH 6 0.3553 (3.27 × 10-3) 2.0 
buffer pH 6.5 0.3623 (3.32 × 10-3) 1.9 
buffer pH 7 0.3771 (3.43 × 10-3) 1.8 
buffer pH 7.5 0.3630 (4.09 × 10-3) 1.9 
kd are values deduced from regression analysis with standard error (in brackets),
 a
 x was set equal to one according to the 
results shown in Table 6. 
 
 
 
  
Chapter 3. Chemical degradation and stability of nobilin 69 
    
 
 
 
 
Figure 4 illustrates the decrease of the nobilin peak area and the simultaneous increase of the peak of 
the different degradation products over time. The corresponding rate constants deduced by fitting 
Equations (2) through (9) to these data are given in Table 5. Degradation product 1 was most abundantly 
present accounting for 36.5% of total degradation followed by products 2 and 4 with 14.4% and 11.5%, 
respectively, while products 3 and 5 were more scarcely represented with 2.2% and 3.3%, respectively.  
Figure 4 further shows that the proportion of each degradation product remains constant in the course 
of the reaction.  
 
 
Figure 4: Peak area of UV chromatograms of nobilin and its degradation products in purified water as a function of time. Data 
points and fitted model curves of nobilin () in blue and its degradation products (other symbols) in red. 
Table 5: Kinetic constants of nobilin degradation and formation of degradation products in purified water. 
Substance  kd [h
-1]a k1-5 [h
-1]a (k1-5/kd) × 100 [%] 
nobilin 0.3581 (3.10 × 10-3) - - 
degradation product 1 - 0.1306 (9.98 × 10-4) 36.5 
degradation product 2 - 0.0515 (3.93 × 10-4) 14.4 
degradation product 3 - 0.0078 (5.99 × 10-5) 2.2 
degradation product 4 - 0.0413 (3.16 × 10-4) 11.5 
degradation product 5 - 0.0119 (9.11 × 10-5) 3.3 
k1-5 and kd are values with standard error (in brackets) deduced from regression analysis, 
a
 x was set equal to one according to 
the results shown in Table 6. 
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The degradation rate constants and the order of reaction kinetics in different vehicles obtained by fitting 
Equation (1) to degradation data with different initial nobilin concentrations are shown in Table 6. The 
degradation process of purified nobilin in aq-TMCaco and FaSSIF-TMCaco followed first order kinetics. For 
FeSSIF-TMCaco, LiposomesFaSSIF, and LiposomesFeSSIF the exponent x acquired values 1.22, 1.19, and 1.11, 
respectively, these being greater than one. This suggests that in these colloidal systems the reaction rate 
had a somewhat stronger dependence on concentration compared to aq-TMCaco. Also, a substantially 
slower degradation is evident for these vehicles compared to aq-TMCaco.  
Table 6: Degradation constant and order of reaction kinetics in different vehicles. 
Vehicle 
 
kd [h
-1 (µg/mL)1-x] x Total lipid conc. 
[mM] 
Particle size 
[nm] 
purified water  0.3581 (0.31 × 10-2) 1a - - 
aq-TMCaco 0.4169 (0.29 × 10
-2) 1.00 (0.31 × 10-2) - - 
FaSSIF-TMCaco 0.3297 (1.36 × 10
-2) 0.97 (1.42 × 10-2)  3.2 83.2 
FeSSIF-TMCaco 0.0204 (0.44 × 10
-2) 1.22 (3.95 × 10-2)  17.8 68.8 
LiposomesFaSSIF 0.0409 (0.28 × 10
-2) 1.19 (1.45 × 10-2)  3.2 120.7 
LiposomesFeSSIF 0.0084 (0.12 × 10
-2) 1.11 (2.36 × 10-2)  17.8 124.9 
kd and x are values with standard error (in brackets) deduced from regression analysis, 
a
 fixed to the value of aq-TMCaco 
The degradation products detected for these vehicles were the same as those found in the stability 
experiment with purified water shown in Figure 1. The relative amount of each of the five degradation 
products measured in the different vehicles was generally the same as the one found with purified 
water, when all five products were present at a detectable level (Table 7).   
Table 7: Proportion of degradation products formed in different vehicles. 
Vehicle 
 
(k1 /kd)  
× 100 [%] 
(k2 /kd)  
× 100 [%] 
(k3 /kd)  
× 100 [%] 
(k4 /kd)  
× 100 [%] 
(k5 /kd)  
× 100 [%] 
purified water  36.47 14.38 2.18 11.53 3.32 
aq-TMCaco 35.47 13.86 1.98 10.51 3.24 
FaSSIF-TMCaco 36.30 14.04 2.00 10.10 3.10 
FeSSIF-TMCaco 45.12 19.44 1.91 15.02 3.87 
LiposomesFaSSIF 39.27 16.95 nd 16.10 nd 
LiposomesFeSSIF 53.38 21.79 nd 24.82 nd 
kd, degradation rate constant of nobilin, k1 through k5, rate constant of formation of degradation product 1 through 5, 
respectively, nd, not detectable 
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3.4.2   Solubility study 
 
 
Figure 5: Concentration of dissolved nobilin () as a function of time and fitted model curves in solubility measurements in 
different vehicles. 
The data of the solubility experiments and the fitted curves of model Equation (14) are shown in 
Figure 5. A sharp increase of the dissolved nobilin concentration is observed at first. Interestingly, this 
concentration did not stay constant but decreased as a function of time although an excess of solid 
material was available in the mixture. The calculated solubility and the degradation rate constant from 
Equation (14) are shown in Table 8. For this calculation, the relative mass frequency of each particle size 
fraction of purified nobilin measured by laser diffractometry (Figure 6) was used. Purified nobilin is very 
slightly soluble in aq-TMCaco while solubility in FaSSIF-TMCaco, FeSSIF-TMCaco, LiposomesFaSSIF, and 
LiposomesFeSSIF was 1.3-, 4.7-, 1.5-, and 6.8-fold, respectively, larger compared to aq-TMCaco. The 
coefficient a was between 0.5 × 10-6 and 1 × 10-6 cm4/(µgh). The degradation rate constant, ks, was 
comparable for aq-TMCaco and FaSSIF-TMCaco and was smaller for FeSSIF-TMCaco, LiposomesFaSSIF, and 
LiposomesFeSSIF suggesting that degradation was slower in the last three vehicles. A similar result was 
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obtained in the stability experiments (Table 6). However, degradation rate constants determined in the 
solubility experiments were considerably larger in comparison to those determined in the same vehicles 
in the stability experiments. This difference was greater for the vehicles exhibiting slow degradation.   
 
 
Figure 6: Particle size distribution of purified nobilin. 
Table 8: Solubility of purified nobilin in different vehicles. 
Vehicle  Cs [µg/mL] a [cm
4/(µgh)] ks [h
-1 (µg/mL)1-x] 
aq-TMCaco 151.3 9.8 × 10
-7 1.7058 
FaSSIF-TMCaco 195.7 4.7 × 10
-7 2.0986 
FeSSIF-TMCaco 714.9 4.5 × 10
-7 0.4776 
LiposomesFaSSIF 225.7 7.2 × 10
-7 0.9690 
LiposomesFeSSIF 1032.4 5.5 × 10
-7 0.4053 
Cs is solubility, a is a coefficient, ks is degradation rate constant. Values are deduced from regression analysis. 
 
3.5  DISCUSSION  
The present work demonstrates that nobilin is a highly unstable compound in aqueous solution. Our 
findings are in agreement with the literature that documents the high susceptibility of germacranolides 
to undergo chemical transformations.44 All the degradation products are acids with cadinane skeleton 
generated from nobilin through transannular cyclization of the trans 1(10) double bond and opening of 
the lactone. The reaction probably proceeds through a C-10 tertiary cation intermediate that can evolve 
in different ways, affording diastereoisomers 1, 2, and 3 after nucleophilic attack by water or product 4 
if deprotonated. Further dehydration of the secondary alcohol bounded at C-3 gave aromatic product 5 
(Figure 7). The kinetic of the reaction in aqueous medium did not show significant changes in a range of 
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pH between 4 and 7.5. The pathway involving addition of water appears to be the predominant pathway 
accounting for > 50% of nobilin degradation products (Table 5). Decay of nobilin concentration not 
accounted for by degradation products may be because of undetected HPLC peaks or variations in the 
UV absorption coefficient. 
 
 
Figure 7: Proposed degradation mechanism of nobilin. 
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The degradation process follows first order kinetics in aq-TMCaco. For FeSSIF-TMCaco, LiposomesFaSSIF, and 
LiposomesFeSSIF on the other hand, a slightly higher order of reaction kinetics was found. This could 
explain the measured degradation rates at different initial nobilin concentrations. The stronger 
dependence of the reaction rate on nobilin concentration may be elicited by the colloidal lipid particles 
that are present in these media (Table 6). It may be suggested that reaction taking place at the surface 
of the colloidal particles has an impact on the kinetic order of the process. This effect was not observed 
for FaSSIF-TMCaco, a fact that could be related to the small lipid content of this medium. It has been 
documented that the interface between two phases can affect the reaction process. Morales et al., for 
example, reported an increased reaction rate of the cyanide-catalyzed aerobic oxidation of the 
B6 vitamers pyriodoxal and pyriodoxal-5'-phosphate in presence of cationic micelles and a change of the 
order of reaction kinetics at the surface of the micelles.45 Sicilia et al. made a similar observation that 
the complexation kinetics of titanium(IV) with Pyrogallol Red and the oxidation of chromium(VI) by 
Pyrogallol Red was increased in presence of dodecyltrimethylammonium bromide micelles, this effect 
being due to the second order reaction at the interface.46 Also, Ghosh et al. suggested the involvement 
of the surface of sodium dodecyl sulfate micelles in the oxidation of formaldehyde by Ce(IV).47  
Significantly, stability of purified nobilin was considerably increased in the three vehicles FeSSIF-TMCaco, 
LiposomesFaSSIF, and LiposomesFeSSIF. It appears therefore that the presence of lipid particles leads to a 
slower nobilin degradation. This effect was stronger for the vehicles with high lipid content and may also 
depend on the nature of the lipid and/or the structure of the colloidal particle as indicated by comparing 
the liposomal vehicles to the mixed micellar FaSSIF-TMCaco and FeSSIF-TMCaco systems (Table 6). The 
degradation product profile in the vehicles did not change in comparison to that in water as long as all 
five degradation products were detectable suggesting that the mechanism of the chemical reaction was 
not affected by the used vehicles. Nobilin is a rather lipophilic compound with a calculated clogP of 
2.572 (± 0.601)48 which suggests that it has the tendency to be incorporated in the colloidal lipid 
particles. This would shield nobilin from the catalytic action of water discussed in the reaction 
mechanism (Figure 7) and may, therefore, explain its improved stability in these vehicles. A similar effect 
was reported for analogs of penicillin that were stabilized by cationic and nonionic micelles in acid 
solutions. It was proposed that this stabilization was because of the lipophilic character of the 
compounds leading to incorporation into the micelles that prevented acid-catalyzed degradation.49 This 
effect also increased solubility of the drugs in the presence of nonionic micelles.49  
In the present study, the solubility of nobilin was increased by the vehicles in the order: FaSSIF-TMCaco <  
LiposomesFaSSIF < FeSSIF-TMCaco < LiposomesFeSSIF. This may also be explained by the incorporation of the 
compound into colloidal lipid particles which is supported by its lipophilicity and was invoked in 
connection with its improved chemical stability in these vehicles. Solubility follows the same rank order 
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as the degree of stability improvement elicited by the vehicles. The increase of solubility is stronger for 
the vehicles with high lipid concentration whereas the liposomal vehicles seem to have a stronger effect 
than the mixed micelles. Saha et al. showed improved solubility and stability of 9-nitrocamptothecin in 
presence of pluronic micelles.18 The same was seen for the drug sirolimus which showed a higher 
solubility and stability in presence of D-α-tocopheryl polyethylene glycol succinate micelles or             
self-microemulsifying drug delivery systems.13,33 Solubility of the poorly water-soluble drug danazol was 
increased by micelles of bile salts, phospholipids, and lipolytic products.9,10,15,19 
For determining solubility, a model was developed that took into account simultaneous dissolution and 
degradation of the compound. This was necessary since no equilibrium concentration was reached in 
the solubility experiments. Instead, nobilin concentration reached rapidly a peak and subsequently 
declined steadily in the presence of excess amount of solid material. This suggests that dissolution of 
nobilin took place at a sharply decreasing rate in the course of the solubility experiment to the effect 
that dissolution rate was overwhelmed by degradation rate at later time points. The high initial 
dissolution rate can be due to the fine particles of the solid material exhibiting a large specific surface 
area which are quickly consumed while the remaining large particles dissolve at a much lower rate 
because of their comparatively small specific surface area. This time dependent decline of the 
dissolution rate is expected to become more pronounced for solid material with a wide particle size 
distribution.  
The developed model accounts for this pattern of dissolution rate by considering dissolution of 
individual size fractions of the solid material accompanied by chemical degradation. This population 
balance approach is new for this application in the literature. The developed model provided adequate 
fits of the experimental concentration data (GOF > 0.999) and allowed the estimation of nobilin 
solubility. Moreover, the good approximation afforded by the model substantiates the assumed 
mechanism of simultaneous dissolution and chemical degradation of a highly unstable compound.  
The coefficient a seemed to be lowered somewhat by the used vehicles (Table 8). This is not surprising 
since incorporation in vesicles or micelles may alter the apparent diffusivity of the compound. Modeling 
of the degradation rate was based on the kinetic equation with the same order used in the stability 
study, whereas the rate constant was treated as adjustable parameter. Interestingly, the deduced 
degradation rate constants of purified nobilin from the solubility study, ks, were larger compared to kd 
that was obtained in the stability experiments. This may be attributed to degradation reaction taking 
place at the surface of solid particles, in analogy to the effect of the surface of colloidal particles on 
degradation reaction kinetics discussed above. This is compatible with the observation that the 
difference between kd and ks is larger for the vehicles exhibiting slow degradation in the stability 
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experiment as the protective effect due to incorporation of nobilin in colloidal particles is partially 
alleviated by reaction at the solid surface.  
The developed model for calculating drug solubility with concurrent rapid chemical degradation can be a 
useful tool in drug development for estimating solubility of an unstable compound. Typically, solubility 
in these cases has been estimated at reduced degradation rate by selecting appropriate conditions, for 
example, of pH or temperature.24-26 In other reports, solubility was determined after addition of an 
excess of solid drug, vigorous agitation and sampling at one time point or at equilibrium.18,21,32-34,49 The 
present study demonstrates that these practices are not universally applicable for determining solubility 
of highly unstable compounds. It is also noteworthy, that rate constants of degradation determined with 
drug solutions in colloidal systems can not be a priori transferred to drug suspensions in these systems. 
Rather, drug solubility in suspensions should be estimated by taking simultaneously into consideration 
the degradation rate in the system.  
Chemical stability and solubility are properties affecting drug bioavailability that are part of routine drug 
profiling programs. Based on the high instability and poor solubility of nobilin in water, a low 
bioavailability of the compound after per-oral administration may be predicted. The presence of lipid 
constituents in the form of colloidal particles markedly improved stability, which is in accord with the 
identified degradation reaction mechanism of the drug, while increasing its solubility in aqueous 
environment. The investigated vehicles constitute biorelevant media simulating the fasted and the fed 
state in the intestinal tract as well as a prototype lipid-based formulation of liposomes. The strong effect 
of FeSSIF-TMCaco suggests that intestinal absorption of nobilin might be improved in the fed state, while 
a lipid formulation-based approach could also have a promising effect on absorption.50 These questions 
are explored in a subsequent study using the Caco-2 model. 
3.6  CONCLUSION 
Nobilin degrades quickly in aqueous solution into five main degradation products by a mechanism 
involving water catalyzed opening of the lactone ring and transannular cyclization followed by water 
addition or proton elimination. Stability can be improved by incorporation of the compound in colloidal 
lipid particles. Degradation reaction is accelerated in the presence of solid nobilin suspension and the 
order of reaction kinetics is altered by colloidal lipids. Water solubility of nobilin is low and is 
considerably increased in mixed micellar biorelevant media and by phospholipid vesicles.  
Determination of solubility of a highly unstable compound requires kinetic modeling of simultaneous 
dissolution and degradation processes taking into account particle size distribution of solid material. 
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Chapter 4 
 
Transport of nobilin conjugation products  
and the use of the extract of Chamomillae romanae flos 
influence absorption of nobilin in the Caco-2 model 
 
4.1  ABSTRACT 
Purpose: The objective of the present study was to investigate the role of bioconversion and carrier 
mediated efflux of conjugation products in the absorption mechanism of nobilin in the Caco-2 model in 
vitro and to elucidate the impact of the extract of Chamomillae romanae flos and its ingredients on 
bioconversion and efflux.   
Methods: Inhibitors of P-gp, BCRP, and MRPs were used to detect efflux and its connection to 
bioconversion and the effect of different ingredients of the extract on absorption processes was 
determined. Permeation and bioconversion parameter values were deduced by means of kinetic multi-
compartment modeling.  
Results: Nobilin exhibited high permeability, low absorption and fast bioconversion producing 
glucuronide, cysteine conjugate, and glutathione conjugate that were transported by P-gp (first two), 
apical MRP2 and basal MRP3 and possibly MRP1 out of the cell. Inhibition of efflux resulted in 
diminished bioconversion and improved absorption. The extract increased the relative fraction absorbed 
primarily by directly inhibiting bioconversion but also by reducing efflux. This was only partly explained 
by the individual ingredients.  
Conclusion: The transport-bioconversion interplay is shown to be a possible mechanism for increasing 
absorption of a compound undergoing extensive bioconversion. Plant extracts may increase absorption 
by this mechanism in addition to metabolic enzyme inhibition.   
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4.2  INTRODUCTION 
Bioconversion by metabolizing enzymes and membrane permeation by efflux and influx transporter 
proteins influence intestinal drug absorption. Absorption can be increased or decreased by the interplay 
between metabolizing enzymes and transporters or by the interaction between co-administered 
compounds; this can be due to inhibition or induction of metabolizing enzymes or transporters.1,2 
Interaction between synthetic drugs has been extensively studied whereas in recent years the interest in 
the absorption of compounds from multi-component mixtures such as phytopharmaceuticals has risen. 
Increased absorption of a compound applied as full plant extract was reported for instance for paclitaxel 
from Taxus yunnanensis, aconitine, mesaconitine, and hypaconitine from Aconitum species, and 
rosmarinic acid from Plectranthus barbatus.3-5 Further, presence of Angelicae sinensis extract increased 
the absorption of formononetin and calycosin from Astragalus membranaceus var. mongholicus 
extract.6     
Several drugs are documented to be substrates of apical and basal efflux and influx carriers. Paclitaxel, 
digoxin, verapamil, and fexofenadine, for example, are transported apically out of the enterocytes by 
the well characterized transporter protein P-gp (P-glycoprotein, ABCB1).7-9 Fexofenadine is in addition 
substrate of the apical MRP2 (multidrug resistance protein, ABCC2) and the basal MRP3 (ABCC3).7,9 
Methotrexate, further, is substrate of MRP2, MRP3, and the basal MRP1 (ABCC1) transporter and is 
additionally transported apically out of the cell by BCRP (breast cancer resistance protein, ABCG2).7,10  
Fexofenadine is not only transported by efflux carriers but also by the influx transporter protein 
OATP2B1 (organic anion transporting polypeptide, SLCO2B1) at the apical membrane.7,9 Further relevant 
influx transporter proteins are PEPT1 (peptide transporter 1, SLC15A1), MCT1 (monocarboxylic acid 
transporter 1, SLC16A1), ASBT (ileal apical sodium bile acid co-transporter) at the apical membrane and 
OCT1 (organic cation transporter 1, SLC22A1) and the heteromeric organic solute transporter  
(OSTα-OSTβ) at the basal membrane.7  
Drugs undergo phase I metabolism by different cytochrome P450 enzymes in the enterocytes, e.g., 
verapamil.8 Other substances are substrates of phase II enzymes for example the flavonoid apigenin 
which is glucuronidated by UDP-glucuronosyltransferase and sulfated by sulfotransferase or busulfan 
which is conjugated by glutathione S-transferase to the glutathione conjugate.11,12 These metabolites are 
often substrates of the above mentioned efflux transporter proteins. The metabolites of verapamil are 
transported by P-gp, apigenin glucuronide and sulfate are substrates of MRPs and/or BCRP and 
glutathione conjugates such as the endogenous leukotriene C4 are transported by MRPs.8,12-14 
Furthermore, the influx carriers OATP transport steroid conjugates.7   
Interestingly, some cases of functional interplay between metabolizing enzymes and transporter 
proteins were observed in recent years. For instance, metabolism of K77 and sirolimus, which are 
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substrates of cytochrome P450 and P-gp, was decreased by inhibition of the efflux transporter in the 
Caco-2 model whereas the inhibition did not reduce metabolism of the non P-gp substrates midazolam 
and felodipine.15,16 Also, interplay between phase II metabolism and transporters was suggested such as 
for the glucuronidation of apigenin and genistein with BCRP or glucuronidation and sulfonation of 
apigenin with MRPs.12,14,17,18 
The in vitro study of intestinal absorption taking into consideration transporter proteins and 
metabolizing enzymes is routinely carried out using the Caco-2 cell culture model.19-22 This is a  
well-established and well characterized model that shows a largely similar expression pattern of 
transporters and metabolizing enzymes as intestinal cells.23-25 In a study involving 10 different 
laboratories, Caco-2 cells were shown to well express the transporters P-gp, BCRP, MRP2, MRP3, MRP1, 
and OATP. In contrast to the intestine, phase I metabolizing enzyme CYP was poorly expressed whereas 
the phase II conjugating enzymes glutathione S-transferase and UDP-glucuronosyltrasferase were well 
expressed.22 
The objective of the present study was to investigate the mechanism of intestinal absorption of nobilin 
in the Caco-2 model. Nobilin is a sesquiterpene lactone of the germacranolide type which is a marker 
compound isolated from Chamomillae romanae flos, the flowers of Anthemis nobilis L.26 No reports 
about the bioavailability of nobilin exist in the literature. The first specific aim of the study was to 
investigate the effect of bioconversion and of carrier mediated efflux of the ensuing conjugation 
products on nobilin absorption and to ascertain a possible interplay between bioconversion and efflux. A 
kinetic model-based approach was employed to this end. The second aim was to elucidate the impact of 
the full extract of Chamomillae romanae flos and its ingredients, i.e., sesquiterpene lactones, essential 
oil, and flavonoids27 on metabolizing enzymes and transporter proteins that influence nobilin 
absorption. By unraveling the interplay between bioconversion and efflux and the interaction between 
the plant extract and nobilin or nobilin bioconversion products with respect to these processes, 
possibilities to improve the absorption of nobilin should be elaborated.  
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4.3  MATERIALS AND METHODS 
4.3.1   Chemicals 
The human colon adenocarcinoma cell line Caco-2 was a gift of Prof. H. P. Hauri, Biocenter, University of 
Basel, and originated from the American Type Culture Collection (ATCC, Rockville, MD, USA). The 
Dulbecco’s modified Eagle’s medium (DMEM) (with L-glutamine, 4500 mg/L D-glucose, without sodium 
pyruvate), MEM non-essential amino acids solution (100×, without L-glutamine), L-glutamine 200 mM 
(100×), fetal bovine serum (FBS), Trypsin 0.5%-EDTA (10×) liquid, Dulbecco’s phosphate buffered saline 
(with and without Ca2+, Mg2+) were all purchased from Gibco® Invitrogen corporation (Paisley, UK). The 
cell culture medium was supplemented with 10% (v/v) FBS, 1.8 mM L-glutamine, and 1% (v/v) MEM. 
The absorption studies were carried out in aq-TMCaco (aqueous transport medium) containing Dulbecco’s 
modified Eagle’s medium (DMEM) base powder (without D-glucose, L-glutamine, phenol red, sodium 
pyruvate, and sodium bicarbonate) (8.6 g/L)28 supplemented with D-glucose (25 mM), L-glutamine 
(6 mM), sodium chloride (34 mM) and HEPES (19.98 mM) was dissolved in purified water. The medium 
was adjusted to a pH 7.4 and sterile filtered (Supor-200, 0.2 μm pore size, Pall Corporation, Port 
Washington, NY, USA).29 The substances were purchased from SIGMA-Aldrich Chemie GmbH (Buchs, 
Switzerland). Petri dishes (56.7 cm2) were purchased from Nunc A/S (Roskilde, Denmark), Petri dishes 
(21 cm2) and 6-well polycarbonate membrane transwell™ plates with an insert area of 4.7 cm2 and 
0.4 μm pore size were ordered from Costar (Corning Incorporated, Corning, NY, USA). 
Nobilin, a sesquiterpene lactone with Mr 346 was kindly provided by Alpinia Laudanum Institute of 
Phytopharmaceutical Sciences AG (ALIPS) (Walenstadt, Switzerland). Nobilin was purified from 
Chamomillae romanae flos (PhEur) as described before.30 The inhibitors verapamil, Ko143, MK-571, and 
leukotriene C4, the solvent dimethyl sulfoxide (DMSO), the detergent Triton® X-100 and the flavonoid 
apigenin were bought from SIGMA-Aldrich Chemie GmbH (Buchs, Switzerland). Luteolin was purchased 
from Extrasynthese (Genay Cedex, France), and essential oil of Chamomillae romanae flos from Essencia 
(Winterthur, Switzerland). Ethanolic extract and the sesquiterpene lactone fraction of Chamomillae 
romanae flos (PhEur) were provided by ALIPS. The sesquiterpene lactone fraction was obtained from 3 L 
of ethanolic extract of Chamomillae romanae flos. The extract was concentrated to a volume of 
approximately 300 mL by rotary evaporation. Fatty acids, phenols, and chlorophyll were precipitated 
with a 5% (w/v) lead(II)acetate solution and filtered over a Celite® 500 fine bed. The yellowish solution 
was applied on an Amberlite® XAD16 column (30 × 360 mm). The column was washed with 1 L of 
EtOH:water (50:50) and the lipophilic compounds were eluted with EtOH. Fractions of 100 mL were 
collected and the sesquiterpene lactone containing fractions were combined. EtOH was evaporated and 
the yellowish oily residue was collected. Ethanol was purchased from Alcosuisse (Bern, Switzerland) and 
all other substances were obtained from SIGMA-Aldrich Chemie GmbH (Buchs, Switzerland).  
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Methanol and ethanol from J.T.Baker (Deventer, Nederland), sodium acetate and formic acid from 
SIGMA-Aldrich Chemie GmbH (Buchs, Switzerland) were of HPLC grade. Water was purified by reversed 
osmosis with the water purification system arium® 61215 of Sartorius (Goettingen, Germany). 
4.3.2   Cell culture 
Caco-2 cells were cultivated in Petri dishes (56.7 cm2) using culture medium at 37°C in a water saturated 
atmosphere of 8% CO2 (Sorvall Heraeus, Heracell, Kendro Labaratory Products, Zürich, Switzerland). The 
cells were passaged by treatment with a solution of 0.25% trypsin and 2.63 mM EDTA with a splitting 
ratio of 1:5-1:10 when the cell monolayer reached 70-90% confluence. Cells of passage numbers 60-65 
were seeded at a density of 1.14 × 105 cells/cm2 in 6-well transwell™ plates and incubated for 19-21 
days. The medium was changed every other day. 
4.3.3   TEER 
The integrity of the Caco-2 cell monolayer in the transwell™ plates was ensured with TEER measurement 
before every permeation experiment. The monolayer was washed with pre-warmed (37°C) D-PBS (with 
Ca2+, Mg2+) (apical 3 mL and basal 4 mL). 1.6 mL of tempered aq-TMCaco was added to the apical and 
2.8 mL aq-TMCaco to the basal compartment. The transwell™ plate was equilibrated for 60 min in the cell 
culture incubator and TEER was measured with an EVOM resistance meter (World Precision 
Instruments, Sarasota, FL, USA) equipped with an EndOhm-24SNAP chamber (World Precision 
Instruments, Sarasota, FL, USA) which was tempered at 37°C with 4.6 mL aq-TMCaco. Caco-2 monolayers 
with TEER values above 470 Ω cm2 were used for permeation experiments. 
4.3.4   Permeation experiment 
After the TEER measurement, the aq-TMCaco was removed and the tempered nobilin containing            
aq-TMCaco was added. Nobilin was dissolved in DMSO (1 mg/mL) and added to aq-TMCaco (final DMSO 
concentration 0.3%) to a starting concentration of around 7 µM. To investigate the permeation in the 
apical-to-basal direction, 1.6 mL of the nobilin solution was added to the apical compartment and 
2.8 mL of blank aq-TMCaco to the basal compartment. For the basal-to-apical direction, 1.6 mL of blank       
aq-TMCaco was added to the apical and 2.8 mL of the nobilin solution to the basal compartment. One 
plate was used for each direction.   
Stock solutions of the inhibitors Ko143 in DMSO (4 mg/mL), MK-571 in aq-TMCaco (5mg/mL) and 
leukotriene C4 in EtOH (26.5 µg/mL) were prepared. Leukotriene C4 was delivered dissolved in methanol 
which was replaced with EtOH. The final concentration of the inhibitors in aq-TMCaco was for verapamil 
100 µM31, Ko143 10 µM32, MK-571 50 µM33, and leukotriene C4 0.035 µM. A combination of verapamil, 
Ko143 and MK-571 at the same concentrations was also used. Nobilin from a stock solution of 1 mg/mL 
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or 2 mg/mL in DMSO was added to a final concentration of 6 to 14 µM. The final DMSO concentration 
was always < 1% (v/v). The inhibitors were added to both compartments.  
The ethanolic extract was diluted 1:200 (v/v) with aq-TMCaco yielding a nobilin concentration of 
approximately 2.5 µM. Stock solutions of the ingredients of the extract were prepared at the following 
concentrations: Essential oil in EtOH (4.1 mg/mL), sesquiterpene lactone fraction in EtOH (2.21 mg/mL), 
apigenin in EtOH (1.1 mg/mL) and in DMSO (1.94 mg/mL), luteolin in DMSO (2.2 mg/mL). The stock 
solutions were added to aq-TMCaco to final concentrations of essential oil 5.56 µg/mL, sesquiterpene 
lactone fraction 7.83 µg/mL, apigenin 2.29 µM from EtOH stock solution (apigenin 1) and 10 µM from 
DMSO stock solution (apigenin 2), luteolin 10 µM, and apigenin 2 plus luteolin each 10 µM. Nobilin was 
added from stock solutions in EtOH or in DMSO to match the solvent of the ingredients of the extract to 
a final concentration of 2 to 12 µM. The final EtOH content was adjusted to 0.5% and that of DMSO was 
< 1% (v/v). The components of the extract were added only to the compartment containing nobilin.  
The transwell™ plate was shaken on an orbital shaker at 37°C in a water saturated atmosphere under an 
incubator hood with a stirring rate of 120 rpm (KS15, Edmund Bühler GmbH, Tübingen & Hechingen, 
Germany). Permeation of nobilin across the cell monolayer was monitored by drawing samples of 
100 µL from both compartments after 10 min, 35 min, 1 h, 1.5 h, 2 h, and 2.5 h. One hundred µL of 
methanol was added and the samples were stored at 4°C. Under these conditions nobilin was chemically 
stable. At each time point one insert was removed and used for cell extraction. 
4.3.5   Cell extraction 
Both sides of the transwell™ were washed with 4°C cold D-PBS (without Ca2+ and Mg2+), the insert was 
transferred to a Petri dish (21 cm2), 750 µL of a 1% Triton X-100® solution in aq-TMCaco was added and 
the dish was shaken at 120 rpm on an orbital shaker for 15 min at 37°C under an incubator hood. The 
cells were scraped of the polycarbonate membrane using a cell scraper (BD Falcon, BD Biosciences 
Discovery Labware, Bedford, USA), transferred into a 1.5 mL tube (Eppendorf AG, Hamburg, Germany), 
and frozen at -80°C.   
The sample was thawed within 3 min at 37°C under shaking with 1400 rpm (Thermomixer comfort, 
Eppendorf AG, Hamburg, Germany), 750 μL MeOH was added, and kept on ice bath for 20 min. After 
shaking for 10 min at 37°C with 1400 rpm, the sample was centrifuged for 3 min at 16,100 g and 25°C 
(5415R, Eppendorf AG, Hamburg, Germany). The supernatant was transferred to a tube and stored at 
4°C. The pellet was disintegrated in 750 μL methanol with 6 pulses of an ultrasonic disintegrator 
(Branson Sonifier 250, Model 101-063-197, Branson Ultrasonics Corporation, Danbury,CT, USA, 
instrument settings: output control 2, duty cycle 30%), shaken for 5 min on the thermomixer (37°C and 
1400 rpm), and centrifuged at 16,100 g and 25°C for 3 min. After repeating the pellet disintegration 
once, the methanolic supernatants were united, and the methanol was evaporated under nitrogen flow. 
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The residue was taken up with the methanol-water supernatant of the first extraction. The sample was 
shaken on the thermomixer at 1400 rpm and 37°C for 3 min and centrifuged for 25 min at 16,100 g and 
25°C before HPLC analysis.  
4.3.6   HPLC 
Nobilin and its conjugates were analysed by HPLC-UV-MS of Agilent series 1200 equipped with a degaser 
G1379B, a binary pump G1312A, an autosampler G1367B, a thermostat G1330B, a column oven 
G1316A, a variable wavelength detector G1314B, and a single quadrupole MS detector G6130A. A C-18 
reversed phase column (Agilent Eclipse XBD-C18, 5 µm, 2 × 125 mm) and mobile phase consisting of     
(A) water with 0.1% (v/v) formic acid and 0.05 mM sodium acetate and (B) methanol with 0.1% (v/v) 
formic acid and 0.05 mM sodium acetate were used. The composition of the mobile phase was varied in 
a gradient mode: 0 min A:B 50:50, 0-18 min linear change to A:B 10:90, 18-22 min A:B 10:90, 22-23 min 
linear change to A:B 50:50, and 23-28 min A:B 50:50 with a flow rate of 0.25 mL/min and a runtime of 
28 minutes. The samples were cooled in the autosampler to 4°C and the column was heated to 40°C. 
The ions were generated by atmospheric pressure electrospray ionisation and the MS detector was run 
in scan mode (m/z 100 - 1000, for all samples) and SIM mode (for samples of the cell extraction) at 
positive polarity with capillary voltage 4000 V, fragmentor 160 V, drying gas flow 10 L/min, drying gas 
temperature 350°C and nebulizer pressure 20 psig. Nobilin was detected at 218 nm in UV and at 
m/z 369, and 716 in MS corresponding to the sodium adduct of nobilin and the sodium adduct of the 
dimer of nobilin, respectively. The glucuronide was detected at m/z 525, the glutathione conjugate at 
m/z 654, and the cysteine conjugate at m/z 468 corresponding to their protonated forms. The 
conjugates were quantified with the calibration curve of nobilin. The LOQ of nobilin for an injection 
volume of 100 µL was 0.02 µg/mL in the UV and 0.004 and 0.0001 µg/mL in MS scan and SIM mode, 
respectively. Linearity was fulfilled in UV for concentrations up to 4 µg/mL and in MS (scan and SIM 
mode) up to 1 µg/mL. Standard deviation of measured concentrations of the calibration curve in UV and 
MS (scan and SIM mode) was at maximum 10%. 
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4.3.7   Kinetic modeling 
To describe the processes taking place in the course of nobilin absorption in the Caco-2 model and 
comprising diffusional and carrier mediated membrane permeation, intra- and extra-cellular 
bioconversion, and chemical degradation, a kinetic model was developed taking into account that: 
1. Nobilin permeates the cell membrane by diffusion.  
2. Nobilin is chemically degraded in aqueous solution following first order kinetics.30 
3. Three conjugation products of nobilin, i.e., glucuronide, cysteine conjugate, and glutathione 
conjugate are formed in the cells. 
4. These conjugation products are transported out of the cells in an asymmetric fashion. 
For the proposed model the following assumptions were made: 
1. The conjugation products of nobilin cross the cell membrane by diffusion and by the action of the 
efflux transporters localized in the apical membrane (e.g., P-gp, BCRP, and MRP2) and transporters 
localized in the basal membrane (e.g., MRP1 and MRP3).7,10,22 
2. Glucuronide is transported apically into the cell (e.g. by OATP) and hydrolyzed in the cell by the 
action of β-glucuronidase.7,34,35 
3. The glutathione conjugate is hydrolyzed by the brush border membrane enzymes                                  
γ-glutamyltranspeptidase and dipeptidase yielding in part cysteine conjugate.36 
4. Conjugation reactions and the hydrolysis of glucuronide and glutathione conjugates obey first order 
kinetics. 
5. Transporter mediated membrane permeation can be described by first order kinetics and the entire 
amount of substance in the compartment of origin, typically the cellular compartment, is substrate 
for the transporter. No back-transport occurs.29,37 
6. Permeability coefficient (diffusional) of nobilin is different for the apical and the basal membrane 
because of the difference between the two membranes whereas for glucuronide, cysteine conjugate, 
and glutathione conjugate the same permeability value applies to both membranes. 
Scheme 1 illustrates the diffusional and carrier mediated membrane permeation, the intra- and extra-
cellular bioconversion of nobilin and its conjugation products, and the chemical degradation of nobilin. 
The noted parameters are used in the equations of the model.  
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Scheme 1: Transport of nobilin and its conjugates. 
A system of differential equations was established describing the change of concentration of nobilin and 
its three conjugation products as a function of time in the apical, the cellular, and the basolateral 
compartments for apical-to-basal and basal-to-apical transport taking into consideration the processes 
shown in Scheme 1. Similar but simpler models were described by this group previously.29,38,39 
The system of equations is given below: 
Nobilin 
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where, CA, CB, and CC are concentration in the apical, basal, and cellular compartments, respectively, Pa 
and Pb are permeability coefficient of the apical and the basal membranes, respectively, Ka/c is the 
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partition coefficient between apical and cellular compartment, kd is the chemical degradation rate 
constant in aq-TMCaco, kdc is the total conjugation rate constant in the cell, VA, VB, and VC are volume of 
the apical, basal, and cellular compartments, respectively, S is the surface area (4.7 cm2), and t is time. 
The cellular volume was 0.0094 mL calculated with a monolayer thickness of 20 µm and kd was 
determined previously to be 1.17 × 10-4 s-1 for nobilin and 1.08 × 10-4 s-1 for nobilin as plant extract.40  
A combined permeability coefficient, P, applying to both membranes was calculated from Pa and Pb by 
Equation (7) and the standard error with Equation (8). 
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The extent of in vitro absorption was introduced to quantify the maximal amount of intact nobilin 
appearing in the basal compartment and was expressed as the relative fraction absorbed given by 
Equation (9). The denominator of Equation (9) gives the amount of nobilin in the basal compartment at 
equilibrium when neither chemical degradation nor bioconversion takes place and was defined as 100% 
in vitro absorption. 
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where, Fa is the relative fraction absorbed, C ab
o  and CCab
o  is concentration in the basal and cellular 
compartment, respectively, when neither chemical degradation nor bioconversion take place, and tma 
  
and tma 
o  is the time at which maximum absorption is observed. C ab
o  and CCab
o  were simulated using the 
determined values of Pb and Ka/c. 
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Glucuronide (conjugate 1) 
apical-to-basal (index ab): 
      
  
                  
 
  
                
 
  
                                                        
                 
 
  
                                                                                                
      
  
                  
 
  
                
 
  
                                                    
      
  
                            
 
  
                  
 
  
                        
                
 
  
                 
 
  
                                                    
                
 
  
                                                                                 
basal-to-apical (index ba): 
      
  
                  
 
  
                
 
  
                                                       
                 
 
  
                                                                                                
      
  
                  
 
  
                
 
  
                                                    
      
  
                            
 
  
                  
 
  
                       
                
 
  
                 
 
  
                                                       
                
 
  
                                                                                 
Cysteine conjugate (conjugate 2) 
apical-to-basal (index ab): 
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basal-to-apical (index ba): 
      
  
                  
 
  
                
 
  
 
         
 
                       
      
  
                  
 
  
                
 
  
                                                    
      
  
                            
 
  
                  
 
  
                       
                
 
  
                
 
  
                                                
Glutathione conjugate (conjugate 3) 
apical-to-basal (index ab): 
      
  
                  
 
  
                
 
  
                                
      
  
                  
 
  
                
 
  
                                                    
      
  
                            
 
  
                  
 
  
                        
                
 
  
                
 
  
                                                
basal-to-apical (index ba): 
      
  
                  
 
  
                
 
  
                                
      
  
                  
 
  
                
 
  
                                                    
      
  
                            
 
  
                  
 
  
                           
                
 
  
                
 
  
                                                
 
where, MA, MB, and MC are concentration of the conjugate in the apical, basal, and cellular 
compartments, respectively, the digit 1, 2, and 3 in the name of the variable or as index denotes 
glucuronide, cysteine conjugate, and glutathione conjugate, respectively, kdc is conjugation rate 
constant, kd1 is the hydrolysis rate constant of glucuronide in the cell, kd3 is hydrolysis rate constant of 
glutathione conjugate at the apical membrane, x is the inverse fraction of glutathione conjugate that is 
metabolized to cysteine conjugate, v is carrier mediated transport rate constant whereas indices a, aa, 
and b indicate apical efflux, apical influx, and basal efflux, respectively, and all other symbols were 
defined above. 
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The total conjugation rate constant in the cell, kdc, was set equal to the sum of the individual rate 
constants kdc1, kdc2, kdc3, and kdcr. 
 
                                                                                                                                           
 
Because conjugation products were quantified using nobilin as a standard and a possible chemical 
degradation of the conjugates or a further metabolite of nobilin were not detected, the parameter kdcr 
was introduced to establish mass balance in the equations.  
The system of differential equations was numerically solved and simultaneously fitted to experimental 
concentration or mass data of nobilin and its three conjugation products in all three compartments in 
both transport directions with Equation (28) as a constraint using the EASY-FIT® software.41 From the 
least square regression analysis, values of the permeability coefficients, carrier mediated transport rate 
constants, and bioconversion constants which were treated as adjustable parameters were deduced.  
Equation (1) to (6) were first fitted only to the nobilin data to deduce kdc and then the system of 
Equation (1) through (6) and (10) through (27) was fitted to all data keeping the kdc value fixed. 
The reduction of the volume in the apical and basal compartment because of sampling was described by 
the following empirical equations. 
 
                                                                                                                          
                                                                                                                          
 
Significance test was carried out based on the incidence of overlap of the confidence intervals at the 
p = 0.01 level of two estimated values of a parameter from different experimental sets. In addition, the 
relation 
 
  
                    
     
       
                                                                                                                          
 
was used where, value(α) and value(β) are two values of a parameter and (SE)α and (SE)β are the 
corresponding standard errors of the estimates. Significance was determined by comparing F with the 
critical value F0.01[1,df], where df is degrees of freedom of residuals for which df = 8 was used. An 
agreement between the two tests was required for declaring statistical significance of the difference 
between two values of a parameter; this agreement was observed in the vast majority of cases. 
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4.4  RESULTS 
4.4.1   Transport of nobilin and its conjugates 
Typical chromatograms of samples of the apical and basal compartments for both transport directions 
of the permeation experiment at 10 min and 2.5 h are shown in Figure 1. Nobilin was detected at 
m/z 369.2 and three additional peaks were detected with m/z 525, 468, and 654. Nobilin is present in 
the donor compartment at 10 min while marked peaks of the three further substances are evident in 
the apical and the basal solutions at 2.5 h. The m/z 525 peak was attributed to a conjugate of nobilin 
with glucuronic acid and addition of two hydrogen atoms detected as [M+H]+. The m/z 468 peak 
indicated the formation of a conjugate of nobilin with cysteine and the m/z 654 peak a conjugation with 
glutathione, both detected as [M+H]+.  
 
 
Figure 1: MS-chromatograms of the apical and basal compartment for the transport direction apical-to-basal (a  b) and    
basal-to-apical (b  a). Chromatograms in dark color with the nobilin peak represent the time point 10 min and the 
chromatograms in red (light) color with m/z 525, 468, and 654 represent the time point 2.5 h. 
Figure 2 shows results of nobilin and Figure 3 results of the three conjugation products of nobilin in the 
Caco-2 permeation experiment. Drawn lines were obtained by simultaneous fitting of the model to all 
experimental data. A rapid permeation of nobilin from the donor into the cells and onward in the 
receiver compartment is observed. Nobilin concentration decreased quickly in all three compartments 
and reached near zero concentrations after 2.5 hours. Fitted curves are in good agreement with the 
data. 
a  b b  a
basalbasal
apical apicalNobilin
525
468
Nobilin
525
468
654
Nobilin
525
468
654
Nobilin
525
468
654654
Chapter 4. Transport of conjugates and the use of the extract influence nobilin absorption 96 
    
 
 
 
 
 
 
 
 
Figure 2: Nobilin concentration in the apical-to-basal (top panel, red) and the basal-to-apical (middle panel, blue) transport 
direction in both compartments and nobilin mass in the cellular compartment (bottom panel) in both transport directions as a 
function of time. () apical concentration, (●) basal concentration, (□) mass in apical-to-basal transport direction (red), (■) mass 
in basal-to-apical transport direction (blue). Symbols represent measured data and lines fitted model curves.  
Rather large concentrations / amounts of all three conjugation products were detected. The 
concentration of glucuronide in the apical solution increased in the beginning and later decreased while 
concentration in the basal solution steadily increased over time. As a result, apical concentration was at 
early time points greater and at later times lower than the basal concentration. This was true for both 
transport directions. The concentration-time profiles of the cysteine conjugate were different. Apical 
and basal concentrations increased constantly with time but the former was considerably greater than 
the latter throughout the experiment in both transport directions. Glutathione conjugate concentration 
pattern, finally, was similar to that of glucuronide, apical concentrations, however, briefly increased and 
then rapidly declined while basal concentrations steadily increased reaching a large difference to the 
apical ones. The amount of all conjugates in the cell increased at first and then decreased to very low 
levels over time in both transport directions. These results demonstrate that transport of the conjugates 
out of the cell was highly asymmetric. Model curves generally described the data adequately. 
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The parameter values deduced by fitting Equation (1) to (6) and (10) to (27) to the data are given in 
Table 1. Nobilin had a quite large permeability coefficient (2.75 × 10-4 cm/s) and a small partition 
coefficient Ka/c = 0.058. Bioconversion rate constant in the cell was much larger than the degradation 
rate constant in solution (kd = 1.17 × 10
-4 s-1 versus kdc = 7.64 × 10
-3 s-1).40 The relative fraction absorbed 
was 38%. 
Conversion of nobilin to glucuronide in the cell took place at the highest rate followed in decreasing 
order by the formation of the glutathione conjugate and the cysteine conjugate. Formation of 
glucuronide, glutathione conjugate, and cysteine conjugate accounted for 51%, 28%, and 10%, 
respectively, of total bioconversion. The introduced correction rate constant kdcr accounted for less than 
11% of total conversion.  
Transport of the conjugation products out of the cell was considered to take place by diffusion and 
carrier mediated efflux. The permeability coefficients of the glucuronide (5.24 × 10-8 cm/s), the cysteine 
conjugate (3.68 × 10-8 cm/s), and the glutathione conjugate (1.24 × 10-7 cm/s) were estimated from the 
experiment with the combination of the inhibitors verapamil, Ko143, and MK-571 by omitting the terms 
of carrier mediated transport. The obtained values were used as fixed parameters in all experiments for 
the estimation of the other parameter values. The permeability coefficients of the conjugation products 
were 2000- to 20,000-fold smaller compared to that of nobilin. The estimated carrier mediated 
transport rate constants differed between the conjugates and also between apical and basal efflux and 
apical influx, where applicable. The glutathione conjugate showed the largest carrier mediated transport 
rate constant for the apical and basal membrane compared to glucuronide (3.4- and 5.5-fold difference) 
and cysteine conjugate (4.9- and 29-fold difference). The glucuronide, in turn, exhibited a slightly larger 
apical and a higher basal efflux rate constant than the cysteine conjugate. Apical efflux rates were higher 
than basal rates for glucuronide and cysteine conjugate while the opposite was true for the glutathione 
conjugate. The apical influx rate constant of glucuronide was marked lower than the efflux constants of 
this conjugate. The hydrolysis rate constant of glucuronide in the cell was found to be almost as large as 
the conjugation rate constant of glucuronidation. The hydrolysis rate constant of the glutathione 
conjugate in the apical compartment was 4-fold smaller than the rate constant of glutathione 
conjugation. Approximately one third of the glutathione conjugate yielded cysteine conjugate after 
hydrolysis.  
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Table 1: Kinetic parameter values of nobilin and its conjugates.
a 
Parameter Nobilin Glucuronide Cysteine conjugate Glutathione conjugate 
P [cm/s] 2.75 × 10-4  
(1.18 × 10-5) 
5.24 × 10-8 3.68 × 10-8 1.24 × 10-7 
Ka/c 0.058 (0.0025) - - - 
Fa 38% - - - 
va   [s
-1cm-2] - 0.79 (0.069) 0.54 (0.063) 2.65 (0.20) 
vaa [s
-1cm-2] - 0.16 (0.027) - - 
vb  [s
-1cm-2] - 0.62 (0.031) 0.12 (0.0064) 3.44 (0.17) 
kdc [s
-1] 7.64 × 10-3 
(3.00 × 10-4) 
- - - 
kdc1,2,3 [s
-1] - 3.88 × 10-3  
(7.25 × 10-4) 
7.77 × 10-4 
(6.67 × 10-5) 
2.13 × 10-3 
(1.03 × 10-4) 
kd1 [s
-1] - 3.10 × 10-3  
(8.89 × 10-4) 
- - 
kd3 [s
-1] - - - 4.97 × 10-4  
(5.00 × 10-5) 
x - - 3.5 (1.35) - 
a
 Deduced values from model fitting and standard error (in brackets). 
P is permeability coefficient, Ka/c is partition coefficient between the apical and the cellular compartment), Fa is the relative 
fraction absorbed, v is the carrier mediated transport rate constant (index a, aa, and b denote apical efflux, apical influx, and 
basal efflux, respectively), kdc is the total conjugation rate constant of nobilin, kdc1,2,3 is conjugation rate constant (index 1, 2, 
and 3 refers to the conjugates), kd1 is hydrolysis rate constant of glucuronide, kd3 is hydrolysis rate constant of glutathione 
conjugate, x is the inverse fraction of glutathione conjugate that is metabolized to cysteine conjugate.  
 
4.4.2   Influence of transporter inhibition on the transport of nobilin and its conjugates 
The estimated parameter values of nobilin in the presence of inhibitors of membrane carriers are shown 
in Figure 4. Concentration profiles of nobilin from the permeation experiments with the inhibitors are 
not shown (see appendix). The added inhibitors had generally no influence on the permeability 
coefficient or the partition coefficient Ka/c. Ko143 and MK-571 caused a significant reduction of the total 
conjugation rate constant of 1.5- and 15-fold, respectively. The inhibitor combination 
verapamil/Ko143/MK-571 yielded a kdc value that was not statistically different from zero. Verapamil 
had no effect on kdc while leukotriene C4 caused a rise of this parameter value. The reduction of the 
total conjugation rate constant was accompanied by an increase of the relative fraction absorbed from 
38% with no inhibitor to 52%, 74%, and 81% for Ko143, MK-571, and the combination 
verapamil/Ko143/MK-571, respectively. The reported value of kdc for the inhibitor combination 
verapamil/Ko143/MK-571 corresponds to three fold the standard error of the estimate because the 
estimated value of the parameter was within the error margin of the calculation.  
Chapter 4. Transport of conjugates and the use of the extract influence nobilin absorption 100 
    
 
 
 
 
 
 
 
 
Figure 4: Deduced values (columns) and standard errors (bars) of permeability coefficient P, partition coefficient Ka/c (dark and 
light columns, respectively, on left panel), total conjugation rate constant kdc, and relative fraction absorbed Fa (dark and light 
columns, respectively, on right panel) of nobilin from model fitting in the presence of inhibitors.  p<0.01. 
The effect of the transport inhibitors on the estimated parameter values of the conjugates is shown in 
Figure 5. The apical and the basal efflux rate constants of glucuronide were reduced by 2- to 3-fold by 
verapamil and 20- to 170-fold by MK-571, respectively. The inhibitor combination did not further 
suppress efflux. The apical influx of glucuronide was not affected by verapamil while for MK-571 and the 
inhibitor combination no independent estimation was possible and the value was fixed to the average of 
the other experiments. The apical and the basal efflux rate constants of the cysteine conjugate were 
reduced 4.5- and 6.3-fold, respectively, by verapamil and MK-571 reduced the apical constant 16.9-fold 
and completely abolished basal efflux. Ko143, additionally, diminished basal efflux of the cysteine 
conjugate, and the inhibitor combination had a comparable effect as MK-571. The apical and the basal 
efflux rate constant of the glutathione conjugate was reduced only by MK-571 13.9- and 61-fold, 
respectively. Ko143 had no effect on the transport of glucuronide and glutathione conjugate and 
verapamil and leukotriene C4 had no effect on the transport of glutathione conjugate. Finally, for the 
basal efflux of glucuronide and cysteine conjugate an increase of the rate constant by leukotriene C4 
was observed.  
The rate constant of formation of glucuronide was significantly diminished in the presence of Ko143, 
MK-571, and the inhibitor combination. The formation rate constant of cysteine conjugate was reduced 
in the presence of MK-571, the inhibitor combination, and leukotriene C4. Finally, formation of the 
glutathione conjugate was diminished in the presence of all used inhibitors. The hydrolysis rate constant 
of glucuronide in the cell, kd1, was reduced only by the inhibitor combination and the apical hydrolysis of 
the glutathione conjugate was not affected by the used inhibitors. The fraction of glutathione conjugate 
metabolized to cysteine conjugate was not affected by the inhibitors and varied between 0.21 and 1. 
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Figure 5: Deduced values (columns) and standard errors (bars) of carrier mediated apical efflux rate va, carrier mediated apical 
influx rate vaa, carrier mediated basal efflux rate vb (dark, diagonally hatched, and light columns, respectively, on left panel),  
conjugation rate constant kdc, and hydrolysis rate constant of glucuronide and glutathione conjugate kd (dark and light columns, 
respectively, on right panel) of the three conjugates (index 1, 2, and 3 refers to the conjugates) from model fitting in the 
presence of inhibitors.  p<0.01. 
4.4.3   Influence of the full extract and extract ingredients on the transport of nobilin and its 
conjugates 
The estimated parameter values of nobilin applied as plant extract and nobilin in the presence of 
different extract ingredients are shown in Figure 6. Concentration profiles of nobilin are not shown (see 
appendix) for these permeation experiments. The full extract and the extract ingredients had no effect 
on the permeability coefficient while the extract, EtOH, and apigenin 2 reduced the partition coefficient 
Ka/c. The total conjugation rate constant was significantly reduced in the presence of the extract, EtOH, 
sesquiterpene lactone fraction, essential oil, luteolin, and the combination of apigenin 2 and luteolin, 
Chapter 4. Transport of conjugates and the use of the extract influence nobilin absorption 102 
    
 
 
 
 
 
 
whereas the full extract exhibited the strongest effect. The relative fraction absorbed was increased 
markedly only for the full extract from 38%, for the pure compound, to 71%.    
 
 
Figure 6: Deduced values (columns) and standard errors (bars) of permeability coefficient P, partition coefficient Ka/c (dark and 
light columns, respectively, on left panel), total conjugation rate constant kdc, and relative fraction absorbed Fa (dark and light 
columns, respectively, on right panel) of nobilin from model fitting in the presence of full extract and ingredients of the extract.  
p<0.01. 
The impact of extract and extract ingredients on the estimated parameter values of the conjugates is 
shown in Figure 7. Application of nobilin as plant extract caused a reduction of the apical efflux rate 
constant of glucuronide, cysteine conjugate, and glutathione conjugate by 2.7-, 2.6-, and 6-fold, 
respectively. The basal efflux rate constant of cysteine conjugate and glutathione conjugate was 
decreased by the extract 2- and 2.7-fold, respectively. Additionally, the extract decreased the 
conjugation constant of glucuronide, cysteine conjugate, and glutathione conjugate in the cell 14-, 4-, 
and 6-fold, respectively. 
The apical efflux rate constant of glucuronide was significantly decreased only by the sesquiterpene 
lactone fraction whereas the basal efflux was reduced by the combination of apigenin 2 and luteolin. 
The apical efflux rate constant of cysteine conjugate was diminished by the sesquiterpene lactone 
fraction, essential oil, and apigenin 1 2.8-, 2.2-, and 6.2-fold, respectively and its basal efflux rate 
constant was 2.4-, 4.3-, and 2.2-fold smaller in the presence of the sesquiterpene lactone fraction, 
apigenin 1, and the combination of apigenin 2 and luteolin, respectively. The apical and the basal carrier 
mediated rate constant of the glutathione conjugate were decreased by the sesquiterpene lactone 
fraction, essential oil, apigenin 1, and the combination apigenin 2 and luteolin between 1.4- and  
7.2-fold.   
The apical efflux rate constant of glucuronide was larger in the presence of apigenin 2 and the basal 
efflux rate constant was increased by EtOH, essential oil, and apigenin 2. The basal efflux of the cysteine 
conjugate was also increased in the presence of apigenin 2.   
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The conjugation rate constant of glucuronide was diminished by EtOH, sesquiterpene lactone fraction, 
apigenin 1, apigenin 2, and luteolin. A decrease of the conjugation rate constant of cysteine and 
glutathione conjugate was observed in the presence of all ingredients of the extract except for 
apigenin 1. The fraction which was metabolized from glutathione conjugate to cysteine conjugate was 
between 0.35 and 1. 
 
 
Figure 7: Deduced values (columns) and standard errors (bars) of carrier mediated apical efflux rate va, carrier mediated apical 
influx rate vaa, carrier mediated basal efflux rate vb (dark, diagonally hatched, and light columns, respectively, on left panel), 
conjugation rate constant kdc, and hydrolysis rate constant of glucuronide and glutathione conjugate kd (dark and light columns, 
respectively, on right panel) of the three conjugates (index 1, 2 and 3 refers to the conjugates) from model fitting in the 
presence of the full extract and ingredients of the extract.  p<0.01. 
  
Chapter 4. Transport of conjugates and the use of the extract influence nobilin absorption 104 
    
 
 
 
 
 
 
4.5  DISCUSSION 
Nobilin has moderate lipophilicity (clogKO/W 2.572 ± 0.601)
42 and a molecular weight of less than 
500 g/mol which are characteristics of a compound with good intestinal permeation.43 The permeability 
coefficient of 2.75 × 10-4 cm/s determined in this study further confirms that according to the 
biopharmaceutics classification scheme a large extent of absorption should be expected.44 Also, the 
determined partition coefficient between aqueous solution and cell interior (Ka/c = 0.058) indicates a 
high affinity of the molecule for the biological tissue which supports good permeation. However, an in 
vitro absorption of only 38% was found in the Caco-2 model while there are no reports about the in vivo 
bioavailability of nobilin. Little is known about the absorption of sesquiterpene lactones in general. The 
few studies with Caco-2 cells in the literature showed that sesquiterpene lactones are well absorbed by 
passive diffusion.45-47 
In the present Caco-2 experiment, nobilin concentration decreased rapidly in all three compartments. 
This and the observed low relative absorption were in part due to the chemical instability of nobilin. The 
degradation kinetics and degradation products of nobilin in aqueous solution were reported 
elsewhere.30 In addition, the present study shows an extensive bioconversion of nobilin taking place in 
the Caco-2 cells resulting in the formation of three conjugation products of nobilin, i.e., with glucuronic 
acid, cysteine, and glutathione. Glucuronidation of nobilin can take place through the action of         
UDP-glucuronosyltransferase most likely at the hydroxyl group at position 3 (Figure 8).48 This enzyme 
was previously reported to be present in Caco-2 cells.22 The conjugation with cysteine is assumed to take 
place by non-enzymatic reaction at position 13 or 18 of the molecule (Figure 8). The α-methylene  
γ-lactone functionality and other αβ-unsaturated carbonyl structures of sesquiterpene lactones were 
reported to react by Michaelis addition with cysteine and glutathione in connection with the cytotoxicity 
of sesquiterpene lactones.49,50 The glutathione conjugate was probably formed enzymatically by 
glutathione S-transferase and by non-enzymatic conjugation at position 13 or 18 (Figure 8).22,48 No 
metabolites were detected in previous absorption studies with sesquiterpene lactones in Caco-2 cells 
even though those compounds had similar functional groups as nobilin.45,46 
 
 
Figure 8: Chemical structure of nobilin with absolute configuration.
26,30
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The three conjugation products exhibited asymmetric efflux from the cells. To describe the 
concentration-time profiles of the three conjugates and that of nobilin in a quantitative fashion and 
evaluate the underlying bioconversion and transport processes, a kinetic model was developed. This 
model included apical and basal efflux of the conjugates by carrier mediated transport potentially 
involving P-gp, BCRP, MRP1, MRP2, and MRP3. These transporters are known to be responsible for the 
efflux of conjugation products of drugs from the cell and were reported to be present in wild type    
Caco-2 cells in a cross-laboratory study.7,10,22 An asymmetric distribution of drug conjugates was also 
observed in earlier studies with Caco-2 cells.12,36 Furthermore, the model considered carrier mediated 
influx of glucuronide by OATPs in order to account for the decrease of the concentration of glucuronide 
in the apical compartment. Glucuronic acid conjugates are substrates of OATPs which were reported to 
be expressed at high levels in Caco-2 cells.7,22,25 Glucuronide was further assumed to be hydrolyzed in 
the cells by β-glucuronidase which was found in Caco-2 cells.34,35 Finally, to account for the decrease of 
glutathione conjugate concentration in the apical compartment, hydrolysis of this conjugate by the 
brush border enzymes γ-glutamyltranspeptidase and dipeptidase was included in the model. A process 
concerning carrier mediated transport of S-(pentachlorobutadienyl)glutathione out of Caco-2 cells and  
metabolism in the apical compartment to the cysteine conjugate was described before.36  
The conjugation rate constant followed the rank order glucuronide > glutathione conjugate > cysteine 
conjugate (Table 1). The enzymatic formation of conjugates seems, therefore, to proceed faster than the 
non-enzymatic one. The faster formation of glucuronide compared to glutathione conjugate is 
congruent with the finding that UDP-glucuronosyltransferase is higher expressed than glutathione  
S-transferase.22 The total bioconversion was considerably more extensive than the chemical degradation 
in solution as inferred from the larger rate constant and the higher nobilin concentration in the cell than 
in solution, indicating that bioconversion was the main reason for the low absorption of nobilin. The 
permeability coefficient of the conjugates was a lot smaller than that of nobilin which is because of the 
increased hydrophilicity and larger molecular size of the conjugates. Carrier mediated transport is the 
predominant process by which the conjugates exit the cells. The determined permeability coefficient of 
glucuronide, for example, corresponds to a clearance value of 2.4 × 10-7 cm3/s which is a lot smaller than 
the clearance value (3 × 10-2 cm3/s) roughly corresponding to the efflux rate constants of this conjugate. 
This comparison is also valid for the other conjugates.  
The reduction of efflux rate constants by the employed inhibitors provides evidence about the role of 
the different transporters for the efflux of the conjugates (Figure 5). Apical efflux of glucuronide is 
shown to take place by P-gp and MRP2 as indicated by the inhibition of this efflux by verapamil and   
MK-571, respectively. The basal efflux of glucuronide took place by MRP3 and possibly MRP1 as 
indicated by the effect of MK-571. The effect of verapamil on basal efflux may be due to inhibition of 
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MRP1 in accordance to observations that verapamil may not be selective and also inhibit MRP1.51,52 
Apical efflux of cysteine conjugate is suggested to take place by P-gp and MRP2 based on the inhibition 
of this efflux by verapamil and MK-571, respectively. The basal efflux of cysteine conjugate appeared to 
take place by MRP3 and possibly MRP1 as indicated by the effect of MK-571. Concerning the effect of 
verapamil on basal efflux, the explanation discussed for glucuronide may apply also to the cysteine 
conjugate, whereas the cause of the effect of Ko143 on basal efflux is presently not clear. Apical and 
basal efflux of the glutathione conjugate is suggested to be mediated by MRP2, and MRP3 (and possibly 
MRP1), respectively, due to the effect of MK-571. Ko143 did not inhibit apical efflux of any of the 
conjugates suggesting that BCRP was not involved in their transport out of the cell. 
The conjugation rate constant of glucuronide was diminished by MK-571 and Ko143 but not affected by 
verapamil (Figure 5). For MK-571, this is most likely related to the inhibition of efflux resulting in an 
accumulation of glucuronide in the cell, which leads to an apparent net slowdown of its formation 
reaction. A considerable accumulation of glucuronide was found in the cells (not shown, see appendix). 
The susceptibility of phase II enzymes to product inhibition17 and a transporter-enzyme interplay 
between MRPs and UDP-glucuronosyltransferase in Caco-2 studies was also proposed before.12,53,54 
Furthermore, the possibility of direct inhibition of UDP-glucuronosyltransferase by MK-571 was 
reported.12 Although the latter can not be excluded in the present study, the cell accumulation of 
glucuronide strongly indicates that the reduction of glucuronide formation was due to efflux inhibition. 
Ko143 seemed to inhibit directly the glucuronidation but not the efflux and caused no accumulation of 
glucuronide in the cells (not shown, see appendix). This was in contrast to other studies which suggested 
an interplay also between BCRP and the enzyme.14 The formation rate constant of cysteine conjugate 
was decreased by MK-571. This was probably because of the reduced efflux which led to a cellular 
accumulation of the conjugate (not shown, see appendix) and an apparent net retardation of the 
conjugation reaction in accordance with the law of mass action. The inhibition of efflux of the cysteine 
conjugate by verapamil produced a buildup in the cells which apparently was not sufficient to reduce 
the net formation of this conjugate. The formation of the glutathione conjugate was hindered by  
MK-571, verapamil, and Ko143. For MK-571, this may be coupled to the inhibition of efflux and also be 
due to a direct effect on the metabolic enzyme as discussed above for glucuronide. Verapamil and 
Ko143 seem to have a direct effect on the conjugation reaction or on glutathione S-transferase. An 
increased efflux of glutathione from the cells elicited by verapamil might also be involved in this 
effect.52,55   
In the experiment with leukotriene C4, the sum of the individual conjugation constants of glucuronide, 
cysteine conjugate, and glutathione conjugate accounted for roughly 30% of the total bioconversion 
constant of nobilin. The reason for this disparity and for the observed increase of the total 
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bioconversion rate constant while the formation of the cysteine and the glutathione conjugate 
diminished is currently not understood, neither is the increase of the basal efflux of the glucuronide and 
the cysteine conjugate elicited by leukotriene C4, although a similar phenomenon was previously 
discussed.12  
The overall reduction of conjugation rate constant comprising the sum of glucuronide, cysteine 
conjugate, and glutathione conjugate formation was larger for MK-571 than for Ko143 while not being 
statistically significant for verapamil (Figure 4). The combination of the three inhibitors showed an 
additive effect and the largest reduction of the conjugation rate constant. The decreasing conjugation 
had as a result an increase of the relative fraction absorbed of nobilin in vitro. This positive effect on 
absorption appeared to be not only because of an inhibition of the bioconversion reaction but, 
significantly, also because of the inhibition of efflux of the conjugation products from the cell. The 
possible role of the interplay between conjugation and efflux for drug bioavailability was discussed 
theoretically before.18 However, an absorption enhancement based on this interplay has rarely been 
demonstrated experimentally to the best of the authors’ knowledge so far. This study, therefore, 
provides evidence of a mechanism of absorption regulation based on efflux inhibition of bioconversion 
products from the cell. This mechanism represents an interesting possibility for improving the 
absorption of drugs exhibiting extensive conjugation type bioconversion in the intestine.  
Interestingly, the full extract increased the relative fraction absorbed of nobilin from 38% to 71%  
(Figure 6). This was related to the nearly 10-fold reduction of the total conjugation rate constant. The 
apical efflux and the conjugation to glucuronide were diminished by the full extract. Also, the apical and 
basal efflux and the formation of the cysteine conjugate and the glutathione conjugate were reduced by 
the full extract. A possible reason for the reduction of the formation of the cysteine conjugate by the 
extract may be the accumulation of this conjugate occurring in the cell (not shown, see appendix) as a 
result of the inhibition of efflux. This was analogous to the effect of MK-571 discussed above. For the 
glucuronide and the glutathione conjugate, the extract may have an inhibitory effect on both, the efflux 
and the conjugation reaction as no notable accumulation of these conjugates was observed in the cell 
(not shown, see appendix). This is different that the results obtained with MK-571 for which an interplay 
between the efflux and the conjugation reaction was proposed. Hence, the increased absorption of 
nobilin elicited by the extract appears to be because of the direct impeding effect on the enzymatic 
conjugation reaction and, to a lesser extent, because of efflux inhibition of conjugates.  
Of the different ingredients of the ethanolic extract of Chamomillae romanae flos all except of apigenin 
were found to decrease the conjugation of nobilin. The sesquiterpene lactone fraction had the same 
effect on efflux and conjugation for all three conjugation products as the full extract. Chamomillae 
romanae flos contains besides nobilin further sesquiterpene lactones which are structurally similar to 
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nobilin26 and could form conjugation products and therefore competitively inhibit the conjugation 
reaction of nobilin and the efflux transporters. No influence of the sesquiterpene lactone fraction on 
apical influx of glucuronide was detected while a diminishing effect of the full extract on this influx 
narrowly missed significance. Such an effect could be due to inhibition of OATP by flavonoids as 
reported before.56-58 The essential oil of Chamomillae romanae flos reduced efflux and formation of 
cysteine and glutathione conjugates but not of glucuronide. Little is known about the effect of essential 
oil on these processes except perhaps that essential oils and terpenoids that are ingredients of essential 
oils were reported to be inhibitors of P-gp and/or MRPs59,60 and that essential oils, albeit of a different 
plant, can inhibit glutathione S-transferase in the rat.61 Ethanol used at the same concentration as in the 
full extract, the sesquiterpene lactone fraction and the essential oil caused a reduction of the formation 
of all three conjugates but did not affect efflux transporters. This is consistent with reports that organic 
solvents including EtOH can inhibit UDP-glucuronosyltransferase62 and glutathione S-transferase.63 
Apigenin and luteolin are representative flavonoids contained in Chamomillae romanae flos. Flavonoids 
and their conjugation products were reported to be substrates and inhibitors of efflux transporters such 
as P-gp and MRPs.58,64 Also, flavonoids were found to be substrates and potential inhibitors of  
UDP-glucuronosyltransferase58 and inhibitors of glutathione S-transferase.65 Moreover, flavonoids were 
reported to stimulate glutathione efflux just like verapamil,55 and P-gp mediated transport.58,66 Although 
individual results of the present study appear to agree with these reports, no overall consistent picture 
is obtained. Apigenin and luteolin generally reduced the formation of the three conjugates and, in 
combination, possibly the efflux of the cysteine and the glutathione conjugate, this effect, however, may 
have been concentration dependent and, additionally for apigenin, the three conjugates accounted only 
for about 30% of the total bioconversion of nobilin. Hence the results with the flavonoids do not seem 
to be conclusive and their role as ingredients of the Chamomillae romanae flos extract for the 
absorption of nobilin requires further investigation. 
Taken together, several of the investigated ingredients of the ethanolic extract are shown to contribute 
to the reduction of the total conjugation of nobilin in the cell. The effect of the individual ingredients on 
the relative fraction absorbed was, however, marginal. The full extract, on the other hand, elicited the 
largest reduction of conjugation and a marked increase of the relative fraction absorbed. These results 
confirm, therefore, that the combination of the ingredients of the extract is necessary for achieving a 
positive effect on absorption. The use of full extract further appears to offer a good possibility for 
improving absorption of compounds undergoing strong enteral bioconversion by inhibiting on one hand 
enzymatic reaction and on the other efflux of conjugation products. 
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4.6  CONCLUSION 
Nobilin shows good permeability by diffusion of the cell membrane of the Caco-2 monolayer but a poor 
absorption because of extensive bioconversion in the cell yielding conjugation products with glucuronic 
acid, cysteine, and glutathione. All three conjugates were substrates of the apical and basal efflux 
transporters MRP2, MRP3, and possibly MRP1 while the glucuronide and the cysteine conjugate were 
also substrates of P-gp. Inhibition of efflux led to reduced bioconversion and increased absorption. This 
transport-bioconversion interplay is proposed to offer a good possibility to increase absorption in case 
of conjugation in the intestine. The full extract of Chamomillae romanae flos directly reduced 
conjugation and inhibited, in part, efflux leading to increased absorption of nobilin. The effect of the 
plant extract appears, therefore, to be due to a combination of mechanisms. This effect could not be 
attributed to a single ingredient; rather, the combination of ingredients of the extract was responsible.   
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4.7  APPENDIX 
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Chapter 5 
 
Influence of biorelevant media and 
lipid based formulations on the in vitro absorption and 
bioconversion of nobilin as pure compound and  
as plant extract in the Caco-2 model 
 
5.1  ABSTRACT 
Nobilin is a well permeable compound undergoing rapid chemical degradation and an even faster 
bioconversion to glucuronide, cysteine conjugate, and glutathione conjugate, which are asymmetrically 
transported out of the intestinal cell, resulting in a low in vitro absorption. The aim of this study was to 
investigate the effect of biorelevant media and lipid based formulations on intestinal relative fraction 
absorbed of nobilin applied as a pure compound or as a full ethanolic extract of Chamomillae romanae 
flos considering chemical stability, bioconversion, and carrier mediated efflux of the conjugates. Fasted 
and fed state simulated intestinal fluid (FaSSIF-TMCaco and FeSSIF-TMCaco, respectively), and two  
self-emulsifying formulations, SMEDSS1 and SMEDDS2, were used. In vitro relative fraction absorbed 
was determined using the Caco-2 cell culture model and permeation and bioconversion parameters 
were deduced by means of kinetic multi-compartment modeling. FaSSIF-TMCaco reduced apical efflux of 
all conjugates but did not affect nobilin absorption while FeSSIF-TMCaco increased absorption which was 
attributed to the increased chemical stability in the medium and decreased bioconversion while 
permeability coefficient was also decreased. SMEDDS1 increased and SMEDDS2 decreased relative 
fraction absorbed due to a decrease and an increase of bioconversion, respectively, although both 
formulations improved chemical stability and decreased permeability coefficient. The effect of  
FeSSIF-TMCaco, SMEDDS1 and SMEDDS2 is consistent with an incorporation of nobilin into colloidal lipid 
particles while FeSSIF-TMCaco, SMEDDS1 appeared to inhibit and SMEDDS2 to promote enzymatic 
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reaction in the cell. In combination with the extract, no additional effect was observed although the 
extract alone markedly improved absorption. Formulation and transport media influence, therefore, in 
vitro absorption by changing bioconversion, chemical stability and permeation parameters. 
 
5.2  INTRODUCTION 
Chemical degradation, solubility, bioconversion by metabolizing enzymes, and membrane permeation 
by efflux and influx transporter proteins influence intestinal absorption. By targeting those properties of 
a compound absorption can be increased.1-3 
Stability and solubility in the gastrointestinal tract are influenced by the aqueous environment, a pH 
range from 1 to 8 and ingredients such as bile salts, phospholipids, digestive enzymes and lipolysis 
products.1,4 Bioavailability of the poorly soluble danazol, for example, was found to be increased by food 
whereas its solubility was increased by incorporating the drug into micelles of bile salts, phospholipids, 
and lipolysis products.5-8 Food effect has become the subject of a guidance for the industry issued by the 
FDA.9 Therefore, several attempts have been made to develop biorelevant media to simulate the 
conditions in the intestine in fasted and fed state.1,7,10-13 A quite good in vitro-in vivo correlation 
between in vivo bioavailability and in vitro dissolution was seen.7,11,12,14-18 Recently biorelevant transport 
media for in vitro absorption studies with the Caco-2 cell model simulating intestinal fluid in the fasted 
and the fed state, FaSSIF-TMCaco and FeSSIF-TMCaco, respectively, were developed.
19 
The approach of incorporating a drug into lipid particles is also attributed by lipid based formulations 
which were extensively discussed in recent years such as self-(micro)emulsifing drug delivery systems 
(S(M)EDDS).20-22 This technique was applied to several poorly water soluble drugs like cyclosporine, for 
example, which is commercially available as a lipid based formulation (Neoral®)23 or sirolimus by 
improving stability and solubility of the drug in presence of D-α-tocopheryl polyethylene glycol succinate 
micelles or SMEDDS.24,25  
Nobilin, a sesquiterpene lactone of the germacranolide type, is a marker compound isolated from 
Chamomillae romanae flos, the flowers of Anthemis nobilis L..26 It is instable in an aqueous solution. 
Stability can be increased accompanied by an increased solubility by incorporating the compound into 
colloidal lipid particles of biorelevant media (FaSSIF-TMCaco and FeSSIF-TMCaco) and liposomal 
formulations with the same molar lipid content as FaSSIF-TMCaco and FeSSIF-TMCaco (LiposomesFaSSIF and 
LiposomesFeSSIF).
27 Previous Caco-2 studies showed that nobilin is a well permeable compound 
undergoing extensive intracellular bioconversion which results in poor in vitro absorption.28 The three 
conjugation products glucuronide, cysteine conjugate, and glutathione conjugate were substrates of 
MRP2 (multidrug resistance protein, ABCC2), MRP3 (ABCC3), and possibly MRP1 (ABCC1). Glucuronide 
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and cysteine conjugate were also transported by P-gp (P-glycoprotein, ABCB1).28 It was assumed that 
glucuronide was further a substrate of the influx carrier OATP (organic anion transporting polypeptide) 
and hydrolyzed in the cell by β-glucuronidase. Glutathione was proposed to be hydrolyzed in the apical 
compartment by γ-glutamyltranspepdidase and dipeptidase to the cysteine conjugate. Scheme 1 
illustrates the diffusional and carrier mediated permeation, the intra- and extracellular bioconversion, 
and chemical degradation.28 Absorption of nobilin was increased on one hand by reducing efflux of the 
conjugation products which resulted in a diminished bioconversion and on the other hand by applying 
nobilin as full extract of Chamomillae romanae flos which directly inhibited bioconversion and also 
indirectly by reducing efflux of the conjugation products.  
Caco-2 cell culture model is routinely used to carry out in vitro study of intestinal absorption taking into 
consideration transporter proteins and metabolizing enzymes.29-32 It is a well-established and well 
characterized model that shows a largely similar expression pattern of transporters and metabolizing 
enzymes as intestinal cells.33-35 In a study involving 10 different laboratories, Caco-2 cells were shown to 
well express the transporters P-gp, MRP2, MRP3, MRP1, and OATP and the phase II conjugating enzymes 
glutathione S-transferase and UDP-glucuronosyltrasferase.32  
The first aim of this study was to investigate the effect of biorelevant media and lipid based formulation 
on nobilin absorption taking into consideration chemical stability, bioconversion, and efflux of the 
conjugation products. The second aim was to study the effect of the extract in combination with 
biorelevant media and lipid based formulations on nobilin absorption. The objective of this study was to 
first use stabilization as a physicochemical approach for absorption improvement that would then be 
investigated as a means to influence biochemical processes relevant for absorption. 
 
 
Scheme 1: Transport of nobilin and its conjugates by diffusional and/or carrier mediated permeation, nobilin chemical 
degradation, and intra- and extracellular bioconversion.
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5.3  MATERIALS AND METHODS 
5.3.1   Chemicals 
The human colon adenocarcinoma cell line Caco-2 was a gift of Prof. H. P. Hauri, Biocenter, University of 
Basel, and originated from the American Type Culture Collection (ATCC, Rockville, MD, USA). The 
Dulbecco’s modified Eagle’s medium (DMEM) (with L-glutamine, 4500 mg/L D-glucose, without sodium 
pyruvate), MEM non-essential amino acids solution (100×, without L-glutamine), L-glutamine 200 mM 
(100×), fetal bovine serum (FBS), Trypsin 0.5%-EDTA (10×) liquid, Dulbecco’s phosphate buffered saline 
(with and without Ca2+, Mg2+) were all purchased from Gibco® Invitrogen corporation (Paisley, UK). The 
cell culture medium was supplemented with 10% (v/v) FBS, 1.8 mM L-glutamine, and 1% (v/v) MEM. 
Petri dishes (56.7 cm2) were purchased from Nunc A/S (Roskilde, Denmark) Petri dishes (21 cm2) and     
6-well polycarbonate membrane transwell™ plates with an insert area of 4.7 cm2 and 0.4 μm pore size 
were ordered from Costar (Corning Incorporated, Corning, NY, USA). 
Nobilin, a sesquiterpene lactone with Mr 346 and the ethanolic extract of Chamomillae romanae flos 
(PhEur) were kindly provided by Alpinia Laudanum Institute of Phytopharmaceutical Sciences AG (ALIPS) 
(Walenstadt, Switzerland). Nobilin was purified from Chamomillae romanae flos (PhEur) as described 
before.27 D-glucose, L-glutamine, 4-(2-Hydroxyethyl)piperazine-1-ethanesulonic acid (HEPES), sodium 
chloride (NaCl), sodium hydroxide (NaOH), maleic acid, Tricaprylin, dimethyl sulfoxide (DMSO), 
Triton® X-100, Dulbecco’s Modified Eagle’s Medium (DMEM) base powder (without D-glucose,  
L-glutamine, phenol red, sodium pyruvate, and sodium bicarbonate),36 sodium oleate were purchased 
from SIGMA-Aldrich Chemie GmbH (Buchs, Switzerland). Lipoid E PC S and Lipoid S 100 were kindly 
provided by Lipoid GmbH (Ludwigshafen, Germany). Glycerol monooleate was purchased from Danisco 
(Copenhagen, Denmark). Sodium taurocholate was bought from Prodotti Chimici e di Alimenttari s. p. a. 
(Basaluzzo, Italy). Capmul MCM was purchased from Abitec Corporation (Columbus, OH, USA). 
Cremophor EL and Lutrol F 68 were kindly provided from BASF (Ludwigshafen, Germany). α-Tocopherol 
was purchased from Hänseler AG (Herisau, Switzerland).  
Methanol and ethanol from J.T.Baker (Deventer, Nederland), sodium acetate and formic acid from 
SIGMA-Aldrich Chemie GmbH (Buchs, Switzerland) were of HPLC grade. Water was purified by reversed 
osmosis with the water purification system arium® 61215 of Sartorius (Goettingen, Germany). 
5.3.2   Media 
The three different TMCaco (transport media) that are compatible with the Caco-2 cell line were 
described by Markopoulos et al.19 The compositions are shown in Table 1 (purely aqueous medium     
[aq-TMCaco], fasted state simulated intestinal fluid [FaSSIF-TMCaco] and fed state simulated intestinal fluid 
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[FeSSIF-TMCaco]). The media contained DMEM base powder, L-glutamine, and D-glucose to support the 
viability of the cells.  
The DMEM base powder was dissolved in autoclaved water. It was supplemented with D-glucose,          
L-glutamine, NaCl (aq-TMCaco), and HEPES (aq-TMCaco) or maleic acid (FaSSIF-TMCaco and FeSSIF-TMCaco). 
After adjusting the pH with sodium hydroxide and sterile filtration (Supor-200, 0.2 μm pore size, Pall 
Corporation, Port Washington, NY, USA) under aseptic conditions FaSSIF-TMCaco and FeSSIF-TMCaco were 
supplemented with sodium taurocholate, lecithin, glycerol monooleate (only FeSSIF-TMCaco), and sodium 
oleate (only FeSSIF-TMCaco). Lecithin and glycerol monooleate were added to the media separately as 
dichloromethane solution and the organic solvent was evaporated with a rotary evaporator (RE 120, 
Büchi, Flawil, Switzerland) at 40°C and 100 mbar.  
Table 1: Composition of the three transport media. 
 aq-TMCaco FaSSIF-TMCaco FeSSIF-TMCaco 
DMEM base powder [g/L]a 8.3 8.3 8.3 
D-glucose [mM] 25 25 25 
L-glutamine [mM] 6 6 6 
NaCl [mM] 34 - - 
HEPES [mM] 19.98 - - 
Maleic acid [mM] - 19.12 55.02 
NaOH  qs qs qs 
Sodium taurocholate [mM] - 3 6.8 
Lecithin (Lipoid E PC S) [mM] - 0.2 6.8 
Glycerol monooleate [mM] - - 3.4 
Sodium oleate [mM] - - 0.8 
pH 7.4 6.5 5.8 
Osmolality [mOsm/kg] 350 320 390 
a
 contains amino acids, vitamins, electrolytes, trace elements
36
; qs: sufficient 
 
5.3.3   Liposomal formulations  
Liposomes were prepared by the film method. Lipoid S 100 was dissolved in ethanol in a round 
bottomed flask and evaporated to dryness with a rotary evaporator at 40°C. The lipid film was 
suspended in tempered aq-TMCaco (37°C) and extruded under nitrogen pressure of 8-9 bar through 
polycarbonate filters (Nucleopore track edge membrane filters, Whatman plc, Kent, UK) pore size 
0.4 μm (3 times), 0.2 μm (5 times), and 0.1 μm (2 × 10 times).19 The two liposomal formulations in  
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aq-TMCaco had the same lipid concentrations as FaSSIF-TMCaco (3.2 mM) and FeSSIF-TMCaco (17.8 mM) and 
were termed LiposomesFaSSIF and LiposomesFeSSIF, respectively. 
5.3.4   Lipid based formulations  
1) Formulation 1 (SMEDDS1) 
The lipid phase consisted of Tricaprylin 35% (w/w) (triglyceride), Capmul MCM 18% (w/w) (mono- and 
diglyceride), Cremophor EL 37% (w/w) (emulsifier), and EtOH 10% (w/w). Nobilin was dissolved in the 
EtOH of the lipid phase and added to that. Alternatively, the ethanolic plant extract was added to the 
lipid phase and EtOH was evaporated with a rotary evaporator (RE 120, Büchi, Flawil, Switzerland) at 
40°C to the final content of 10% (w/w).The lipid phase was suspended in one third of tempered            
aq-TMCaco, homogenized for 5 min at 15,000 rpm with a polytron homogenizer (Polytron PT 3000, 
Kinematica AG, Littau, Switzerland) and adjusted to 1:200 (w/v) with aq-TMCaco to the final volume.  
2) Formulation 2 (SMEDDS2) 
The lipid phase containing Lutrol F 68 90% (w/w) and α-Tocopherol 10% (w/w) was melted in a water 
bath at 60°C. Ethanol containing nobilin or the ethanolic plant extract was added and mixed with the 
lipid phase. Ethanol was evaporated to dryness with a rotary evaporator at 40°C. The lipid phase was 
suspended 1:200 (w/v) in tempered aq-TMCaco. The described formulation is based on the patent  
WO 2007/104173.37 
5.3.5   Particle size measurement 
The particle size of the mixed micelles of FaSSIF-TMCaco and FeSSIF-TMCaco, the two liposomal 
formulations (LiposomesFaSSIF and LiposomesFeSSIF), and lipid based formulations (SMEDDS1 and 
SMEDDS2) were measured by dynamic light scattering using a Zetasizer (Nano ZS, Malvern Instruments, 
Worcestershire, UK). The solutions were equilibrated at least 30 min at 37°C before measurement.  
5.3.6   Kinetics of chemical degradation  
Purified nobilin was dissolved in DMSO at a concentration of 1 mg/mL and added to aq-TMCaco to a 
starting concentration of 50 µg/mL, and to the biorelevant media and liposomal formulations to a 
starting concentration of around 3 µg/mL. The lipid based formulations were suspended 1:200 (w/v) in 
aq-TMCaco as described above to a starting concentration of 2-5 µg/mL nobilin. The ethanolic plant 
extract was diluted 1:200 (v/v) with the media or the liposomal formulations and the lipid based 
formulations were suspended 1:200 (w/v) in aq-TMCaco as described above to a starting concentration of 
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around 1-2 µg/mL nobilin. Degradation of nobilin was monitored in all preparations for 5-7 hours under 
magnetic stirring at 37°C. 
The degradation process was described by pseudo first order kinetics: 
 
 ( )   ( )                                                                                                                                                 ( ) 
 
where, C(t) is the measured concentration at a specific time point, C(0) is the concentration at time 
point 0, kd is the degradation rate constant, and t is time. The degradation rate constant, kd, was 
determined by fitting Equation (1) to the data. 
5.3.7   Cell Culture  
Caco-2 cells were cultivated in Petri dishes (56.7 cm2) using culture medium at 37°C in a water saturated 
atmosphere of 8% CO2 (Sorvall Heraeus, Heracell, Kendro Labaratory Products, Zürich, Switzerland). The 
cells were passaged by treatment with a solution of 0.25% trypsin and 2.63 mM EDTA with a splitting 
ratio of 1:5-1:10 when the cell monolayer reached 70-90% confluence. Cells of passage numbers 60-65 
were seeded at a density of 1.14 × 105 cells/cm2 in 6-well transwell™ plates and incubated for 19-21 
days. The medium was changed every other day. 
5.3.8   TEER 
The integrity of the Caco-2 cell monolayer in the transwell™ plates was ensured with TEER measurement 
before every permeation experiment. The monolayer was washed with pre-warmed (37°C) D-PBS (with 
Ca2+, Mg2+) (apical 3 mL and basal 4 mL). 1.6 mL of tempered aq-TMCaco was added to the apical and 
2.8 mL aq-TMCaco to the basal compartment. The transwell™ plate was equilibrated for 60 min in the cell 
culture incubator and TEER was measured with an EVOM resistance meter (World Precision 
Instruments, Sarasota, FL, USA) equipped with an EndOhm-24SNAP chamber (World Precision 
Instruments, Sarasota, FL, USA) which was tempered at 37°C with 4.6 mL aq-TMCaco. Caco-2 monolayers 
with TEER values above 470 Ω cm2 were used for permeation experiments. 
5.3.9   Permeation experiment  
After the TEER measurement, the aq-TMCaco was removed and the tempered nobilin containing            
aq-TMCaco was added. Nobilin was dissolved in DMSO (1 mg/mL) and added to aq-TMCaco (final DMSO 
concentration 0.3%) to a starting concentration of around 7 µM. To investigate the permeation in the 
apical-to-basal direction, 1.6 mL of the nobilin solution was added to the apical compartment and 
2.8 mL of blank aq-TMCaco to the basal compartment. For the basal-to-apical direction, 1.6 mL of blank       
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aq-TMCaco was added to the apical and 2.8 mL of the nobilin solution to the basal compartment. One 
plate was used for each direction.   
The biorelevant media, FaSSIF-TMCaco and FeSSIF-TMCaco were added to the apical compartment and the 
liposomal formulation with the corresponding amount of lipids to the basal compartment due to 
cytotoxic effects of the biorelevant media.19 Nobilin was added from the DMSO stock solution either to 
the biorelevant medium or to the liposomal formulation depending on the transport direction. The two 
lipid based formulations were suspended in aq-TMCaco as described above and added to both 
compartments depending on the transport direction with nobilin or as placebo. The starting nobilin 
concentrations were around 7 µM. 
The ethanolic extract of Chamomillae romanae flos was diluted 1:200 (v/v) with the media or the 
liposomal formulations yielding a nobilin concentration of approximately 3 µM. Extract was added to 
both formulations as described above and added to the plate depending on the transport direction to 
the apical or basal compartment with a starting nobilin concentration of 2 µM for SMEDDS1 and 
SMEDDS2(1), and 9 µM for SMEDDS2(2).     
The transwell™ plate was shaken on an orbital shaker at 37°C in a water saturated atmosphere under an 
incubator hood with a stirring rate of 120 rpm (KS15, Edmund Bühler GmbH, Tübingen & Hechingen, 
Germany). Permeation of nobilin across the cell monolayer was monitored by drawing samples of 
100 µL from both compartments after 10 min, 35 min, 1 h, 1.5 h, 2 h, and 2.5 h. One hundred µL of 
methanol was added and the samples were stored at 4°C. Under these conditions nobilin was chemically 
stable. Samples containing lipids were centrifuged for 30 min at 16,100 g and 4°C (5415R, Eppendorf AG, 
Hamburg, Germany) before HPLC measurement. At each time point one insert was removed and used 
for cell extraction. 
5.3.10  Cell extraction 
Both sides of the transwell™ were washed with 4°C cold D-PBS (without Ca2+ and Mg2+), the insert was 
transferred to a Petri dish (21 cm2), 750 µL of a 1% Triton® X-100 solution in aq-TMCaco was added and 
the dish was shaken at 120 rpm on an orbital shaker for 15 min at 37°C under an incubator hood. The 
cells were scraped of the polycarbonate membrane using a cell scraper (BD Falcon, BD Biosciences 
Discovery Labware, Bedford, USA), transferred into a 1.5 mL tube (Eppendorf AG, Hamburg, Germany) 
and frozen at -80°C.   
The sample was thawed within 3 min at 37°C under shaking with 1400 rpm (Thermomixer comfort, 
Eppendorf AG, Hamburg, Germany), 750 μL MeOH was added and kept on ice bath for 20 min. After 
shaking for 10 min at 37°C with 1400 rpm, the sample was centrifuged for 3 min at 16,100 g and 25°C 
(5415R, Eppendorf AG, Hamburg, Germany). The supernatant was transferred to a tube and stored at 
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4°C. The pellet was disintegrated in 750 μL methanol with 6 pulses of an ultrasonic disintegrator 
(Branson Sonifier 250, Model 101-063-197, Branson Ultrasonics Corporation, Danbury,CT, USA, 
instrument settings: output control 2, duty cycle 30%), shaken for 5 min on the thermomixer (37°C and 
1400 rpm) and centrifuged at 16,100 g and 25°C for 3 min. After repeating the pellet disintegration 
once, the methanolic supernatants were united and the methanol was evaporated under nitrogen flow. 
The residue was taken up with the methanol-water supernatant of the first extraction. The sample was 
shaken on the thermomixer at 1400 rpm and 37°C for 3 min and centrifuged for 25 min at 16,100 g and 
25°C before HPLC analysis.  
5.3.11  HPLC 
Nobilin and its conjugates were analysed by HPLC-UV-MS of Agilent series 1200 equipped with a degaser 
G1379B, a binary pump G1312A, an autosampler G1367B, a thermostat G1330B, a column oven 
G1316A, a variable wavelength detector G1314B and a single quadrupole MS detector G6130A. A C-18 
reversed phase column (Agilent Eclipse XBD-C18, 5 µm, 2 × 125 mm) and mobile phase consisting of 
(A) water with 0.1% (v/v) formic acid and 0.05 mM sodium acetate and (B) methanol with 0.1% (v/v) 
formic acid and 0.05 mM sodium acetate were used. The composition of the mobile phase was varied in 
a gradient mode: 0 min A:B 50:50, 0-18 min linear change to A:B 10:90, 18-22 min A:B 10:90, 22-23 min 
linear change to A:B 50:50, and 23-28 min A:B 50:50 (all samples apart from SMEDDS1) or 0 min A:B 
35:65, 0-18 min linear change to A:B 10:90, 18-22 min A:B 10:90, 22-23 min linear change to A:B 35:65, 
and 23-28 min A:B 35:65 (samples with SMEDDS1) with a flow rate of 0.25 mL/min and a runtime of 
28 minutes. The samples were cooled in the autosampler to 4°C and the column was heated to 40°C (all 
samples apart from SMEDDS1) or 20°C (samples with SMEDDS1). The ions were generated by 
atmospheric pressure electrospray ionisation and the MS detector was run in scan mode  
(m/z 100 - 1000, for all samples) and SIM mode (for samples of the cell extraction) at positive polarity 
with capillary voltage 4000 V, fragmentor 160 V, drying gas flow 10 L/min, drying gas temperature 350°C 
and nebulizer pressure 20 psig. Nobilin was detected at 218 nm in UV and at m/z 369, and 716 in MS 
corresponding to the sodium adduct of nobilin and the sodium adduct of the dimer of nobilin, 
respectively. The glucuronide was detected at m/z 525, the glutathione conjugate at m/z 654, and the 
cysteine conjugate at m/z 468 corresponding to their protonated forms. The conjugates were quantified 
with the calibration curve of nobilin. The LOQ of nobilin for an injection volume of 100 µL was 
0.02 µg/mL in the UV and 0.004 and 0.0001 µg/mL in MS scan and SIM mode, respectively. Linearity was 
fulfilled in UV for concentrations up to 100 µg/mL and in MS (scan and SIM mode) up to 1 µg/mL. 
Standard deviation of measured concentrations of the calibration curve in UV and MS (scan and SIM 
mode) was at maximum 10%. 
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5.3.12  Kinetic modeling 
To describe the processes taking place in the course of nobilin absorption in the Caco-2 model and 
comprising diffusional, intracellular bioconversion, and chemical degradation, a kinetic model was 
developed taking into account that: 
1. Nobilin permeates the cell membrane by diffusion.  
2. Nobilin is chemically degraded in aqueous solution following first order kinetics.27 
3. Three conjugation products of nobilin, i.e., glucuronide, cysteine conjugate and glutathione 
conjugate are formed in the cells.28 
For the proposed model the following assumptions were made: 
1. Conjugation reactions and the degradation of glucuronide and glutathione conjugates obey first 
order kinetics. 
2. Permeability coefficient (diffusional) of nobilin is different for the apical and the basal membrane 
because of the difference between the two membranes. 
A system of differential equations was established describing the change of concentration of nobilin as a 
function of time in the apical, the cellular, and the basal compartments for apical-to-basal and  
basal-to-apical transport taking into consideration chemical degradation, bioconversion, and diffusional 
permeation as shown in Scheme 1. Similar models were described by this group previously.5,19,28,38 
The system of equations is given below: 
apical to basal (index ab): 
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where, CA, CB, and CC are concentration of nobilin in the apical, basal, and cellular compartments, 
respectively, Pa and Pb are permeability coefficient of the apical and the basal membranes, respectively, 
Ka/c is the partition coefficient between apical and cellular compartment, u is the partition coefficient 
between the apical and the basal compartment, kd is the chemical degradation rate constant, kdc is the 
total conjugation rate constant in the cell, VA, VB, and VC are volume of the apical, basal, and cellular 
compartments, respectively, S is the surface area (4.7 cm2), and t is time. The cellular volume was 
0.0094 mL calculated with a monolayer thickness of 20 µm. 
A combined permeability coefficient, P, applying to both membranes was calculated from Pa and Pb by 
Equation (8) and the standard error with Equation (9). 
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The extent of in vitro absorption was introduced to quantify the maximal amount of intact nobilin 
appearing in the basal compartment and was expressed as the relative fraction absorbed given by 
Equation (10). The denominator of Equation (10) gives the amount of nobilin in the basal compartment 
at equilibrium when neither chemical degradation nor bioconversion takes place and was defined as 
100% in vitro absorption. 
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where, Fa is the relative fraction absorbed, CBab
o  and CCab
o  is concentration in the basal and cellular 
compartment, respectively, when neither chemical degradation nor bioconversion take place, and tma 
  
and tma 
o  is the time at which maximum absorption is observed. CBab
o  and CCab
o  were simulated using the 
determined values of Pb and Ka/c. 
The system of differential equations (2) through (7) was numerically solved and simultaneously fitted to 
experimental concentration or mass data of nobilin and its three conjugation products in all three 
compartments in both transport directions using the EASY-FIT® software.39 From the least square 
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regression analysis, values of the permeability coefficients, partition coefficients (Ka/c and u), and total 
conjugation rate constant which were treated as adjustable parameters were deduced.  
The reduction of the volume in the apical and basal compartment because of sampling was described by 
the following empirical equations. 
 
                                                                                                                     (  ) 
                                                                                                                     (  ) 
 
Significance test was carried out based on the incidence of overlap of the confidence intervals at the 
p = 0.01 level of two estimated values of a parameter from different experimental sets. In addition, the 
relation 
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was used where, value(α) and value(β) are two values of a parameter and (SE)α and (SE)β are the 
corresponding standard errors of the estimates. Significance was determined by comparing F with the 
critical value F0.01[1,df], where df is degrees of freedom of residuals for which df = 8 was used. An 
agreement between the two tests was required for declaring statistical significance of the difference 
between two values of a parameter; this agreement was observed in the vast majority of cases. The 
significant tests of the chemical degradation rate constant, kd, deduced using Equation (1) was also 
carried out with Equation (13) and df between 3 and 7 depending on the number of measurements. 
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5.4  RESULTS 
5.4.1   Stability study 
The estimated parameter values of nobilin and nobilin as plant extract in presence of different media, 
liposomes, and lipid based formulations are shown in Table 2. The degradation rate constant of nobilin 
in aq-TMCaco was 1.17 × 10
-4 s-1. It was decreased by FaSSIF-TMCaco, FeSSIF-TMCaco, LiposomesFaSSIF, 
LiposomesFeSSIF, SMEDDS1, and SMEDDS2 1.3-, 8-, 8.7-, 44.8-, 5.3-, and 2.1-fold, respectively. Similar 
results were obtained for nobilin as a full extract in presence of different media, liposomes, and lipid 
based formulations.  
Table 2: Degradation constant of nobilin (pure compound) and nobilin as a full extract in different media, liposomes, and lipid 
based formulations. 
 pure compound extract particle size [nm] total lipid conc. [mg/mL] 
 kd [s
-1] kd [s
-1] (pure compound)  
aq-TMCaco 1.17 × 10
-4 1.08 × 10-4 -  - 
FaSSIF-TMCaco 9.02 × 10
-5 7.85 × 10-5 83.2  1.76 
FeSSIF-TMCaco 1.46 × 10
-5 2.33 × 10-5 68.8  10.39 
LiposomesFaSSIF 1.34 × 10
-5 1.66 × 10-5 120.7  2.37 
LiposomesFeSSIF 2.61 × 10
-6 2.36 × 10-6 124.9  13.2 
SMEDDS1  2.22 × 10-5 2.47 × 10-5 79.7  5 
SMEDDS2 5.65 × 10-5 5.29 × 10-5 28.3  5 
 
5.4.2   Influence of media on the transport of nobilin and its conjugates 
Figure 1 shows the result of nobilin in the media in the Caco-2 permeation experiment. Drawn lines 
were obtained by fitting the model to the experimental data of nobilin. A rapid permeation of nobilin in 
aq-TMCaco from the donor into the cells and onward in the receiver compartment was observed. Nobilin 
concentration decreased quickly in all three compartments and reached near zero concentrations after 
2.5 hours. Same observations were reported before.28 Concentration-time profiles were different in 
presence of FaSSIF-TMCaco. The concentration in the basal compartment was higher than in the apical 
compartment. The permeation was slower in FeSSIF-TMCaco and concentrations were equal in the apical 
and basal compartments in the apical-to-basal transport direction and a higher concentration in the 
basal compartment than in the apical compartment in the basal-to-apical transport direction whereas 
the intracellular amount was increased after 2.5 h. Fitted curves are in good agreement with the data. 
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The estimated parameter values of nobilin in the media are shown in Figure 2. Nobilin in aq-TMCaco had a 
quite large permeability coefficient (2.69 × 10-4 cm/s) and a partition coefficient Ka/c of 0.057. 
FaSSIF-TMCaco did not have an effect on the permeability coefficient or the partition coefficient Ka/c 
whereas FeSSIF-TMCaco decreased the former 5-fold and increased the latter almost 2-fold. The partition 
coefficient u in the experiment with FaSSIF-TMCaco was slightly smaller than the one with FeSSIF-TMCaco. 
The conjugation rate constant was considerably larger than the chemical degradation rate constant of 
nobilin in aq-TMCaco. FaSSIF-TMCaco did not have an effect on the total conjugation rate constant whereas 
this constant was not statistically different from zero in presence of FeSSIF-TMCaco. The relative fraction 
absorbed of nobilin in aq-TMCaco was 37% and in FaSSIF-TMCaco 38%. FeSSIF-TMCaco increased it to 96%.  
 
 
Figure 2: Deduced values (columns) and standard errors (bars) of permeability coefficient P, partition coefficient Ka/c, partition 
coefficient u (dark, light, and crosshatched columns, respectively, on left panel), total conjugation rate constant kdc, chemical 
degradation rate constant kd, and relative fraction absorbed Fa (dark, diagonally hatched, and light columns, respectively, on 
right panel) of nobilin from model fitting in different media.  p<0.01. 
Figure 3 and Figure 4 show the results of the three conjugation products of nobilin in aq-TMCaco and 
FaSSIF-TMCaco, respectively, in the Caco-2 permeation experiment. Rather large concentrations / 
amounts of all three conjugation products were detected in aq-TMCaco (Figure 3). The concentration of 
glucuronide in the apical solution increased in the beginning and later decreased while concentration in 
the basal solution steadily increased over time. As a result, apical concentration was at early time points 
greater and at later times lower than the basal concentration. This was true for both transport 
directions. The concentration-time profiles of the cysteine conjugate were rather different. Apical and 
basal concentrations increased constantly with time but the former was considerably greater than the 
latter throughout the experiment in both transport directions. Glutathione conjugate concentration 
pattern, finally, was similar to that of glucuronide, apical concentrations, however, briefly increased and 
then rapidly declined while basal concentrations steadily increased reaching a large difference to the 
apical ones. The amount of all conjugates in the cell increased at first and then decreased to very low 
levels over time in both transport directions. These results demonstrate that transport of the conjugates 
out of the cell was highly asymmetric which was reported before.28 
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In presence of FaSSIF-TMCaco (Figure 4) concentration of glucuronide steadily increased in the apical and 
basal compartment over time whereas the latter was considerably greater than the former in both 
transport direction. Also a constant increase of cysteine conjugate and glutathione conjugate in the 
basal compartment was observed but none of these conjugates were detected in the apical 
compartment in both transport direction. After 2.5 h all three conjugates were still present in the cells. 
Cell extraction was carried out at the end of the experiment as described elsewhere.19 In presence of 
FeSSIF-TMCaco no conjugates were detected in all three compartments. 
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5.4.3   Influence of SMEDDS on the transport of nobilin and its conjugates 
Figure 5 shows the result of nobilin in presence of the lipid based formulations in the Caco-2 permeation 
experiment. Drawn lines were obtained by fitting the model to the experimental data of nobilin. Slow 
permeation of nobilin in presence of SMEDDS1 from the donor into the cells and onward in the receiver 
compartment was observed whereas nobilin was detected in all three compartments after 2.5 h in both 
transport directions. A slightly slower permeation of nobilin was observed in presence of SMEDDS2 
compared to no formulation (Figure 1). Rapid decline of the nobilin concentration in all three 
compartments was found which reached near zero after 2.5 h in both transport directions. Fitted curves 
are in good agreement with the data. 
 
 
Figure 5: Nobilin concentration in presence of (left to right) SMEDDS1 and SMEDDS2 in the apical-to-basal (top panels, red) and 
the basal-to-apical (middle panels, blue) transport direction in both compartments and nobilin mass in the cellular 
compartment (bottom panels) in both transport directions as a function of time. () apical concentration, (●) basal 
concentration, (□) mass in apical-to-basal transport direction (red), (■) mass in basal-to-apical transport direction (blue). 
Symbols represent measured data and lines fitted model curves.  
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The estimated parameter values of nobilin in presence of SMEDDS are shown in Figure 6. SMEDDS1 and 
SMEDDS2 decreased the permeability coefficient 3.4- and 1.5-fold, respectively, whereas the partition 
coefficient Ka/c was increased by SMEDDS1 and SMEDDS2 4.2- and 1.7-fold, respectively. The total 
conjugation rate constant was decreased by SMEDDS1 3.2-fold and was increased by SMEDDS2 2.3-fold 
which was accompanied by an increased and reduced relative fraction absorbed of 70% and 24%, 
respectively.  
 
 
Figure 6: Deduced values (columns) and standard errors (bars) of permeability coefficient P, partition coefficient Ka/c, partition 
coefficient u (dark and light columns, respectively, on left panel), total conjugation rate constant kdc, chemical degradation rate 
constant kd, and relative fraction absorbed Fa (dark, diagonally hatched, and light columns, respectively, on right panel) of 
nobilin from model fitting in the presence of SMEDDS (lipid based formulations).  p<0.01. 
Figure 7 shows the results of the three conjugation products of nobilin in presence of SMEDDS2 in the 
Caco-2 permeation experiment. The concentration-time profiles of the conjugates in presence of 
SMEDDS2 were similar to those with no formulation in both transport directions (Figure 3). Rapid 
increase of glucuronide concentration followed by a decline was observed in the apical compartment 
whereas the concentration steadily increased in the basal compartment over time, resulting in a higher 
concentration in the basal than in the apical compartment. Concentration of cysteine conjugate 
constantly increased in both compartments, although, remarkably faster in the apical than in the basal 
compartment. Glutathione conjugate concentration increased in the apical and basal compartment, 
however, it decreased in the apical compartment over time which resulted in a higher concentration in 
the basal than in the apical compartment after 2.5 h. The amount of conjugates in the cells declined 
during the experiment. The concentration-time profiles of the conjugates in presence of SMEDDS1 are 
not shown (see appendix). Almost no conjugates were detected apart from a slow increase of 
concentration of glucuronide and cysteine conjugate in the apical compartment. 
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5.4.4   Influence of biorelevant media and SMEDDS on transport of nobilin and its conjugates in full  
            extract  
The estimated parameter values of nobilin applied as full plant extract and in the presence of different 
media and lipid based formulations are shown in Figure 8. Concentration-time profiles are not shown 
(see appendix). The full extract did not have an effect on the permeability coefficient whereas a 
significant reduction of the partition coefficient was observed. The extract reduced the total conjugation 
rate constant almost 10-fold and increased the relative fraction absorbed from 37% to 72%. For the 
combination of the full extract with biorelevant media or lipid based formulations the following results 
were obtained: FeSSIF-TMCaco, SMEDDS1, SMEDDS2(1), and SMEDDS2(2) decreased the permeability 
coefficient 3.8-, 3.6-, 1.5-,and 1.5-fold, respectively, accompanied by a 3-, 3.8-, 1.7-, 1.5-fold increased 
partition coefficient Ka/c, respectively. A significant reduction of the partition coefficient Ka/c was 
obtained in the presence of FaSSIF-TMCaco. The partition coefficient u was 0.14 and 0.37 of FaSSIF-TMCaco 
and FeSSIF-TMCaco, respectively. FaSSIF-TMCaco, FeSSIF-TMCaco, SMEDDS1, and SMEDDS2(1) reduced the 
total conjugation rate constant 5.8-, 3.6-, 6.9-, and 1.7-fold respectively, and it was abolished in 
presence of SMEDDS2(2). The relative fraction absorbed was increased by the biorelevant media and 
the lipid based formulations. 
 
 
Figure 8: Deduced values (columns) and standard errors (bars) of permeability coefficient P, partition coefficient Ka/c, partition 
coefficient u (dark, light, and crosshatched columns, respectively, on left panel), total conjugation rate constant kdc, chemical 
degradation rate constant kd, and relative fraction absorbed Fa (dark, diagonally hatched, and light columns, respectively, on 
right panel) of nobilin applied as a full extract from model fitting in different media and in presence of SMEDDS (lipid based 
formulations).  p<0.01. 
The results of the three conjugates of nobilin applied as a full extract in aq-TMCaco, FaSSIF-TMCaco, and in 
presence of SMEDDS2(1) and SMEDDS2(2) in the Caco-2 permeation experiment are shown in Figure 9, 
Figure 10, Figure 11, and Figure 12 respectively. Concentrations of glucuronide increased in the apical 
and basal compartment simultaneously and were more or less the same after 2.5 h in the presence of 
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the full extract (Figure 9). The concentration of cysteine conjugate rose in the apical and basal 
compartment over time whereas it was higher in the apical compartment after 2.5 h. The  
concentration-time profiles of glutathione conjugates show that the concentration in the apical 
compartment increased and declined during the experiment whereas it increased in the basal 
compartment which resulted in a higher concentration in the basal than in the apical compartment at 
the end of the experiment. The amount of conjugates in the cells diminished over time and a slight 
accumulation of cysteine conjugate was observed. These observations were made for both transport 
directions.  
Full extract & FaSSIF-TMCaco increased the concentration of all three conjugates in the apical 
compartment whereas only a slight increase of glucuronide concentration was observed in the basal 
compartment in both transport directions (Figure 10). No conjugates were found in the cells. In 
presence of full extract & FeSSIF-TMCaco no conjugates were detected in all three compartments in both 
transport directions. 
Full extract & SMEDDS2(1) increased the concentration of glucuronide and glutathione conjugate in the 
apical and basal compartment whereas it was higher in the basal compartment after 2.5 h (Figure 11). 
The concentration of cysteine conjugate was increased in the apical compartment in both transport 
directions.  
Full extract & SMEDDS2(2) increased the concentration of glucuronide in the apical and basal 
compartment simultaneously which resulted in an equal concentration in both compartments 
(Figure 12). The concentrations of cysteine conjugate and glutathione conjugate rose in the apical and 
basal compartments over time whereas only a small concentration of cysteine conjugate was measured 
at time point 2.5 h in the basal compartment in both transport directions. No conjugates were detected 
in the cellular compartment. 
In combination with SMEDDS1 a low concentration of cysteine conjugate was found only in the apical 
compartments in both transport directions, therefore, the concentration-time profiles are not shown 
(see appendix).  
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5.5  DISCUSSION 
Nobilin is a well permeable but highly instable compound undergoing chemical degradation and 
extensive bioconversion resulting in a low relative fraction absorbed of 37% in the Caco-2 model which 
was already reported before.28 A previous study showed that stability and solubility of nobilin can be 
increased by the incorporation of the compound into colloidal lipid particles of biorelevant media and 
liposomes that protects it from degradation in water.27 This study confirms this observation with lipid 
based formulations. Chemical stability of nobilin in an aqueous solution in the presence of colloidal lipid 
particles was significantly improved in the following rank order: LiposomesFeSSIF > LiposomesFaSSIF ≥ 
FeSSIF-TMCaco > SMEDDS1 > SMEDDS2 > FaSSIF-TMCaco. Intracellular bioconversion of nobilin to the three 
conjugation products glucuronide, cysteine conjugate, and glutathione conjugate was reported to be 
almost 10-fold faster than the chemical degradation.28 These conjugation products exhibited 
asymmetrical transport out of the cells. The same study showed that the three conjugates were 
substrates of MRP2 at the apical membrane, and MRP3 and possibly MRP1 at the basal membrane. 
Glucuronide and cysteine conjugate were also shown to be transported by P-gp at the apical membrane. 
The decline of glucuronide concentration in the apical compartment (Figure 3) was assumed to be due 
to the carrier mediated influx by OATP at the apical membrane and hydrolysis reaction by  
β-glucuronidase in the cell. The reduction of glutathione conjugate concentration in the apical 
compartment (Figure 3) was attributed to the brush border membrane enzymes  
γ-glutamyltranspeptidase and dipeptidase to the cysteine conjugate.28 The full mechanism is shown in 
Scheme 1 and explains the concentration-time profiles in Figure 3. It was proposed that the chemical 
degradation and mainly the more rapid bioconversion in the cell were responsible for the poor in vitro 
absorption of nobilin.27,28 
The biorelevant medium FaSSIF-TMCaco did not have an effect on the relative fraction absorbed of nobilin 
whereas FeSSIF-TMCaco increased it from 37% to 96%. FaSSIF-TMCaco did not have an effect on the 
estimated values of permeability coefficient, partition coefficient Ka/c, and the total conjugation rate 
constant. The partition coefficient u was 0.14 which indicated that nobilin is better soluble in 
LiposomesFaSSIF than in FaSSIF-TMCaco. This observation is consistent with the previously reported higher 
solubility of nobilin in LiposomesFaSSIF than in FaSSIF-TMCaco.
27 The increased solubility and also the 
improved stability in LiposomesFaSSIF caused a higher concentration in the basal compartment than in the 
apical compartment at the end of the experiment (Figure 1). Interestingly, the concentration-time 
profiles of the conjugates showed that FaSSIF-TMCaco nearly abolished the apical efflux of all conjugates. 
It was reported that FaSSIF can inhibit apical efflux of P-gp substrates such as digoxin, cyclosporine A, 
doxorubicin, and etoposide.40-43 As a result no conversion of glutathione conjugate to cysteine conjugate 
took place in the apical compartment while the amount of glutathione conjugate in the basal 
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compartment was strongly increased (Figure 4). The overall reduced apical efflux did not affect the 
conjugation rate constant in the cell which shows that no interplay between transporter and 
bioconversion was elicited by FaSSIF-TMCaco.  
FeSSIF-TMCaco increased the partition coefficient Ka/c accompanied by a decreased permeability 
coefficient which were consistent with the decreased amount of nobilin in the cells (Figure 1). The 
reduced permeability coefficient in presence of biorelevant media was reported to be a result of 
incorporation of a compound into colloidal lipid particles.41-44 The relationship between the partition 
coefficient Ka/c and the permeability coefficient was discussed before where an increase in lipid content 
of the media resulted in a decreased permeability coefficient and simultaneously increased partition 
coefficient Ka/c.
19 The partition coefficient u was slightly larger for FeSSIF-TMCaco than in the experiment 
with FaSSIF-TMCaco. Also, indicating that nobilin is better soluble in LiposomesFeSSIF than in  
FeSSIF-TMCaco.
27 The increased partition coefficient Ka/c was also accompanied by a markedly decreased 
chemical degradation rate constant which further confirms the high affinity of nobilin to the colloidal 
lipid particles as discussed before.27 The abolished bioconversion of nobilin was in agreement with the 
results that no conjugates were detected in presence of FeSSIF-TMCaco. FeSSIF-TMCaco was suggested to 
be compatible with the Caco-2 cells for three hours.19 Even though no loss of membrane integrity and no 
cytotoxic effect in the MTT assay was reported over 300 min of incubation, the LDH assay showed 
cytotoxicity of 10% over the first 180 min and 20% over 300 min.19 This observation does not exclude a 
reduced metabolism due to some adverse on enzymes of the cells.  
Hence, FaSSIF-TMCaco diminished apical efflux of the conjugates which did not result in reduced 
bioconversion and therefore no interplay between transporter and conjugation reactions and no 
increase of absorption was observed. FeSSIF-TMCaco increased stability in the medium and reduced 
bioconversion, causing an increased relative fraction absorbed.  
The two lipid based formulations showed an opposite effect on absorption of nobilin. SMEDDS1 
increased the relative fraction absorbed from 37% to 70% and SMEDDS2 decreased it to 24%. The 
colloidal lipid particles of SMEDDS1 increased the partition coefficient Ka/c and reduced the permeability 
coefficient as well as chemical degradation. These observations are related to the high affinity of nobilin 
to the lipid particles in analogy to FeSSIF-TMCaco. Additionally the increased concentration in the apical 
and basal compartments and reduced amount of nobilin in the cells was because of the increased Ka/c 
compared to aq-TMCaco (Figure 5). Bioconversion was reduced by SMEDDS1 which is consistent with the 
considerably low concentrations of conjugates in all three compartments (not shown, see appendix). 
Only low concentrations of glucuronide and cysteine conjugates were detected in the apical 
compartment whereas SMEDDS1 completely abolished the formation of glutathione conjugates. It is 
well known that surfactants such as Cremophor EL have an inhibitory effect on cell enzymes.45-48  
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SMEDDS2 increased the partition coefficient Ka/c accompanied by a reduction of the permeability 
coefficient and the degradation rate constant as discussed above for SMEDDS1. However, bioconversion 
of nobilin was increased which is currently not understood. A biological effect of the antioxidant  
α-Tocopherol may play a role by counteracting the known prooxidative activity of sesquiterpene 
lactones such as nobilin which might be responsible for reduction of metabolic activity of the cells.49,50 
Although, Lutrol F 68 and α-Tocopherol were reported to inhibit P-gp and the later also MRP2,46,51,52 no 
reduction of the efflux was observed in this study (Figure 7). The concentration-time profiles of the 
conjugates were similar to those with no formulation (Figure 3).  
Finally, the lipid based formulation SMEDDS1 improved the relative fraction absorbed of nobilin. This 
effect was attributed to the increased chemical stability and more important to the reduced 
bioconversion of nobilin in presence of SMEDDS1. SMEDDS2 reduced chemical degradation but not 
bioconversion and therefore no increase in absorption was observed.   
The full extract increased the relative fraction absorbed to 72%. It did not have an influence on the 
chemical degradation rate constant whereas the conjugation rate constant was markedly decreased.28 
This effect was reported to be due to a direct inhibitory effect of the extract on the conjugation 
reactions and to a lesser extend also on efflux carriers which resulted in a decreased bioconversion 
because of the interplay between transporter and conjugation reactions. Additionally, the extract was 
assumed to inhibit influx by OATP as indicated by the parallel increase of glucuronide concentration in 
the apical and basal compartment (Figure 9).28  
Biorelevant media or lipid based formulations had the same effect on the chemical degradation rate 
constant, the partition coefficient Ka/c, and the permeability coefficient when used with the extract as 
with pure nobilin. The combination of the extract with the media and the formulations produced the 
same effect on the bioconversion rate constant as the extract or the media and formulations alone, 
however, possible interactions between them were not further investigated. Interestingly, the increase 
of bioconversion elicited by SMEDDS2 was dependent on the concentration of the extract. At low 
extract concentration (SMEDDS2(1)) the bioconversion rate constant was smaller compared to the one 
of nobilin in aq-TMCaco but it was larger than the one in presence of the extract (Figure 8). This 
observation suggests a competing effect of the extract and the formulation. At 3-fold higher extract 
concentration (SMEDDS2(2)) the effect of the extract dominated and the bioconversion was abolished 
which resulted in a larger relative fraction absorbed. The concentration-time profiles of the conjugates 
show the same effects of FaSSIF-TMCaco, FeSSIF-TMCaco, and SMEDDS1 on the efflux and formation of the 
conjugates as discussed above for pure nobilin. In presence of SMEDDS2 the competing effect of the 
extract and the formulation was also seen in the concentration-time profiles of the conjugates. While 
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those in presence of SMEDDS2(1) were similar to those with SMEDDS2 with pure nobilin, the 
SMEDDS2(2) resembled the extract in aq-TMCaco.  
5.6  CONCLUSION 
FaSSIF-TMCaco reduced the apical efflux of the three conjugates glucuronide, cysteine conjugate, and 
glutathione conjugate which did not result in a decreased bioconversion due to transporter conjugation 
reaction interplay and did not increase nobilin absorption. Also the lipid based formulation SMEDDS2 
did not have an improving effect on absorption even though chemical stability was increased.         
FeSSIF-TMCaco and SMEDDS1 increased chemical stability, reduced bioconversion accompanied by an 
increased absorption. An inhibitory effect on cell enzymes was assumed to be a reason for the 
decreased bioconversion. In combination with the full extract of Chamomillae romanae flos no additive 
effect of the extract on chemical stability, bioconversion, and on absorption was observed. 
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5.7  APPENDIX 
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